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Preface 
 
This Thesis describes the data obtained during the research work 
performed from October 2005 to February 2011 at the Instituto 
Gulbenkian de Ciência and Weill Cornell Medical College under the 
scientific supervision of Miguel Soares, PhD and Josef Anrather, V.M.D. 
 
The Thesis is organized in 5 chapters, which are preceded by a 
summary written both English and Portuguese. An introductory review 
on the subject is provided in Chapter I. In Chapters II, III, and IV the 
original observations obtained during the research period are presented 
and discussed. Chapter V consists in an extended discussion aiming at 
integrating the results presented in the previous Chapters. 
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Summary 
 
Living in an ever-changing environment, cells have evolved numerous 
mechanisms that allow their assessment of the environment, their 
communication with each other and the integration of the information in 
order to adapt to the environmental changes and to maintain their 
homeostasis. In the presence of harmful stimuli, such as infection or 
tissue damage, a series of defensive sequential events, including the 
activation of vascular endothelial cells (EC), are initiated and result in the 
inflammatory stress response. Much of the inflammatory response is 
regulated at the level of gene transcription through the expression of a 
number of proinflammatory genes such as adhesion molecules and 
stress-responsive cytoprotective genes, e.g. heme oxygenase 1 (HO-1). 
The nuclear factor kappa B (NF-κB)/Rel family of transcription factors 
(TF) plays a predominant role in regulating these responses. NF-κB 
activation is strictly required to trigger the expression of proinflammatory 
genes associated with inflammation. However, uncontrolled NF-κB 
activity can result in a failure to resolve inflammation. This in turn may 
contribute to the establishment of a growing number of pathological 
conditions. It is therefore imperative to temporally restrict NF-κB activity 
to target gene subsets needed to execute specific stages of the 
inflammatory process such as activation, resolution and termination. 
Among other mechanisms, post-translational modifications, including 
those exerted directly on Rel proteins, and especially the major 
transcriptionally active subunit RelA, probably have a key role in the fine-
tuning of NF-κB-dependent transcription. While rapidly and reversibly 
regulating RelA activity by modulating its interaction with cofactors of the 
transcriptional machinery (i.e. RelA phosphorylation) and RelA DNA 
binding (i.e. RelA acetylation), post-translational modifications can also 
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promote RelA translocation to specific subnuclear compartments, 
through, for example, RelA ubiquitination and phosphorylation, thereby 
adding an additional layer of control over NF-κB-dependent gene 
transcription. These distinct functional outcomes determined by specific 
post-translational modifications have presumably evolved to ensure the 
specific temporal and spatial transcriptional rate of a subset of RelA-
dependent genes. 
 The aim of this Thesis was to reveal regulatory mechanisms 
conferring specific outcomes via modulation of RelA post-translational 
modifications. We have asked whether inflammatory mediators, such as 
HO-1, dictate the outcome of inflammatory response by inducing and/or 
inhibiting RelA post-translational modifications. Moreover, we 
characterized the mechanism regulating gene-restricted transcriptional 
activity of differentially phosphorylated serine (S) 276 RelA molecules. 
Finally, we set to identify evolutionary conserved regulators of RelA 
transcriptional activity. Overall, the findings presented in this Thesis 
suggest three mechanisms regulating RelA transcriptional activity in a 
manner that resolves inflammation. 
 1) RelA phosphorylation by protein kinase A (PKA) at S276 
induces RelA conformational changes, promoting its interaction with 
cofactors of transcriptional machinery, thereby providing a mechanism 
critical for the expression of a subset of NF-κB-dependent genes. 
Sustained S276 phosphorylation is associated with an increasing 
number of inflammatory diseases. We hereby demonstrate that, under 
oxidative stress, HO-1 inhibits RelA S276 phosphorylation, down-
modulating TNF-induced transcription of adhesion molecules associated 
with the proinflammatory phenotype of activated EC. This anti-
inflammatory and cytoprotective effect is mediated via the ability of HO-1 
to reduce the level of intracellular non protein-bound iron (labile Fe) and 
hence the production of reactive oxygen species (ROS), which can 
 XVII 
promote NF-κB-dependent transcription via PKA-induced RelA S276 
phosphorylation.  
 2) Phosphorylation of RelA S276 is not globally required. 
Hypophosphorylated RelA, mimicked by S276A mutation, has similar 
transcriptional activity on a subset of promoters, compared to wild type 
RelA. We found that RelA S276A phosphorylation mutant translocates to 
promyelocitic leukemia (PML) nuclear bodies, an event possibly 
associated with its gene-specific transcriptional activity. We suggest that 
RelA S276 phosphorylation prevents this translocation via a mechanism 
that depends on RelA DNA binding. This occurs presumably via the 
activation of PKA. 
 3) Rel proteins and the mechanisms controlling its transcriptional 
activity are evolutionary conserved. This is also true for post-translational 
modifications, which can regulate the transcriptional activity of 
Drosophila Rel protein Dorsal. We identified chaperonin containing 
TCP1 (CCT) as a regulator of transcriptional activity of Drosophila Rel 
proteins, i.e. Dorsal and Dorsal-related immunity factor (Dif), using a 
RNA interference (RNAi) screening approach. The CCT also regulated 
NF-κB transcriptional activity in mammalian cells, acting in a promoter-
specific context. While promoting NF-κB-dependent transcription during 
the early phase of RelA activation, CCT diminished gene expression 
during the late phase of RelA transcriptional activity. The later effect was 
associated with decreased RelA DNA binding and termination of NF-κB 
activity via a mechanism involving the modulation of RelA lysine (K) 122 
and K123 acetylation, presumably by altering the activity of histone 
acetyl transferase CREB-binding protein (CBP). 
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Sumário 
 
Por viverem num ambiente em constante mudança, as células 
desenvolveram numerosos mecanismos que lhes permitem detetar 
mudanças no ambiente, comunicar essas mudanças entre si, bem como 
integrar estas informações de maneira a adaptarem-se a tais mudanças, 
mantendo a sua homeostase. Na presença de estímulos nocivos, como 
infeções ou danos teciduais, uma série de eventos sequenciais, 
incluindo a ativação de células endoteliais (CE), são iniciados, com o 
objetivo de defender o organismo, culminando na resposta inflamatória. 
Grande parte da resposta inflamatória é regulada ao nível transcricional, 
através da expressão de vários genes pró-inflamatórios, tais como 
moléculas de adesão, mas também de genes com propriedades 
citoprotetoras, como por exemplo a enzima heme oxigenase-1 (HO-1). A 
família de fatores de transcrição (FT) factor nuclear kappa B (NF-
κB)/Rel tem um papel fundamental na regulação da resposta 
inflamatória. A ativação do NF-κB é essencial para a expressão de 
genes pró-inflamatórios. No entanto, a ativação descontrolada deste FT 
pode impedir a resolução do processo inflamatório, levando ao 
desenvolvimento de uma grande variedade de patologias. Desta forma, 
é imperativo que a atividade do NF-κB seja controlada de maneira a 
permitir que os conjuntos de genes envolvidos nos diferentes estágios 
do processo inflamatório, ativação, resolução e término, sejam 
expressos nas fases adequadas. Um dos principais mecanismos 
envolvidos na regulação da transcrição, mediada pelo NF-κB, são as 
modificações pós-traducionais, incluindo as que ocorrem diretamente 
nas proteínas Rel, e mais especificamente na subunidade com maior 
atividade transcricional, o RelA. Diferentes modificações pós-
traducionais do RelA afetam de maneira diferente a sua atividade. A 
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fosforilação do RelA pode afetar a sua interação com co-fatores da 
maquinaria transcricional, enquanto a acetilação afeta a ligação do RelA 
ao DNA. Para além disso, a ubiquitinação e fosforilação do RelA podem 
induzir a sua translocação para compartimentos subnucleares, assim 
adicionando mais uma camada de controlo na transcrição de genes 
dependents do NF-κB. Possivelmente, todos estes mecanismos 
evoluíram de maneira a assegurar a transcrição de conjuntos de genes 
específicos adequados às diversas fases do processo inflamatório. 
Esta Tese tem por objetivo revelar a especificidade dos 
mecanismos reguladores capazes de alterar a atividade do RelA, via 
modificações pós-traducionais. Concretamente, estudamos se 
mediadores inflamatórios, como a HO-1, são capazes de alterar o 
processo inflamatório através da indução de modificações pós-
traducionais no RelA. Além disso, identificamos que a fosforilação da 
serina (S) 276 do RelA é responsável pela modificação da atividade 
desta molécula. Finalmente, realizamos experiências visando identificar 
moléculas conservadas evolutivamente, envolvidas na regulação da 
atividade transcricional do RelA. Os resultados apresentados nesta 
Tese sugerem três mecanismos reguladores da atividade transcricional 
do RelA envolvidos na resolução da inflamação. 
1) A fosforilação da S276 do RelA pela proteína cinase A (PCA) 
induz modificações conformacionais que promovem a interação do RelA 
com co-fatores da maquinaria transcricional. Esse mecanismo induz a 
expressão de uma fração de genes dependentes do NF-κB. A 
fosforilação continuada da S276 está associada a uma série de doenças 
inflamatórias. Neste estudo, demonstramos que em condições de 
stresse oxidativo, a HO-1 inibe a fosforilação da S276 do RelA, dessa 
forma inibindo a transcrição de moléculas de adesão, induzida por 
tratamento com TNF, em células endoteliais. Este efeito anti-inflamatório 
e citoprotetor, é mediado pela capacidade da HO-1 de reduzir os níveis 
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intracelulares de ferro (Fe) não ligado a proteínas (Fe lábil). A 
diminuição dos níveis intracelulares de Fe lábil reduzem o nível de 
espécies reativas de oxigénio (ROS), que por sua vez, atuam de 
maneira a promover a transcrição de genes dependentes de NF-κB, via 
fosforilação da S276 pela PCA. 
2) A mutação da S276A no RelA, recriando um RelA hipo-
fosforilado, tem uma atividade transcricional semelhante à do RelA do 
tipo selvagem, numa fração de genes dependentes do NF-κB. Os 
nossos resultados demonstram que o RelA S276A mutante transloca-se 
para o núcleo e localiza-se nos corpos nucleares da leucemia 
promielocítica, um evento possivelmente associado com o fato da sua 
atividade transcricional ser específica, ou seja, dependente do gene em 
questão. Os nossos resultados sugerem que a fosforilação da S276 no 
RelA impede a sua translocação através de um mecanismo dependende 
da ligação do RelA ao DNA. Possivelmente, este efeito ocorre através 
da ativação da PCA. 
3) As proteínas Rel e os mecanismos que controlam a sua 
atividade transcricional são conservados evolutivamente. Isto também 
se aplica para modificações pós-traducionais, uma vez que este 
mecanismo regula a atividade transcricional da proteína Dorsal, 
equivalente de RelA em Drosophila. Utilizando um rastreio baseado em 
RNA de interferência,  identificamos a chaperonina contendo TCP1 
(CCT) como um regulador da atividade transcricional das proteínas Rel 
presentes em Drosophila, Dorsal e factor de imunidade relacionado com 
o Dorsal (Dif). A CCT também regula a atividade transcricional do NF-κB 
em células de mamíferos, atuando de forma específica no contexto de 
cada promotor. A CCT promove a transcrição de genes dependentes do 
NF-κB na fase inicial da ativação do RelA. No entanto, diminui a 
expressão destes genes na fase final da ativação. Este último efeito 
 XXI 
está associado a uma diminuição da ligação do RelA ao DNA e ao fim 
da atividade do NF-κB através de um mecanismo que envolve a 
acetilação das lisinas (K) 122 e K123 do RelA, possivelmente pela 
alteração da atividade da acetiltransferase das histonas, a proteína de 
ligação a CREB (CBP). 
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CHAPTER I 
GENERAL INTRODUCTION 
 
 3 
I. Prologue 
 
“When we consider the extreme instability of our bodily structure, its 
readiness for disturbance by the slightest application of external forces 
and the rapid onset of its decomposition as soon as favoring 
circumstances are withdrawn, its persistence through many decades 
seems almost miraculous. The wonder increases when we realize that 
the system is open, engaging in free exchange with the outer world, and 
that the structure itself is not permanent but is being continuously broken 
down by the wear and tear of action, and as continuously built up again 
by processes of repair.” 
- Walter Bradford Cannon - “The wisdom of the body” 
 
Claude Bernard first recognized the significance of the body’s “milieu 
intérieur” (internal environment), which was later defined by Walter 
Bradford Cannon as “homeostasis“ (from Greek: οµοιος (hómoios), 
“same” and στασις (stásis), “standing”), i.e. “remaining the same” (1). 
Homeostasis is a fundamental principle of all living organisms and if one 
considers “same” as “self”, homeostasis can be defined as an ability of 
the organism to “remain self”. A variety of strategies have therefore 
evolved from unicellular organisms to humans recognizing “self” from 
“non-self”. The outcome of this so called “self-non-self” discrimination 
can vary from establishing a life long symbiotic relationship to the 
destruction and elimination of “non-self”, as it occurs for commensal 
microbiota and pathogens, respectively. 
 In bacteria, “self-non-self” discrimination relies on the expression 
of various specialized proteins that include antimicrobial peptides activity 
such as microcins that interfere with the cell cycle of “non-self” 
microorganisms or enzymes, i.e. restriction endonucleases, recognizing 
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and eliminating nucleic acids sequences specific to “non-self” (2). As for 
other unicellular organisms, bacteria developed mechanisms that assure 
not only maintenance of their individual homeostasis but also that of 
entire bacterial populations, thus manifesting the first traits of multi-
cellular behavior, as seen in eukaryotes. Bacteria have also developed 
mechanism eliminating “altered self” and eventually “self”, inducing 
programmed cell death (PCD) (3). Examples include phage-induced 
PCD, an effect that prevents phage, i.e. “non-self”, growth (4), DNA 
damage-induced PCD, maintaining the genetic continuity of population 
by eliminating “altered self” (5) and PCD of a part of bacterial population, 
i.e. “self”, providing nutrients for the surviving bacterial population (6). 
These mechanisms described above rely in most cases on newly gene 
transcription and protein synthesis. Gene transcription in bacteria is 
mostly turned on by default and is negatively regulated by the presence 
of specific repressor proteins (7). This mechanism of gene transcription 
allows bacteria to rapidly adapt to changes in the environment.  
 The emergence of more complex multi-cellular eukaryotes 
obliged new mechanism of “self-non-self” discrimination, supplementing 
those first developed by unicellular prokaryotes. These include the 
emergence of specialized receptors recognizing “non-self”, “altered-self” 
as well as “self”, triggering a series of coordinated adaptive events 
eventually leading to the elimination of inciting stimuli and the return to 
homeostasis, responses collectively referred to as stress responses (8). 
Depending on the nature and the extent of stimuli sensed by a given 
receptor, appropriate stress responses are induced, which can occur at 
the cellular level, tissue level, referred to as parainflammation, or 
systemically, referred to as inflammatory response (8, 9).  
 Inflammation has been known to humans for almost two 
thousand years, initially as “rubor et tumor cum calore et dolore“ 
(redness and swelling with heat and pain) and later on as “functio laesa” 
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(disturbance of function) and will be briefly described hereby to illustrate 
the diversity of mechanisms that evolved in order to maintain the 
homeostasis of complex multi-cellular organisms (see Figure 1.1.). The 
initiation of inflammatory response relies on the recognition of microbial 
 
 
        
 
Figure 1.1. The inflammatory response. The initiation of inflammatory response 
relies on the recognition of microbial associated molecular patterns (MAMP) as 
well as non microbial molecules by different sensors including pattern recognition 
receptors (PRR), expressed on tissue resident macrophages and in some tissues 
by mast cells, triggering a series of signal transduction pathways leading to the 
expression of inflammatory mediators, i.e. TNF, IL-1β, histamine. These can 
target vascular endothelial cells (EC), which express several adhesion molecules, 
i.e. VCAM, ICAM, that play a key role in recruiting circulating leukocytes, i.e. 
neutrophils and monocytes to the site of inflammation, leading to elimination of the 
noxious agent upon phagocytosis or via the release of a various molecules with 
the microbicidial activity, e.g. ROS, RNS. 
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associated molecular patterns (MAMPs) as well as non-microbial 
molecules that reveal the presence of “non-self” or “altered self” and as 
such alert for possible deviations from homeostasis. These molecules, 
also known as inducers of inflammation, are recognized by specialized 
sensors, which include evolutionary conserved germline encoded pattern 
recognition receptors (PRRs), such as toll like receptors (TLRs), 
recognizing MAMPs as well as other less well characterized sensors 
recognizing directly or indirectly distinct effects of the inducers on host 
tissues. The examples include but are not restricted to NACHT-leucine-
rich-repeat- and pyrin-domain-containing protein (NALP3) inflammasome 
recognizing efflux of potassium (K)+ ions, resulting from pore formation 
during Gram-positive bacterial infection (10) and purinoceptors 
recognizing adenosine triphosphate (ATP) (11). Engagement of PRR 
triggers a series of signal transduction pathways leading to the activation 
of several transcription factors (TF). These can act in a concerted 
manner to regulate the expression of genes that include mostly a series 
of inflammatory mediators, such as cytokines, chemokynes and lipid 
mediators (see Table 1.1.). Inflammatory mediators are recognized by 
specific receptors expressed by different cell types such as vascular 
endothelial cells, which play a key role in providing adaptation of blood 
flow as well as recruiting circulating leukocytes (e.g. neutrophils and 
monocytes), acting as the effector components of inflammation. As such, 
the inducers, e.g. MAMPs, sensors, e.g. PRR, mediators and effectors 
define different types of inflammatory responses aimed at reestablishing 
homeostasis following its disruption by the presence of toxic molecules 
associated with the inflammation (8). 
 In the case of microbial infections, probably the most common 
cause of inflammation, circulating neutrophils and monocyte/ 
macrophages (Mø) provide the first line of defense aimed at pathogen 
killing  (see Figure 1.1.).  A  critical  mechanism  relies  on  the release of  
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INFLAMMATORY MEDIATORS NF-κB DEPENDENT 
REGULATING 
NF-κB 
Vasoactive amines     
histamine   (12) 
serotonin     
Vasoactive peptides     
substance P   (13)  
kinins   (14)  
Complement fragments     
C3a   (15) 
C5a   (15) 
Lipid mediators     
prostaglandins *(16) (17) 
leukotrienes   (18) 
Cytokines     
tumor necrosis factor (TNF) (19, 20) (21, 22) 
interleukin-1 (IL-1) (23) (21)  
IL-6 (24) (25)  
Chemokines     
chemokine (C-C motif) ligand 2 (CCL2) (26)  (27) 
CCL3 (28, 29)   
IL8 (30) (31) 
Proteolytic enzymes     
elastase  (32) 
cathepsins (33)    
matrix metalloproteinases (34)   
Prothrombotic peptides     
tissue factor (35)   
Gases     
nitric oxide (NO) *(36, 37) (38) 
Adhesion molecules     
endothelial (E) selectin (39, 40)    
platelet (P) selectin (41)    
intercellular adhesion molecule 1 (ICAM-1) (42)    
vascular adhesion molecule 1 (VCAM-1) (43)   
 
Table 1.1. The inflammatory mediators. Examples of mediators that coordinate the 
initiation of inflammation. The expression of several of these mediators is induced via the 
activation of NF-κB and/or can regulate NF-κB activity. *The generation of 
prostaglandins and NO is indirectly dependent on NF-κB activity via the inducton of 
cyclooxygenase-2 (COX-2), and nitrix oxide synthase (NOS). 
 
 8 
antimicrobial cytotoxic molecules from secretory vesicles called 
granules, a process referred to as degranulation. The microbicidial 
activity of activated neutrophils as well as that of Mø is further enhanced 
via the activation of nicotinamide adenine dinucleotide phosphate 
reduced (NADPH) phagocyte oxidase complex, generating high levels of 
superoxide and triggering the formation of other highly toxic reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) aimed at 
eliminating the invading pathogen. Given the broad cytotoxic effect of 
ROS and RNS, their production must be tightly regulated in order to 
avoid unfettered tissue damage. 
 Inflammatory responses must be terminated as soon as 
pathogen clearance has been achieved, as to restore homeostasis, a 
highly regulated process involving the expression of a variety of stress-
responsive genes (see Figure 1.2.) (44). Many of these genes exert their 
effect directly on vascular endothelial cells inhibiting signal transduction 
pathways preceding vascular changes, leukocyte infiltration and 
activation. For example, the enzyme cyclooxygenase-2 (COX-2) 
produces 15-deoxy-Δ12,14-prostaglandin (PG) J2, a lipid mediator that 
restrains the expression of proinflammatory genes in many cells, 
including intercellular adhesion molecule 1 (ICAM-1) and vascular 
adhesion molecule 1 (VCAM-1) in endothelial cells (45), or inducible 
nitric oxide synthase (iNOS) in Mø (46, 47). Concomitantly, the 
production of several pro-inflammatory mediators during the initial phase 
of inflammation is switched towards the production of anti-inflammatory 
molecules, promoting the resolution of inflammation. This is well 
illustrated by the transition from the generation of proinflammatory lipid-
mediators such as leukotrienes to anti-inflammatory lipoxins, inhibiting 
further the recruitment of circulating neutrophils into the site of infection 
(48). At the same time, activated neutrophils involved in pathogen 
clearance start undergoing PCD, a regulated mechanism limiting tissue 
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damage caused by the local production of ROS. Neutrophil PCD is 
associated with the expression of cell surface phosphatidylserine, 
recognized specifically by receptors expressed by infiltrating Mø (49, 
50). This triggers a genetic program in Mø characterized by the 
 
 
        
 
Figure 1.2. The resolution of inflammation. The inflammatory responses must 
be terminated after pathogen clearance. The expression of several anti-
inflammatory mediators inhibits signal transduction pathways preceding vascular 
changes, leukocyte infiltration and activation. Activated neutrophils at the site of 
inflammation undergo PCD, limiting tissue damage caused by ROS and RNS 
production. Expression of phosphatidylserine (PtdSer) results in neutrophil 
recognition and phagocytosis by infiltrating monocytes, which triggers the 
production of immunomodulatory molecules such as IL-10 and TGF-β helping 
resolution of inflammation. At the same time, pro-oxidant environment (ROS and 
RNS) induces the expression of so-called stress-responsive genes, such as heme 
oxygenase 1 (HO-1), contributing to the termination of inflammation. 
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production of immunomodulatory molecules, e.g. transforming growth 
factor beta (TGF-β), interleukin 10 (IL-10), that limit the proinflammatory 
phenotype and hence cytotoxic effect associated with the onset of 
inflammatory reactions (51). Production of free radicals, i.e. ROS and 
RNS, aimed at destruction of pathogens also induces the expression of 
genetic programs characterized by the expression of cytoprotective 
stress-responsive genes such as heme oxygenase-1 (HO-1), 
contributing further to the termination of inflammation (see Chapter IV). 
 Expression of HO-1 appears to be critically involved in the return 
of homeostasis associated with the resolution of inflammatory 
responses. HO-1 is a cytoprotective enzyme that catalyzes the cleavage 
of protoporphyrin IX ring of heme into labile iron (Fe), carbon monoxide 
(CO) and biliverdin (BV), the latest being converted by a biliverdin 
reductase into the anti-oxidant bilirubin (see Figure 1.3.) (52, 53). Labile 
Fe, on the other hand, induces heavy chain ferritin (FtH) expression, 
which mediates cytoprotective effects under a variety of conditions (54-
56). CO, while originally thought to be a toxic by-product of heme 
catabolism, can act as a signalling mediator with anti-inflammatory, 
cytoprotective and vasodilator properties (57, 58). 
 The salutary effects of HO-1 appear to be driven by its capacity 
to limit the deleterious effect of heme. Under homeostasis, heme exists 
as a prosthetic group of hemoproteins that are essential for various 
cellular functions including the oxygen transport, i.e. hemoglobin, and 
storage, i.e. myoglobin (59), generation of cellular energy, i.e. redox 
cytochromes (60), antioxidant defences, i.e. catalase and production of 
superoxide anions, i.e. NADPH oxidase, or nitric oxide (NO), i.e. NOS 
(61, 62). Under oxidative stress, however, some of these hemoproteins 
are rapidly oxidized, releasing and augmenting the concentrations of 
non-protein bound (free) heme. This abundant source of Fe is highly 
deleterious to cells as it can participate in the Fenton reaction, catalyzing 
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the production of free radicals thus amplifying the cytotoxic effect of ROS 
(63, 64). Besides this, free heme can be recognized by Mø and 
neutrophils activating their proinflammatory phenotype, i.e. cytokine 
expression and ROS production (65-67). 
 The critical role of HO-1 in the regulation of homeostasis is 
suggested by the observation that HO-1 deficiency leads to chronic 
inflammation, characterized by increased number of blood leukocytes, 
splenomegaly, accumulation of monocyte/Mø in tissues, vascular injury, 
Figure 1.3. The HO-1 system. The cleavage of protoporphyrin IX ring of free heme 
produces biliverdin (BV), which is converted by biliverdin reductase (BVR) into the 
bilirubin (BR), CO and labile iron (Fe) that is stored by the ferritin H chain (FtH). Image 
from (68). 
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cell death and Fe depositions in tissues and renal damage (69-71). 
Moreover HO-1 deficiency and heme-mediated oxidative damage have 
been associated with a growing number of inflammatory-mediated 
diseases (72). While limiting the accumulation of free heme should per 
se contribute to the salutary effects of HO-1, the products of heme 
degradation, i.e. Fe, CO and BV, also contribute critically to the salutary 
effects of HO-1 (68). As demonstrated under Chapter IV, this occurs in 
part via the regulation of specific TFs regulating the expression of 
proinflammatory genes, such as the nuclear factor kappa B (NF-κB) 
family of TF (73).  
 Tissue repair response is another crucial step in restoring 
homeostasis in the context of inflammatory responses. Injured tissues 
are repaired by regeneration of parenchymal cells (the main specialized 
cells of the tissue or the organ) or, in the event when regeneration is not 
capable per se to restore homeostasis, by connective tissue repair in 
which scar tissue, e.g. fibroblasts, is substituted for the specialized 
parenchymal cells of the injured tissue. Numerous chemical mediators 
and growth factors orchestrate this healing process acting as 
chemoattractants or promoting cell proliferation. Among many others, 
chaperonin containing TCP-1 (CCT) have a critical role in sustaining cell 
proliferation, cytoskeletal proteins polymerization and have been shown 
to regulate fibroblast motility and contractility (74, 75). As such, CCT will 
be briefly introduced in the Section II.3.1.  
 Alike in prokaryotes, many of the responses described above are 
regulated at the level of transcription, a process that relies on a group of 
proteins known as TFs (76). Comparative genome analysis suggest that 
increase in gene and TF number cannot account per se for all the 
diversity of mechanisms maintaining homeostasis in multi-cellular 
eukaryotes (77). Rather, the complexity of mechanisms regulating gene 
transcription are accountable for the specific response to a given 
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environmental change (77). Unicellular eukaryotes in principal have 
short regulatory DNA sequences located immediately upstream of the 
coding sequence of their genes that can interact with one or two TFs, 
driving their transcription. Higher organisms, on the other hand, contain 
highly structured regulatory sequences scattered both upstream and 
downstream of the gene coding sequence as well as within introns and 
often require multiple TFs to regulate gene transcription. This 
combinatorial mechanism implies not only the coordinated binding of 
multiple TFs but also their interaction with co-regulators of transcriptional 
machinery (78). On the other hand, a single TF can drive the expression 
of hundreds of putative target genes in a cell- and stimulus-specific 
context, an effect dependent on post-translational regulation of TF (see 
Figure 1.4.). As eukaryotic transcription and translation are spatially 
isolated, a first layer of regulation is provided by the TF sequestration in 
the cytoplasm, requiring their nuclear translocation. While some TFs are 
newly synthesized in response to a specific stimulus, many are 
constitutively expressed and retained inactive in the cytoplasm often via 
the interaction with specific cytoplasmic inhibitory proteins or in the form 
of inactive precursors (see Section II.2.2). These can be rapidly 
activated upon stimulus-induced liberation from their respective inhibitors 
or through post-translational modifications, allowing the active form of 
the TF to translocate into the nucleus and bind to specific DNA binding 
sequences in the cis-regulatory DNA region of target genes, eliciting 
rapid and controlled responses to environmental changes. TFs act often 
as homo- or hetero-dimeric complexes, further increasing the complexity 
of possible regulatory mechanisms (see Section II.2.1.). Other than 
regulation of nuclear translocation, dimerization and DNA binding, TF 
can contain transactivation domains (TAD) that interact with different 
transcriptional co-regulators, as well as with chromatin remodeling 
complexes (see Section II.2.4.). Thus, TF lacking TAD can act as a 
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Figure 1.4. Transcriptional regulation. Transciption factors (TF) can be 
ubiquitously expressed and retained inactive in the cytoplasm via the interaction 
with specific inhibitory proteins (Inh) or in the form of inactive precursors (TF3 l 
Inh). Engagement of different receptors can trigger signal transduction pathways 
(Int1-4), which liberate TF from their respective Inh through post-translational 
modifications (Inh degradation or TF3 l Inh processing), allowing for TF nuclear 
translocation. Other than regulation of nuclear translocation, dimerization (TF1-
TF2 and TF2-TF3) and DNA binding, TF can contain transactivation domains 
(TF1 l TAD), defining those transcriptionally active. On the other hand, TF dimer 
lacking TAD acts as a repressor of transcription (TF2 l TF3). Besides inducing Inh 
degradation, post-translational modifications can also target TF as well as 
histones within promoters of target genes, fine-tuning transcriptional response 
(positively in green or negatively in red) via a mechanism involving TF nuclear 
translocation, interaction with other proteins, DNA binding, stability, translocation 
to specific subnuclear compartments so called nuclear bodies (NB) and 
chromatin remodeling. 
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repressor of transcription. Post-translational modifications are 
increasingly recognized as a key mechanism regulating transcriptional 
activity, acting often as a pre-requisite for TF nuclear translocation, 
interaction with other proteins, DNA binding and stability (see Section 
II.2.3.). Moreover, post-translational modifications have been recently 
implicated in TF translocation into different subnuclear compartments 
collectively known as nuclear bodies (see Section II.2.5.), which have an 
important role in regulating gene transcription. While regulation of TF 
activity is probably the best studied mechanism controlling gene 
expression there are several other layers of regulation that include: i) 
chromatin modifications, ii) transcriptional co-factor localization, 
modifications and degradation, iii) messenger (m) RNA splicing, 
polyadenylation and localization and iv) micro RNA.  
 Among the many TF involved in the regulation of inflammatory 
responses, the pleiotropic TF NF-κB appears to play a central role in 
these processes. Many of the inducers of inflammation including MAMPs 
recognized by PRR activate NF-κB. These include molecules associated 
with bacterial and viral infection, inflammatory cytokines produced in 
response to microbial recognition, physical and oxidative stress, e.g. 
ultra violet (UV)-radiation and reactive oxygen intermediates, 
respectively, resulting in the production inflammatory mediators such as 
proinflammatory cytokines, chemokines, cell adhesion molecules, 
immunoreceptors, stress responses genes, cytoprotective genes and 
growth factors, arguing further for the involvement of NF-κB in the 
regulation of inflammation (79, 80). 
 The physiological relevance of NF-κB in the regulation of 
inflammation has been clarified by loss of function studies in model 
organisms lacking specific core components of the NF-κB pathway (81-
83). Despite the considerable knowledge that these studies have 
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provided, the detailed aspects of the complexity of NF-κB regulation 
during the inflammatory responses is only starting to emerge. While NF-
κB is essential for the initiation of inflammatory response, e.g. 
transcription of various proinflammatory mediators (see Table 1.1.), tight 
regulation and proper termination of NF-κB-dependent transcriptional 
response is also necessary for the resolution of inflammation and return 
to homeostasis, e.g. switch from proinflammatory to anti-inflammatory 
gene transcription, neutrophil PCD. Uncontrolled NF-κB activity has 
been implicated in the pathogenesis of immune-mediated inflammatory 
diseases, including some acting as major causes of morbidity and 
mortality worldwide such as rheumatoid arthritis, asthma and 
inflammatory bowel disease (84). Moreover, deregulated NF-κB activity 
has been also associated with cancer development. Presumably, this is 
related to the fact that persistent NF-κB activity can lead to sustained 
tissue damage, inflammatory cell infiltration and production of cytokines, 
chemokines, free radicals and growth factors, which together with the 
anti-apoptotic effect of the NF-κB promote DNA damage, mutagenesis, 
cell proliferation and eventually tumor formation (85). As such, regulation 
of NF-κB activity has been in focus of research in the past twenty-five 
years and will be the focus of this Thesis.  
 
II. The NF-κB family of transcription factors 
 
The NF-κB signaling system comprises a family of Rel homology domain 
(RHD)-containing TF (hence the name Rel proteins) and their respective 
inhibitors, referred to as inhibitors of κB (IκBs) (86). While originally 
discovered as a nuclear factor binding selectively to the immunoglobulin 
κ enhancer in B-cells (87), NF-κB family members were later found to be 
ubiquitously expressed as well as highly conserved throughout evolution. 
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To date five Rel proteins have been identified in mammals, namely 
p65/RelA, RelB, cRel, p105/p50 and p100/p52, that exist as homo- or 
hetero-dimeric complexes (see Figure 1.5.). The dimer RelA-p50, the 
first identified, is expressed in the majority of cell types (88). RelA, RelB 
and c-Rel contain a TAD within their C-terminal domain, conferring them 
with intrinsic transcriptional activity. Since NF-κBs are constitutively 
expressed in most cells, they can respond rapidly to a variety of triggers 
and multiple layers of control have evolved ensuring the tight regulation 
of their transcriptional activity (see Section II.2.). The central mechanism 
 
Figure 1.5. The NF-κB family of transcription factors. All mammalian NF-κB 
members, i.e. RelA, RelB, c-Rel, p100 and p105, contain the N-terminal REL-homology 
domain (RHD) responsible for DNA binding, dimerization with other members of NF-κB 
family, IκB binding and nuclear translocation (NLS, nuclear localization sequence). On 
their C-terminal region RelA, RelB and c-Rel contain transactivation domain (TAD), 
which makes these members transcriptionally active. The leucine zipper (LZ) of RelB is 
required for its transactivation activity. p100 and p105 contain IκB-like ankyrin repeat 
responsible for their cytoplasmic sequestration. Glycine-rich region (GRR) is important 
for their processing to p52 and p50, respectively. Adopted and modified from (86). 
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relies on the presence of multiple ankyrin repeats within the C-terminus 
domain of IκBs that bind and sequester NF-κB in the cytoplasm (89). In 
the case of transcriptionally active members, IκBs bind to the specific 
sequence within NF-κB RHD, masking their nuclear localization 
sequence (NLS). p105 and p100, on the other hand, do not contain TAD, 
but instead contain ankyrin repeats within their C-terminal region, 
functioning as IκB molecules. Dissociation of NF-κB from its inhibitors is 
achieved by proteasome-mediated IκB proteolytic-degradation resulting 
in nuclear translocation of NF-κB dimers aided by NLS within their RHD. 
 NF-κB is evolutionary conserved, being extensively studied in 
different model organisms, including Drosophila (90). The role of NF-κB 
signaling pathway in Drosophila was first demonstrated in the context of 
embryonic development (91, 92). However, soon after the discovery that 
Toll receptor can activate Drosophila immune response, several genes 
involved in Drosophila embryonic development have been also shown to 
regulate its antimicrobial responses (93). Three Drosophila Rel proteins 
have been described to date, namely Dorsal, Dorsal-related immunity 
factor (Dif) and Relish. Dorsal and Dif share the C-terminal TAD and are 
sequestered in the cytoplasm by an IκB-like protein Cactus (94, 95). The 
third NF-κB member Relish, alike p100 and p105, contains C-terminal 
ankyrin repeats, which proteolytic degradation precedes its nuclear 
translocation and transcription of antibacterial peptides (96).  
 The evolutionary origin and functional conservation of NF-κB are 
traced back as far as 550 million years to the most ancient arthropod 
horseshoe crab, Carcinoscorpius rotundicauda (Cr) (97). Host defense 
systems against infection in horseshoe crab consists of granular 
hemocytes that, when activated by MAMPs, such as bacterial 
lipopolysaccharide (LPS), secrete various molecules providing host 
protection against those pathogens (98). In keeping with this findings 
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TLRs (99) as well as molecules of the NF-κB signaling transduction 
pathway, i.e. CrNF-κB, CrRelish and IκB-like member, i.e. CrIκB, have 
also been identified in horseshoe crabs (97). Using bioinformatics 
approach, NF-κB-like molecules have been identified in the genome of 
the most recent ancestor to living bilaterians, i.e. cnidarian Nematostella 
vectensis (Nv) (100), or in even older demosponge Amphimedon 
queenslandica (Aq) (101). Moreover, the physiological role of NvNF-κB 
has been recently demonstrated (102), further arguing for the central 
importance of NF-κB as a stress-mediating TF regulating homeostasis 
throughout evolution. 
 
1. Two pathways to NF-κB activation  
 
The first evidences that bacterial LPS can induce the release of NF-κB 
from its cytoplasmic inhibitor IκB (103) started an era of extensive 
research on detailed biochemical pathway regulating NF-κB 
transcriptional activity and its physiological relevance. Ever since, 
stimulus-induced IκB phosphorylation and degradation has been widely 
studied and is today perceived as a central mechanism regulating NF-κB 
activity (see Section II.2.2.). The function of the IκB kinase, regulating 
the phosphorylation and hence the degradation of IκB molecules, was 
first assigned to a 700 kDa multi-subunit kinase complex, namely IκB 
kinase (IKK) signalosome (104, 105). IKK consists of two catalytically 
active subunits, i.e. IKKα (IKK1) and IKKβ (IKK2) and a regulatory 
subunit IKKγ (NF-κB essential modulator, NEMO). Depending on the 
stimuli leading to the IKK activation, the IKK subunits phosphorylating 
IκB and the NF-κB members associated with IκB, two distinct NF-κB 
signal transduction pathways have been revealed (see Figure 1.6.). 
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Stress stimuli generally associated with inflammation, e.g. LPS, tumor 
necrosis factor (TNF), elicit the so called canonical signal transduction 
pathway, converging at the level of the IKK complex composed of both 
 
 
                
 
 
Figure 1.6. Mammalian NF-κB signaling pathway. NF-κBs are ubiquitously 
expressed as pre-existing transcription factors (TF) sequestered in the cytoplasm 
via the interaction with their inhibitors IκBs. Stimulus induced IκB degradation 
leads to NF-κB nuclear translocation and induction of gene transcription. The 
canonical pathway is generally induced under the stress conditions associated 
with inflammation (LPS, IL-1, TNF) leading to the activation of the IKK complex 
composed of both catalytic (IKKα and IKKβ) and a regulatory (IKKγ) subunits, 
which mediate phosphorylation-dependent IκBα degradation and nuclear 
translocation of NF-κB dimer, RelA-p50 being prototypical one. On the other 
hand, the non-canonical pathway is induced by stimuli such as lymhotoxin-β, 
CD40 and BAFF mainly during the development of secondary lymphoid organs. It 
is mediated via the NIK-induced activation of IKKα homodimeric complex, leading 
to the processing of p100 and RelB-p52 nuclear translocation. 
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catalytic and a regulatory subunit. IKKγ-dependent IKKβ activation is 
necessary and sufficient for IκBα and/or IκBβ phosphorylation and 
subsequent degradation, leading to NF-κB dimer (e.g. RelA-p50) nuclear 
translocation. The physiological significance of canonical pathway has 
been demonstrated using a loss of function approach in which the genes 
encoding for IKKβ , IKKγ and RelA were specifically deleted in mice, i.e. 
Ikbkb-/-, Ikbkg-/- and Rela-/- respectively, all of which exhibit embryonic 
lethality caused by hepatocyte PCD in the developing liver (106-108). 
Disrupting signaling by TNF in RelA deficient mice (Rela-/-Tnfr-/-) restores 
embryonic development, but results in increased susceptibility to 
microbial infection, confirming the expected role of NF-κB in 
proinflammatory gene induction (109). Moreover, IKKβ deficient cells 
(Ikbkb-/-) stimulated with proinflammatory cytokines (e.g. TNF, IL-1β) do 
not induce NF-κB-dependent transcription (107). Together with other 
similar studies, these findings reveled an irreplaceable role of NF-κB as 
a cytoprotective TF suppressing PCD, thus uncoupling the 
proinflammatory effect of TNF from cytotoxicity. The possibility to 
specifically target NF-κB activation in different cell lineages is, however, 
starting to reveal a rather tissue-specific and sometimes opposing role of 
NF-κB in a diversity of inflammatory responses. For example, IKKβ 
(Ikbkb-/-) and IKKγ (Ikbkg-/-) deletion and inhibition of the canonical 
pathway in epithelial cells results in PCD, disruption of epithelial barrier 
integrity and increased inflammation caused by commensal bacteria via 
the activation of tissue Mø arguing for an anti-inflammatory and 
cytoprotective role for the canonical NF-κB pathway (110, 111). In 
contrast, specific deletion of IKKβ (Ikbkb-/-) in neutrophils attenuates 
PCD, suggesting the pro-apoptotic role of NF-κB in these cells (112, 
113). In a model of pneumonia induced by Streptococcus agalactiae, on 
the other hand, IKKβ deletion (Ikbkb-/-) in lung epithelial cells results in 
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decreased neutrophil recruitment and bacterial clearance, while 
enhancing these responses in mice with IKKβ deletion in Mø (113). 
 In contrast to canonical pathway, other stimuli such as 
lymphotoxin-β, CD40 and B cell-activating factor (BAFF) activate NF-κB-
inducing kinase (NIK), a common denominator of the non-canonical NF-
κB signal transduction pathway, which acts irrespectively of IKKβ and 
IKKγ and is mediated via the IKKα homodimeric complex-dependent 
processing of p100 and RelB-p52 nuclear translocation (see Figure 1.6.) 
(114). The non-canonical pathway is involved mainly in the development 
of secondary lymphoid organs and B-lymphocyte function, a notion 
supported by a loss of function approach in mice lacking p100 (Nfkb2-/-), 
RelB (Relb-/-) and NIK (Map3k14-/-) expression (115, 116). It should be 
noted, however, that studies with Map3k14-/- mice, reveled an anti-
inflammatory role for RelB as well. Map3k14-/- mice develop multiorgan 
inflammation, a pathology thought to involve impaired T cell function 
(117). 
 Though originally thought to act independently from each other, 
the two pathways can interact at different levels. Genetic studies using 
mice with conditional deletion of IKKα (Chuk-/-) and IKKβ (Ikbkb-/-) 
uncovered the redundant function of these kinases in mediating 
canonical NF-κB signaling pathway. This is supported by the notion that 
only the combined deletion of both kinases (Chuk-/-Ikbkb-/-) sensitizes 
liver parenchymal cells to LPS-induced PCD (118). Moreover, IKKα can 
phosphorylate canonical IκBs in the absence of IKKβ (118). In the 
absence of sufficient IKKα activation, on the other hand, excess of p100 
can bind to RelA-containing dimers acting as an inhibitor of the canonical 
pathway (119). As p100 is a RelA-inducible gene, this serves as another 
negative feedback mechanism involved in the termination of NF-κB-
dependent transcription. Moreover, RelB transcription has also been 
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shown to be RelA-dependent (120), suggesting that the canonical signal 
transduction pathway can control the non-canonical one. 
 As in mammals, two similar cascades are present in Drosophila, 
suggesting the functional conservation of the NF-κB signal transduction 
pathways throughout evolution and also providing Drosophila as a model 
organism to study NF-κB signaling system (see Figure 1.7.). Indeed, our 
understanding of NF-κB signaling cascades comes in part from studies 
in Drosophila, e.g. Toll receptor that was first identified in Drosophila 
(121-123) and its homologue was identified only thereafter in mammals 
(124, 125). While the canonical IκB kinase still remains to be identified, 
activation of the canonical pathway by Toll activation and myeloid 
differentiation primary response gene 88 (MyD88)-Tube-Pelle complex 
formation (homologues to mammalian MyD88, an adapter protein and 
IRAK, respectively) precedes Cactus (homologue to mammalian IκB) 
phosphorylation and degradation (126-128). This liberates Dorsal and 
Dif to undergo nuclear translocation leading to the up-regulation of 
antimicrobial genes such as Drosomycin (129). Contrary to mammalian 
cells, however, Toll ligand in Drosophila, Spätzle, is activated in 
response to fungi and gram-positive bacteria (82, 130). Gram-negative 
bacterial LPS, on the other hand, triggers the non-canonical Immune 
deficiency (Imd) signaling cascade, leading to the activation of 
Drosophila IκB kinase complex (IKK) and resulting in Relish activation 
(see Figure 1.7.) (83, 96, 131, 132). As for p100 and p105, proteolytic 
degradation of ankyrin repeats within the C-terminal region of Relish is 
necessary for its nuclear translocation and induction of antibacterial 
peptides including Diptericin and Defensin (133, 134). As in mammals, 
synergistic activations of two pathways in Drosophila have been recently 
revealed. Depletion of components acting on the non-canonical Imd 
pathway can interfere with the canonical Toll induced expression of 
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antimicrobial genes (135). Moreover, Relish-Dorsal and Relish-Dif 
dimers have been identified as the most potent inducers of Defensin and 
Drosomycin, respectively (136). 
 
  
 
 
 
                
 
 
 
Figure 1.7. Drosophila NF-κB signaling pathway. NF-κB family members, 
signaling pathways leading to their activation and mechanisms regulating their 
activity are evolutionary conserved. In Drosophila, canonical pathway is activated 
in response to fungi and gram-positive bacteria. Upon Toll activation by Spätzle, 
MyD88-Tube-Pelle complex formation precedes Cactus phosphorylation and 
degradation liberating Dorsal and Dif to undergo nuclear translocation leading to 
the expression of antimacrobial genes. Gram-negative bacterial infection triggers 
the non-canonical Imd pathway leading to TAK1-induced IKK activation, 
processing of Relish and its nuclear translocation. 
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2. Regulation of NF-κB transcriptional activity 
 
The complex role of NF-κB in re-programming gene transcription and 
hence the expression of numerous inflammatory mediators has been 
established (137, 138). While the specificity of these responses is known 
to be largely dependent on different types of stress and targeted tissues, 
the molecular mechanisms regulating these responses are not fully 
understood. Thus the transcriptional regulation of the inflammatory 
response is an important subject of research in many laboratories. 
Current understanding of mechanisms controlling NF-κB transcriptional 
activity will be described in this section. 
 
2.1. NF-κB dimerization 
Transcriptional response in multi-cellular eukaryotes involves the 
combinatorial action of multiple TFs and the potential of TFs to 
oligomerize serves as one mechanism controlling transcriptional activity. 
Dimeric TFs are grouped into families, which often expand with the 
organism complexity, providing a mechanism for increased diversity of 
transcriptional responses (139). As for other evolutionary conserved 
TFs, NF-κB evolved in a similar manner, from a single TF in 
demosponge and cnidarians to three members in Drosophila and five in 
mammals, acting as homo- or hetero-dimeric complexes (see Section II). 
Despite extensive research reveling the specific function of these 
dimers, their physiological role remains to be fully understood. 
 Five mammalian NF-κB members can hypothetically form up to 
fifteen homo- or hetero-dimeric complexes, contributing to the regulation 
of distinct sets of genes, in that the individual dimers have distinct 
specificities depending on the stimulus and the cell type responding to 
that particular stimulus (89). However, some NF-κB members have been 
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found exclusively in specific dimeric complexes, such as RelB that 
dimerizes only with p50 and p52 (89). Moreover, NF-κB dimers that do 
not contain TAD, i.e. p50 and p52 homo- or hetero-dimers, can act as 
transcriptional repressors (140, 141). Different dimers are preferentially 
activated by distinct NF-κB signaling cascades. Those activated via the 
canonical pathway (see Figure 1.6.) include RelA and cRel, which form 
either homodimers or heterodimers with the transcriptionally inactive 
p50. While RelA-p50 is the most abundant NF-κB dimer in the majority 
of cell types, loss of function studies using cRel deficient mice (Rel-/-) 
showed an essential role of this NF-κB member for lymphocytes function 
as well as hematopoetic cell lineages development (142). Furthermore, 
contrary to RelA-containing dimers, which are constitutively expressed in 
their non-active form, c-Rel-p50 heterodimers are constitutively active in 
B cells (143). RelA and cRel, however, can have overlapping functions, 
in that the combined lack of both RelA and cRel proteins (Rela-/-Rel-/-) 
accelerates the embryonic lethality observed with Rela-/- deficient mice  
(144) (see Section II.1.). The p50 is ubiquitously expressed and present 
in different NF-κB dimeric complexes. Surprisingly, lack of p50 protein 
(Nfkb1-/-) is tolerated during embryonic development, although these 
mice show multifocal defects in stress responses in that they are highly 
susceptible to certain microbial challenge, e.g. Streptococcus 
pneumoniae, while they respond normally, e.g. Haemophilus influenza, 
or are even more resistant to others, e.g. encephalomyocarditis virus 
(145). While RelA and c-Rel containing dimers are the major players of 
canonical pathway, non-canonical NF-κB signal transduction pathway 
leads to the activation of the major RelB-p52 heterodimers (see Figure 
1.6.), which have an essential role during the development of lymph 
nodes and B cell maturation. 
 Upon nuclear translocation, NF-κB dimers bind to the κB sites in 
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the promoter region of NF-κB-dependent genes, where the conventional 
binding sequence is represented as KGGRHTYYCC (where K= G or T, 
H= not G, R= purine, Y= pyrimidine). While most κB sites have a similar 
affinity for different NF-κB dimers, selective κB sites have been identified 
for specific dimers, i.e. RGGAGAYTTR site found in the promoter 
regions of specific genes, i.e. the chemokines CXCL13 and CCL19 
regulated by RelB-p52 upon activation of non-canonical NF-κB signaling 
pathway (146). Moreover, c-Rel-RelA heterodimers have been shown to 
preferentially bind to the consensus sequence, HGGARNYYCC (where 
N indicates any base), which differs from the κB consensus established 
for binding RelA-p50 (GGGRNNYYCC) (147). 
 
2.2. NF-κB-IκB interaction 
The canonical and best-characterized member of IκB family is IκBα, 
which under homeostatic conditions binds to the RelA-containing NF-κB 
dimers such as RelA-p50. As the other members of the IκB family, IκBα 
contains multiple ankyrin repeats within its C-terminal region, which 
mask the NLS of RelA, thus restraining its DNA binding and 
transcriptional activity (see Figure 1.8.). Contrary to RelA, IκBα does not 
mask the NLS of p50, which together with the nuclear export sequence 
(NES) of IκBα promotes constant RelA-p50-IκBα shuttling between the 
cytoplasm and the nucleus (148). Induction of IκBα phosphorylation and 
its subsequent degradation in response to a variety of stimuli is required 
for NF-κB nuclear localization, DNA binding and initiation of gene 
transcription (149). On the other hand, RelA-dependent IκBα re-
synthesis is essential for timely termination of NF-κB transcriptional 
activity (150, 151). While not bearing a traditional NLS, IκBα contains a 
cis-acting nuclear import sequence within its C-terminal domain that 
promotes nuclear translocation, association with the promoter bound 
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RelA and termination of the transcriptional response (152). Given the 
diversity of physiological responses controlled by NF-κB, it is not 
surprising that ablation of IκBα and hence increased and sustained NF-
κB activity is detrimental. Indeed, mice deficient in IκBα (Nfkbia-/-) have 
enhanced expression of proinflammatory mediators and die within 7-10 
days of birth with severe inflammatory dermatitis (153).  
 The canonical IκB family consists of additional proteins, including 
IκBβ and IκBε (see Figure 1.8.). Unlike IκBα, IκBβ phosphorylation 
regulates its ability to sequester NF-κB dimers in the cytoplasm (154). 
While phosphorylated IκBβ binds to NF-κB dimers and masks their NLS 
thus interfering with nuclear translocation and DNA binding, 
dephosphorylated IκBβ can bind NF-κB without interfering with DNA 
binding. As such, binding of dephosphorylated IκBβ can prevent IκBα 
binding and consequent nuclear export of RelA, thus promoting 
Figure 1.8. The IκB family of NF-κB inhibitory proteins. IκB family of proteins 
consists of canonical members i.e. IkBα, IkBβ and IkBε, precursor NF-κB members, i.e. 
p100 and p105, and two atypical members, i.e. IkBζ and Bcl-3. All IκB members contain 
multiple ankyrin repeats within their C-terminal region, whose degradation is a 
prerequest for NF-κB transcriptional activity. Bcl-3 contains a TAD, capable of driving 
NF-κB-dependent transcription. Adopted and modified from (86). 
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persistent NF-κB transcriptional activity (155). On the other hand, IκBε 
contains a NES, can bind RelA and remove it from the promoter region 
of NF-κB-dependent genes, thus providing an additional negative 
feedback loop regulating NF-κB activity (156). Delayed kinetics of IκBβ 
and IκBε degradation and RelA-dependent re-synthesis of these IκB 
isoforms is probably the major functional characteristic determining 
these IκB members, suggesting their role in the late phase of the NF-κB-
dependent transcription (157, 158). This is suggested by the observation 
that replacing IκBα coding region with that of IκBβ, results in normal 
kinetics of NF-κB activation and termination (159). 
 The precursor NF-κB members p100 and p105, termed IκBδ and 
IκBγ, respectively, function both as NF-κB members as well as their 
inhibitors (see Figures 1.5. and 1.8.) (89). Cleavage of p100 and p105 
leads to the production of nuclear NF-κB member p52 and p50, 
respectively (160-164). Both p100 and p105 can bind other NF-κB 
members, inhibiting their transcriptional activity (165, 166). Expression of 
p100 is associated primarily with RelB, stabilizing and sequestering 
RelB-containing dimers in the cytoplasm (167). Processing of p100 
following stimulation, releases RelB-p52 dimers leading to their nuclear 
translocation (see Figure 1.6.) (114). RelA-dependent transcription and 
subsequent expression of p100 can also bind and inhibit the 
transcriptional activity of RelA-p50 heterodimers, contributing to the 
termination of NF-κB driven transcription (119). Constitutive processing 
of p105, on the other hand, results in the production of p50, the main 
partner of RelA-containing dimers (168). In addition, p105 can bind other 
NF-κB dimers suggesting its role as a general inhibitor of NF-κB 
transcriptional activity (165). 
 The IκB family of proteins contains two additional atypical 
members, namely IκBζ and Bcl-3, which can bind NF-κB and regulate its 
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transcriptional activity (see Figure 1.8.). Expression of IκBζ and Bcl-3 is 
restricted to the nucleus and it remains unclear how these proteins 
regulate NF-κB transcriptional activity. Both IκBζ and Bcl-3 associate 
preferentially with p50 or p52 homo- or hetero-dimers enhancing NF-κB 
activity (169, 170). Bcl-3 contains a TAD, providing a transcriptional 
activity to otherwise repressors of NF-κB-dependent transcription (171). 
On the other hand, IκBζ does not contain an apparent TAD, but has 
been suggested to induce gene transcription, i.e. Il6, in response to 
stimuli such as IL-1 or LPS (169). Alternatively, binding of IκBζ and Bcl-3 
to p50 or p52 homo- or hetero-dimers could help replacing these dimers 
with the transcriptionally active NF-κB members on the promoter regions 
of NF-κB-dependent genes (169). 
 
2.3. NF-κB post-translational modifications 
 While NF-κB dimerization and binding to IκBs serve as central 
components controlling its transcriptional activity (see Sections II.2.1. 
and II.2.2.), these regulatory mechanisms cannot explain alone the wide 
range of specificity provided by the NF-κB system (172). One of the 
mechanisms via which this is achieved is through post-translational 
modification of different NF-κB family members. These comprise 
covalent modifications of amino acids, providing a general mechanism 
increasing protein functional diversity (173). It is often the combinatorial 
usage and competition between distinct post-translational modifications 
of an individual protein that offer the potential for specificity. Some of the 
most common post-translational modifications include phosphorylation, 
acylation, e.g. acetylation and ubiquitination, alkylation, e.g. methylation, 
glycosylation and oxidation (174). All of these can influence protein 
structure and function by various ways, modulating protein interaction 
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with other partners including proteins, lipids or DNA.  
 In the context of NF-κB system, post-translational modifications 
can alter the activity of various core components of NF-κB signaling 
pathway, e.g. phosphorylation of IκB promotes its ubiquitination and 
proteolytic degradation. While post-translational modifications can target 
RelA directly, regulating its transcriptional activity (175, 176), the 
physiological relevance underlying these modifications remains largely 
unknown. The biological significance of RelA post-translational 
modifications is however strongly supported by the fact that these can 
regulate the transcriptional activity of Drosophila Rel protein Dorsal, 
targeting evolutionary conserved amino acid residues (177). The 
biological role of RelA post-translational modifications will be addressed 
in more details below. 
 
2.3.1. RelA phosphorylation 
Phosphorylation remains probably the best characterized of all post-
translational modifications (178). It consists essentially on the addition of 
a negatively charged phosphate group usually on a serine (S), threonine 
(T) or tyrosine (Y) residues via the activity of protein kinases (173). This 
induces conformational changes of proteins, often exposing the hidden 
hydrophobic domains for the interaction with other partners, including 
proteins, lipids or DNA. The same is true for RelA for which several 
protein kinases have been shown to target specific phospho-acceptors 
within its RHD as well as TAD, activating or repressing its transcriptional 
activity (see Figure 1.9.) (175). The first to be identified, i.e. S276, is 
targeted by protein kinase A (PKA), regulating RelA transcriptional 
activity (179, 180). Phosphorylation of S276 promotes conformational 
modifications of RelA inducing its interaction with the transcriptional co-
activators such as cyclic AMP-responsive element binding protein 
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(CREB)-binding protein (CBP)/p300 (181), while diminishing binding of 
transcriptional co-repressor histone deacetylase HDAC1 (182). The 
physiological relevance of RelA S276 phosphorylation is illustrated by 
the finding that mice expressing the constitutively active form of RelA, 
mimicked by S276D mutation, display systemic increase in 
proinflammatory cytokines and chemokines induced by TNF signaling 
succumbing to hyperinflammatory conditions within 8-20 days of birth 
(183). Generation of mice expressing the hypophosphorylated RelA, 
mimicked by S276A point mutation, however, revealed a rather complex 
role of RelA S276 phosphorylation in regulating gene transcription (184). 
Contrary to the RelA deficient mice (Rela-/-) that die from massive 
         
 
Figure 1.9. RelA phosphorylation. Schematic representation of various known 
kinases and phosphatases regulating RelA transcriptional activity via modulation 
of its phosphorylation on different serine and threonine residues. Phosphorylation 
that promotes RelA transcriptional activity is represented in green, while that 
inhibiting its activity in red. S468 phosphorylation has been shown to both 
promote and inhibit RelA transcriptional activity in the context-dependent manner. 
PKA, protein kinase A; MSK1, mitogen- and stress-activated protein kinase-1; 
PKCz, protein kinase Cζ; IKK, IκB kinase; GSK3b, glycogen-synthase kinase-3β; 
Chk1, checkpoint kinase 1; CKII, casein kinase II; TBK1, TANK binding kinase; 
RSK1, ribosomalsubunit kinase-1; PP protein phosphatase; WIP1, wild-type p53-
induced phosphatase. 
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hepatocyte PCD during the embryonic development (see Section II.1.), 
mice expressing RelA S276A mutant die from multifaceted 
developmental abnormalities. This can be explained to some extent by 
the recruitment of the transcriptional co-repressor HDAC to the promoter 
region of some NF-κB-dependent genes, repressing the transcription of 
subset of genes surrounding putative NF-κB sites (184). 
 RelA interaction with CBP/p300 can occur in response to RelA 
phosphorylation by several kinases, including PKA, mitogen- and stress-
activated kinase-1 (MSK1), IKK and protein kinase C (PKC) ζ, which 
phosphorylate specific RelA residues, e.g. S276, S311, S536 (see 
Figure 1.9.) (185-188). The existence of distinct pathways targeting 
different RelA phospho-acceptors and providing a similar biological 
outcome, i.e. enhanced gene transcription, argues strongly for the 
biological relevance of this post-translational modification in the 
regulation of NF-κB transcriptional activity. In keeping with this notion, 
regulation of NF-κB activity by phosphorylation also occurs in Drosophila 
in which the PKA homologue, i.e. DmPKA, phosphorylates the RelA 
homologue Dorsal on conserved S276 site, i.e. Dorsal S312, controlling 
its nuclear translocation (177, 189). 
 Other than interaction with transcriptional cofactors, RelA 
phosphorylation can also promote other RelA post-translational 
modifications, i.e. acetylation, methylation and ubiquitination, as well as 
modulate its nuclear translocation, DNA binding and stability (176). For 
example, RelA S468 phosphorylation by IKKε promotes RelA 
translocation to specific subnuclear compartments (see Section II.2.5.), 
decreasing its transcriptional activity (190). RelA S468 phosphorylation 
can also promote RelA ubiquitination by the copper metabolism MURR1 
(COMM) domain-containing protein (COMMD1) leading to RelA 
proteasomal degradation and decrease of NF-κB transcriptional activity 
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(191). In addition, RelA S536 phosphorylation by ribosomal protein S6 
kinase polypeptide 1 (RSK1) or TANK-binding kinase 1 (TBK1) 
diminishes RelA affinity for IκBα, thus increasing its DNA binding (192).  
 While the phosphorylation status of RelA results from opposing 
actions of kinases and phosphatases, little is known about how 
dephosphorylation regulates RelA transcriptional activity. While two 
phosphatases, i.e. protein phosphatase 2A (PP2A) and wild-type p53-
induced phosphatase 1 (WIP1), can dephosphorylate RelA S536, 
decreasing its transcriptional activity (193), RelA S435 
dephosphorylation by phosphatase 4 increases its transcriptional activity 
(194). Identification of novel phosphatases as well as specific 
mechanisms underlying their activity will be therefore needed to fully 
understand the effect of reversible RelA phosphorylation on the 
expression of distinct gene profiles. 
 
2.3.2. RelA acetylation 
Acetylation, initially discovered on histones, consists on the addition of 
an acetyl group to the amino-terminal residues or to the ε-amino group of 
lysine (K) residues on proteins (173). By neutralizing the positively 
charged protein region, acetylation regulates multiple functions of 
proteins including DNA binding, interaction with other proteins, 
subcellular localization and stability (195). The acetylation status of 
proteins results from the opposing action of histone acetyltransferases 
(HATs) and HDAC, enzymes that catalyze the addition and removal of 
an acetyl group, respectively. Alike several other TFs, RelA acetylation 
controls its transcriptional activity. It took couple of years to identify the 
inducible acetylation of RelA by CBP since their interaction was first 
established (196, 197). CBP/p300 is to date the best characterized RelA 
acetyltransferase in that it can acetylate seven different RelA K residues 
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(see Figure 1.10.) (176). Some of these are also acetylated by the 
p300/CBP-associated factor (P/CAF) (198). Acetylation is mostly a 
nuclear event (176), controlling RelA transcriptional activity as well as 
the duration of NF-κB activation via regulation of DNA binding and 
association with IκBα. While K310, K314 and K315 acetylation enhances 
RelA transcriptional activity without affecting DNA binding (199, 200), 
K218 and K221 acetylation increases NF-κB transcriptional activity, 
inhibiting its removal from DNA by newly synthesized IκBα (199). In 
contrast, K122 and K123 acetylation reduce RelA transcriptional activity 
by decreasing DNA binding in an IκBα-independent manner (198). 
HDAC3 is the best-characterized RelA deacetylase, regulating its 
transcriptional activity by targeting RelA K122, K123, K221 and K310 
         
 
 
Figure 1.10. RelA acetylation. Schematic representation of known acetyl 
transferases and deacetylases regulating RelA transcriptional activity via 
modulation of its acetylation on different lysine (K) residues. Acetylation that 
promotes RelA transcriptional activity is represented in green, while that inhibiting 
its activity in red. pCAF, p300/CBP-associated factor; CBP, CREB-binding 
protein; HDAC, histone deacetilase; SIRT, sirtuin. 
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(197, 198). Three other deacetylases, i.e. HDAC1, sirtuin 1 (SIRT1) and 
SIRT2, have been shown to deacetylate K310, decreasing RelA 
transcriptional activity (201, 202). Overall, these findings suggest that 
acetylation is important in regulating duration of RelA transcriptional 
activity and future studies will be needed to reveal physiological 
implications of RelA acetylation in maintaining homeostasis.  
 
2.3.3. RelA methylation 
The ε-amino group of protein K residues can also undergo, in addition 
from acetylation, mono-, di- and tri-methylation, a process that consists 
on the addition of methyl groups increasing protein hydrophobicity and 
disrupting intra- or intermolecular hydrogen-bond interactions or creating 
new protein binding sites (173). RelA can undergo methylation by 
different histone lysine methyltransferases (HKMTs) that influence RelA 
interaction with transcriptional cofactors (see Figure 1.11.). For example, 
under the homeostasis, RelA K310 is monomethylated by suppressor of 
variegation-enhancer of zeste-trithorax (SET) domain containing protein 
6 (SETD6). This promotes RelA interaction with the transcriptional co-
repressor histone methylase G9A-like protein (GLP), which can 
methylate histone H3 Lys9, repressing gene transcription on a subset of 
NF-κB-dependent genes (203). In addition, RelA methylation can 
promote other post-translational modifications, as illustrated for RelA 
K314 and K315 mono-methylation mediated by SET domain HKMT 9 
(Set9) that promotes RelA ubiquitination and proteasomal degradation 
thus decreasing NF-κB dependent transcription (204). RelA methylation 
can also promote NF-κB transcriptional activity, e.g. K218 and K221 
methylation by nuclear receptor-binding SET domain-containing protein 
1 (NSD1) (205). While RelA methylation status results from the opposing 
effect of HKMT and histone lysine demethylases (HKDM), only one 
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HKDM has been identified to date, i.e. F-box and leucine-rich repeat 
protein 11 (FBXL11) that demethylates RelA K218 and K221, decreasing 
cell proliferation and colony formation of HT29 cancer cells (205). 
Further experiments will be needed to identify specific demethylases for 
different K residues providing new insights into the regulation of NF-κB 
by reversible methylation.  
 
2.3.4. RelA ubiquitination 
Ubiquitination consists on the addition of ubiquitin to a side chain of a 
protein K residue via a tree step process: i) ubiquitin activation by an 
ubiquitin-activating enzyme (known as E1), ii) transfer of activated 
ubiquitin to the ubiquitin conjugating enzyme (known as E2) and iii) 
         
 
 
Figure 1.10. RelA methylation. Schematic representation of various known 
methyltransferases and demethylases regulating RelA transcriptional activity via 
modulation of its methylation on different lysine residues. Methylation that 
promotes RelA transcriptional activity is represented in green, while that inhibiting 
its activity in red. SETD, suppressor of variegation-enhancer of zeste-trithorax 
domain containing protein; NSD1, nuclear receptor-binding SET domain-
containing protein 1; FBXL11, F-box and leucine-rich repeat protein 11. 
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transfer of ubiquitin from E2 to a K residue in the target protein, 
mediated by an ubiquitin-protein ligase (known as E3) (206). Mono- or 
poly-ubiquitination regulates vast array of cellular functions some of 
which via modulation of NF-κB activity (207). IκB ubiquitination and 
subsequent proteasomal degradation has been long known to control 
NF-κB nuclear translocation and activation (see Section II.2.2.). 
Ubiquitination can also directly target RelA (see Figure 1.12.), first 
illustrated for the ubiquitin ligase suppressor of cytokine signaling 1 
(SOCS1), leading to its degradation and contributing to termination of 
NF-κB transcriptional activity (208, 209). While initially associated with 
protein degradation via the 26S proteasome, RelA ubiquitination can 
induce its lysosomal degradation as well (210). Moreover, RelA 
ubiquitination and degradation are often associated with its trafficking to 
specific insoluble nuclear compartments such as shown for RelA 
translocation into promyelocytic leukemia (PML) nuclear bodies 
 
 
         
 
 
 
Figure 1.12. RelA ubiquitination. Schematic representation of the identified 
lysine residues undergoing ubiquitination as well as four known ubiquitin ligases 
that regulating RelA transcriptional activity via modulation of its ubiquitination. 
COMMD, copper metabolism MURR1 domain-containing protein; PDLIM, protein 
containing postsynaptic density 65-disc large-zonula occludens 1 (PDZ) and 
abnormal cell lineage 11-islet 1-mechanosensory abnormal 3 (LIM) domains; 
SOCS, suppressor of cytokine signaling; TRAF, TNF receptor associated factor. 
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mediated by the ubiquitin ligase PDLIM2, a nuclear protein containing 
postsynaptic density 65-disc large-zonula occludens 1 (PDZ) and 
abnormal cell lineage 11-islet 1-mechanosensory abnormal 3 (LIM) 
domains (see Section II.2.5.) (211). Ubiquitination of Rel proteins seems 
to be an evolutionary conserved mechanism regulating NF-κB activity. In 
keeping with this notion, loss of function of SkpA-containing ubiquitin 
ligase complex in Drosophila results in the increased expression of 
Drosophila NF-κB member Relish and hence higher expression of its 
target antimicrobial gene Diptericin (134). Non-degradative forms of 
RelA ubiquitination have also been identified, suggesting a regulatory 
role for ubiquitination independently of proteolysis (212). 
 
2.4. NF-κB-DNA binding 
Eukaryotic genes are tightly embedded around histones forming 
complex and dynamic structures known as chromatin, which in its default 
state may limit TF accessibility to promoters, thus acting as a 
transcriptional barrier regulating gene expression (213, 214). Changes in 
chromatin structure are therefore often required to increase promoter 
access for TF as well as components of the basic transcriptional 
machinery allowing the initiation of transcription. These include 
chromatin remodeling as well as reversible histone tail post-translational 
modifications, such as provided upon phosphorylation, acetylation, 
methylation and ubiquitination (215). With regard to promoter 
recruitment, there seem to be two kinds of NF-κB-dependent genes: 
those that are readily accessible and those that require chromatin 
remodeling (216). NF-κB phosphorylation induces conformational 
changes allowing its interaction with a transcriptional activator HAT 
CBP/p300, which can acetylate histone tails, a critical step required for 
the expression of a subset of NF-κB target genes (181, 217-219). 
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Besides CBP/p300, NF-κB can recruit other HATs as well as HDACs, 
such as P/CAF and HDAC1, respectively, regulating the accessibility of 
chromatin for transcriptional machinery (182, 220). As discussed above, 
opposing action of HATs and HDACs also regulate the strength and 
duration of the NF-κB transcriptional response, influencing its DNA 
binding as well as its interaction with IκBα (see Section II.2.3.2.). 
Besides acetylation, histones can undergo other post-translational 
modifications such as phosphorylation, influencing the promoter 
accessibility for TF and components of the transcriptional machinery in a 
similar way as histone acetylation (221). Activation of IKKα in response 
to TNF leads to its recruitment to the promoter of some NF-κB 
dependent genes in a complex with CBP and RelA, leading to histone 
phosphorylation (222, 223). Two other kinases, i.e. PKA and MSK1, 
which also regulate NF-κB transcriptional activity (see Section II.2.3.1.), 
can mediate histone phosphorylation in response to different stimuli 
(224, 225). Thus the combined effect of NF-κB and histones post-
translational modifications is probably needed for a stimulus specific 
pattern of gene expression (226). 
 
2.5. NF-κB subnuclear compartmentalization 
Cell nucleus comprises a heterogeneous group of complex and highly 
dynamic subnuclear compartments collectively known as nuclear bodies 
(227). Other than chromosomes and nucleoli, these include Cajal 
bodies, splicing factor compartments (i.e. speckles), PML bodies and 
many others that are often associated with specific gene loci regulating 
replication and transcription. As such, the nucleoli are constitutively 
associated with genes encoding 35S ribosomal (r)RNA and are involved 
in rRNA transcription, processing and ribosomal subunit assembly (228). 
On the other hand, Cajal bodies, speckles and PML bodies are only 
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transiently associated with specific genomic loci and are involved in 
biogenesis of small nuclear ribonucleoproteins, storage of splicing 
factors and control of transcription, respectively (229-231). Translocation 
of TFs, including NF-κB, to different nuclear bodies is now recognized as 
a mechanism controlling TF access to gene promoters, regulating gene 
transcription (232). Protein post-translational modifications such as 
ubiquitination is emerging as an important mechanism regulating TF 
subcellular localization, including for RelA (see Figure 1.13.), whose 
              
 
Figure 1.12. RelA subnuclear compartmentalization. In response to stress, 
anti-inflammatory drugs and proteasome inhibition, COMMD1-mediated RelA 
ubiquitination precedes its nucleolar translocation. Upon LPS stimulation, RelA 
undergoes PDLIM2-mediated ubiquitination and translocation to promyelocytic 
leukemia protein (PML) nuclear bodies. TRAF7 mediated RelA ubiquitination and 
IKKε-mediated RelA phosphorylation lead to RelA translocation to nuclear 
punctuated structures. 
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translocation and sequestration in the nucleoli induced by stress, anti-
inflammatory drugs and proteasome inhibition can result in down-
regulation of NF-κB-dependent transcription and cell apoptosis (233-
235). On the other hand, RelA ubiquitination and proteasomal 
degradation involved in the termination of NF-κB transcriptional activity 
can occur in PML nuclear bodies (211). Several other proteins involved 
in NF-κB-dependent transcription (e.g. CBP/p300, IKKε) can also be 
sequestered in PML nuclear bodies (190, 236), suggesting that nuclear 
bodies may enable the fine control of NF-κB transcriptional activity in the 
nucleus presumably independently of RelA degradation. 
 
3. Identification of NF-κB regulatory proteins by RNA interference 
screening 
 
RNA interference (RNAi) has emerged as an efficient method to 
suppress gene expression specifically, thus allowing the assessment of 
gene function. Although RNAi gene screens came into common use 
there are still significant technical challenges that devoid this approach 
to be commonly used in mammalian cells. This is not the case for 
Drosophila cells, which incorporate double stranded RNA (dsRNA) with 
nearly 100% efficiency, acting as a potent RNAi. Sequencing of 
Drosophila genome (237) and generation of dsRNA libraries targeting all 
Drosophila genes individually (238) allows functional screen of large sets 
of genes in Drosophila cells. Various Drosophila and human genes as 
well as signal transduction pathways are evolutionary conserved and 
around 60% of genes involved in human diseases have a homologue in 
Drosophila (239). Major components of the NF-κB signal transduction 
pathway and mechanisms controlling NF-κB transcriptional activity are 
also conserved between Drosophila and mammalian cells (see Sections 
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II. and II.1.).  Gene screens in Drosophila cells have been used 
successfully to identify several evolutionary conserved processes 
regulating NF-κB activity, e.g. the involvement of G protein-coupled 
receptor kinase 2 (Gprk2) (mammalian G protein-coupled receptor 
kinase 5, GRK5), a Cactus (mammalian IκB homologue) interacting 
protein (240) as well as Defense repressor 1 (Dnr1) (mammalian 
inhibitor of apoptosis protein, IAP) (241) in the regulation of Drosophila 
NF-κB activity. Using this approach, we identified CCT as an 
evolutionary conserved regulator of NF-κB activity (see Chapter II). 
 
3.1. Chaperonin containing TCP-1 (CCT) 
 
Chaperonins are one of the major classes of folding-assisting proteins 
found in all living organisms being essential for organism viability. There 
are two structurally distinct groups of chaperonins: group I chaperonins, 
such as Escherichia coli GroEL, which are found in prokaryotic cells and 
endosymbiotic organelles, and group II chaperonins, such as CCT, 
found in Archea and eukaryotic cells (242). CCT is a ubiquitously 
expressed multimeric protein complex involved in protein folding as well 
as assembly of protein complexes in an ATP-dependent manner. It 
consists of eight subunits (CCTα-θ) that share domains and amino acid 
sequences conserved across species (243-245). Though originally 
described as a cytosolic protein involved in actin and tubulin folding 
(246, 247), a range of non-cytoskeletal CCT substrates have now been 
identified (248). These include von Hippel-Lin (VHL)-elongin BC tumor 
suppressor complex (249), cell-division cycle protein 20 (Cdc20) (250), 
sphingosine kinase 1 (251), Polo-like kinase 1 (PLK-1) (252), HDAC3 
(253), huntingtin (254), cyclin E (255). This supports the notion that CCT 
is involved in various cellular functions such as cell cycle, transcription, 
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chromatin remodeling and protein degradation. Recessive mutation in 
CCTδ subunit results in sensory neuropathy (256), while point mutations 
in the CCT-binding site of the VHL, leading to its severe protein 
misfolding are found in the renal cell cancer (249). While not directly 
implicated in controlling NF-κB activity, CCT is required for HDAC3 
activity that plays a critical role in NF-κB-dependent transcription (253). 
Moreover, other CCT substrates, such as VHL and PLK-1, have also 
been shown to regulate NF-κB transcriptional activity (257, 258). This 
supports the hypothesis that CCT might regulate NF-κB activity, which 
we found to be the case (see Chapter II). 
 
III. Objectives 
 
The overall goal of this work was to provide a novel insight into the 
regulatory mechanisms controlling NF-κB transcriptional activity.  More 
specifically, we have focused on: 
 
1. Identifying evolutionary conserved genes regulating RelA 
transcriptional activity using an RNAi based gene screen in Drosophila 
cells. 
 
2. Characterizing the crosstalk between different mechanisms regulating 
RelA transcriptional activity, i.e. RelA phosphorylaton and its subnuclear 
localization.  
 
3. Determining whether stress responsive genes that play a central role 
in the control of inflammatory responses regulate NF-κB transcriptional 
activity. 
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I. Summary 
 
The nuclear factor kappa B (NF-κB) family of transcription factors (TF) is 
central to inflammation and immunity. Post-translational modifications of 
the NF-κB p65/RelA family member regulate its transcriptional activity. 
The purpose of this study was to identify and characterize evolutionary 
conserved genes modulating p65/RelA activity. We identified chaperonin 
containing TCP1 subunit η (CCTη) as a regulator of the transcriptional 
activity of Drosophila Rel proteins, Dorsal and Dorsal-related immunity 
factor (Dif), using a RNA interference screening approach. CCTη was 
also found to regulate NF-κB-driven transcription in mammalian cells, 
acting in a promoter-specific context, downstream of IκB kinase (IKK). 
CCTη knockdown repressed IκBα and CXCL2/MIP2 transcription during 
the early phase of NF-κB activation while impairing the termination of 
CCL5/RANTES and CXCL10/IP10 transcription, the later effect being 
associated with increased DNA binding and reduced p65/RelA 
acetylation. We identified lysine (K) 122 and K123 as the target residues 
mediating the CCTη-driven p65/RelA regulation. Finally, CCTη was 
found to enhance cyclic AMP-responsive element binding protein 
(CREB)-binding protein (CBP) activity, probably facilitating NF-κB 
removal from DNA and hence terminating NF-κB activity. We propose 
that CCTη regulates NF-κB activity in a manner that resolves 
inflammation. 
 
II. Background 
 
The NF-κB family of eukaryotic TF controls the expression of a large 
number of genes regulating inflammation and immunity as well as 
developmental processes including cellular growth and apoptosis (259). 
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Unfettered NF-κB activation has been associated with the pathogenesis 
of a number of inflammatory diseases (84). In their active form, NF-κB 
proteins are nuclear homo- or hetero-dimeric complexes composed of 
p65/RelA, RelB, cRel, p105/p50, and p100/p52. The prototypical and 
most ubiquitously expressed NF-κB dimer is composed of p50 and p65 
subunits where p65 is the main transcriptional activator (260).  
Under homeostatic conditions, p65 activity is constitutively 
repressed by its interaction with the cytoplasmic NF-κB inhibitors (IκB) 
(261). While inducible degradation of IκB molecules is a central 
mechanism regulating p65 transcriptional activity, post-translational 
modifications also regulate its activity (175, 176). These include 
phosphorylation, which modulates DNA binding, interactions with other 
proteins as well as p65 stability (175). Phosphorylation often precedes 
other post-translational modifications such as acetylation and 
ubiquitination (181, 187, 191, 208). For example, p65 phosphorylation at 
serine (S) 276 facilitates interaction with CBP/p300 and diminishes 
histone deacetylase 1 (HDAC1) binding leading to p65 acetylation (182). 
Acetylation is mostly a nuclear event (176), controlling p65 
transcriptional activity (197, 199, 200, 262) as well as the duration of NF-
κB activation via regulation of DNA binding (198, 199) and association 
with IκBα (199). Specific p65 K residues may be preferentially targeted 
by different histone acetyltransferases (HAT) that include CBP, p300 and 
p300/CBP-associated factor (P/CAF) (198-200). The acetylation status 
of p65 is controlled by the opposing activities of HATs and HDACs 
including HDAC1 (201), HDAC3 (197, 198), sirtuin 1 (SIRT1) (263), and 
SIRT2 (202). Beside acetylation, p65 K residues can be modified by 
methylation and ubiquitination resulting in altered transcriptional activity 
or proteasomal degradation (204, 209, 211, 264, 265). 
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 Rel proteins and the signal transduction pathways leading to their 
activation are highly evolutionary conserved. As in mammals, Drosophila 
p65 homologues Dorsal and Dif are constitutively inhibited by the IκB 
like molecule Cactus (94), (266). Toll receptor activation leads to Cactus 
degradation, Dorsal and Dif nuclear translocation and transcription of 
NF-κB dependent genes such as Drosomycin and Cecropin (82, 267, 
268). Little is known about the impact of post-translational modifications 
on Dorsal and Dif transcriptional activity. Yet, several phospho-acceptors 
as well as K residues targeted for post-translational modifications in p65 
are conserved in Dorsal and Dif. Supporting this view, S312 and S317 
phosphorylation can control Dorsal nuclear translocation (177, 189).  
 We set to identify evolutionary conserved genes regulating 
NF-κB-dependent gene transcription using a functional RNA interference 
(RNAi) based gene screen in Drosophila cells. We reveal the CCTη as a 
novel gene regulating NF-κB acetylation and activity. 
 
III. Results 
 
1. Inhibition of Tcp-1/CCTη  expression modulates NF-κB-
dependent reporter activity 
To identify evolutionary conserved genes regulating NF-κB pathway, we 
employed a dsRNA library targeting 265 putative Drosophila kinases and 
kinase regulatory proteins. Drosomycin-driven luciferase (Drs-luc) 
expression can be induced by a constitutively active form of Toll (Toll 
10b) as well as by Drosophila p65 homologues Dorsal and Dif (135, 
269). Drs-luc expression increased significantly in Drosophila S2 cells 
co-transfected with Toll 10b, Dorsal or Dif, as compared to cells 
transfected with Drs-luc alone (see Figure 2.1.a). We used the same 
assay to perform a RNA interference (RNAi) based gene screen in S2 
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Figure 2.1. Identification of Tcp-1/CCTη  as a novel gene regulating NF-κB 
transcriptional activity. (a) S2 cells were transiently co-transfected with the Drs-
luc reporter plus or minus Dorsal, Dif or Toll 10b and exposed to LacZ dsRNA. 
Illustrated data represent mean firefly luciferase normalized to Renilla luciferase 
units ± SEM (n≥11 derived from four independent experiments) (b) S2 cells were 
transiently co-transfected with the Drs-luc reporter plus Toll 10b and seeded into 
wells of a 384-well plate containing 265 Drosophila kinases and kinase regulatory 
subunits. Firefly and Renilla luciferase values from two independent experimental 
plates were plotted. Control wells not containing dsRNA are illustrated with light 
gray diamonds. (c) S2 cells were transiently co-transfected as in (a) and exposed 
to Tcp-1η or LacZ dsRNA. Illustrated data represent mean firefly luciferase 
normalized to Renilla luciferase units ± SEM (n=9, derived from three independent 
experiments). (d) HEK293 cells were transiently transfected with κB-luc reporter 
together with CCTη or scrambled shRNA, incubated for three days and stimulated 
with TNF (10 ng/ml, 6 h) or left untreated (control). Results shown are mean firefly 
luciferasenormalized to β-galactosidase units ± SEM (n≥7, derived from three 
independent experiments). 
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cells transiently transfected with Drs-luc reporter, Toll 10b expression 
construct and a constitutively active pAct5-Renilla reporter. Firefly and 
Renilla luciferase values were plotted and dsRNA treatments that 
significantly modulated firefly luciferase expression (values lying outside 
the mean ± 2SD) with no effect on Renilla luciferase values were further 
validated (see Figure 2.1.b). We identified chaperonin containing Tcp-1 
subunit eta (Tcp-1η), an evolutionary conserved gene not previously 
implicated in regulation of NF-κB signaling. We confirmed that Tcp-1η 
regulates NF-κB activity in a reporter assay in S2 cells. Tcp-1η dsRNA 
inhibited Toll 10b-, Dorsal- and Dif-induced Drs-luc expression, as 
compared to control LacZ dsRNA (see Figure 2.1.c). 
 The mammalian Tcp-1η homologue, CCTη (CCT7), is a member 
of the type II chaperonins. To investigate whether CCTη controls 
mammalian NF-κB signal transduction pathway we assessed its effect 
on TNF-induced NF-κB reporter activity. HEK293 cells were transiently 
co-transfected with a κB-luc reporter and CCTη shRNA or scrambled 
shRNA as a control. In contrast to S2 cells, CCTη knockdown in 
mammalian cells enhanced TNF-driven reporter activity, as compared to 
scrambled shRNA transfected controls (see Figure 2.1.d). The same 
result was observed when two other CCT subunits, CCTα (TCP1) and 
CCTζ (CCT6A), were targeted by shRNA (data not shown), suggesting 
the involvement of the intact chaperonin CCT complex in the regulation 
of NF-κB activity in mammalian cells. 
 
2. CCTη  modulates NF-κB-dependent gene expression 
The canonical NF-κB signal transduction pathway can be activated via 
different receptors, including tumor necrosis factor receptor (TNFR) and 
the Interleukin-1 receptor (IL-1R) that elicit signal transduction pathways 
converging at the level of the IKK complex (270). To assess whether 
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CCTη regulates both the TNFR and IL-1R pathways we analyzed mRNA 
expression of NF-κB target genes by quantitative RT-PCR in HeLa cells 
transfected with CCTη or scrambled siRNA. We found that CCTη affects 
NF-κB-dependent gene expression in a promoter-specific context. 
                         
 
Figure 2.2. CCTη modulates TNF and IL-1β-induced gene expression in a 
promoter specific way. HeLa cells were exposed to CCTη or scrambled siRNA 
for three days and stimulated with (a) TNF (10 ng/ml) or (b) IL-1β (10 ng/ml) for 
indicated times. mRNA levels were analyzed by qPCR as described under 
“Materials and Methods”. Data represent mean relative mRNA levels ± SEM 
(n≥3). 
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Whereas IκBα and CXCL2 mRNA expression was reduced at 1 h after 
TNF stimulation in CCTη siRNA transfected cells, expression of TNF, IL-
8, CXCL10 and CCL5 mRNA increased at 3 and/or 16h after TNF 
stimulation, as compared to scrambled siRNA transfected controls (see 
Figure 2.2.a). Similarly to TNF stimulation, CCTη knockdown led to an 
increase of IL-8 and CXCL10 mRNA expression 3 and 16 h after IL-1β 
addition (see Figure 2.2.b). This suggests the involvement of CCTη in 
initiation as well as termination of NF-κB-driven transcription, revealing a 
multi-faced role in regulating NF-κB-dependent genes, possibly acting 
downstream of IKKs. 
 
3. CCTη  regulates NF-κB-DNA binding 
Proteolytic IκB degradation is required for NF-κB nuclear translocation, 
binding to the κB enhancer and transcription initiation (175). In addition, 
NF-κB-dependent IκBα re-synthesis is critical for termination of NF-κB 
signaling pathway (150, 151). Thus, we investigated whether CCTη 
modulates IκBα protein expression. CCTη knockdown had no apparent 
impact on TNF-induced IκBα degradation, as compared to scrambled 
siRNA transfected cells (see Figure 2.3.a). In accordance, cytoplasmic 
and nuclear p65 and p50 protein levels were not influenced in 
TNF-treated cells transfected with CCTη siRNA (see Figure 2.3.), 
suggesting that CCTη exerts its effect independently of IκBα, 
presumably after p65 nuclear translocation. Indeed, we found that CCTη 
knockdown was associated with increased NF-κB binding to DNA κB 
consensus sequence at 3 h and 16 h after TNF stimulation, while not 
affecting binding at 30 min and 1 h, as analyzed by electromobility shift 
assay (EMSA) (see Figure 2.4.a). Resolved DNA protein complexes 
were identified as p50/p65 heterodimers by specific binding of these 
complexes by both p50 and p65 specific antibodies (see Figure 2.4.b). 
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Composition of NF-κB heterodimers was not changed at different time 
points after TNF stimulation or by CCTη knockdown (see Figure 2.4.b), 
indicating that CCTη does not affect NF-κB dimer formation. This 
suggests that increased DNA binding at 3 and 16 h after TNF stimulation 
could account for increased expression of NF-κB target genes at these 
time points in CCTη siRNA transfected cells. Impaired gene expression 
                        
 
 
Figure 2.3. CCTη does not influence NF-κB subcellular distribution. HeLa 
cells were exposed to CCTη or scrambled (sc) siRNA for three days and 
stimulated with TNF (10 ng/ml) for indicated times. Preparation of cytoplasmic and 
nuclear extracts was carried out as described under “Materials andMethods”. (a) 
IκBα, p65, p50, CCTη and GAPDH were detected in cytoplasmic extracts and (b) 
p65, p50 and Sp1 were detected in nuclear extracts by western blotting. 
Immunoblots are representative of three independent experiments. 
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at 1 h after TNF, on the other hand, cannot be explained by altered DNA 
binding. Several post-translational modifications that have been shown 
to modulate NF-κB transcriptional activity without affecting its DNA 
binding (176) could account for this effect. 
 
     
 
 
          
 
Figure 2.4. CCTη increases NF-κB-DNA binding. HeLa cells were exposed to 
CCTη or scrambled (sc) siRNA for three days and stimulated with TNF (10 ng/ml) 
for indicated times. (a) Nuclear extracts were analyzed by EMSA using a κB 
consensus dsDNA oligonucleotide. Data shown represent mean intensity ± SEM 
(n=3). (b) Supershift analysis of NF-κB complexes composed of p65/p50 hetero-
dimers representative of two independent experiments. Ab, antibody; *, free probe. 
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4. CCTη  modulates p65 transcriptional activity via a mechanism 
that targets K122/123 acetylation 
Beside de novo IκBα expression, p65 acetylation by CBP/p300 can 
control the “strength” and duration of NF-κB activity. For example, 
acetylation of p65 K221 enhances its transcriptional activity by 
increasing DNA binding and impairing its assembly with IκBα (199). 
Contrary, acetylation at K122 and K123 reduces p65 binding to DNA κB 
consensus sequence, thus mediating its export from the nucleus (198). 
HDAC3 can antagonize the effect of CBP/p300 by deacetylation of p65 
K122, K123 and K221 (198, 199). Given that the chaperonin CCT is 
required for HDAC3 activity (253) we hypothesized that CCTη regulates 
NF-κB DNA binding via modulation of HDAC3-dependent p65 
deacetylation. If this were the case then depletion of CCTη should 
increase p65 binding to DNA κB consensus sequence supposedly by 
increasing p65 K221 acetylation (199). To test this hypothesis HEK293 
cells were co-transfected with myc-tagged p65, CBP encoding 
expression vector and either CCTη or non-targeting shRNA constructs 
and p65 acetylation was assessed by immunoblotting with anti-acetyl 
lysine antibody. Contrary to what would be expected, CCTη knockdown 
decreased CBP-induced p65 acetylation (see Figure 2.5.a) ruling out 
HDAC3 as a target of CCTη-mediated effect on NF-κB activity in this 
experimental system. We next tested whether reduced CBP activity 
could account for the decreased p65 acetylation in CCTη-depleted cells. 
As the hypoacetylated form of CBP/p300 has reduced catalytic activity 
(271), we assessed CBP acetylation status in CCTη depleted cells. 
CCTη knockdown did not alter CBP protein levels, but reduced CBP 
acetylation when compared to scrambled shRNA transfected control 
(see Figure 2.5.b). This suggests that CCTη regulates NF-κB 
transcriptional activity via a mechanism involving the modulation of p65 
 57 
 
           
 
Figure 2.5. CCTη  regulates p65 transcriptional activity by modulating CBP-
dependent p65 acetylation of lysines 122 and 123. (a) HEK293 cells were 
transfected with CBP, pCDNA3 (control) or myc-p65 and scrambled (sc) or CCTη 
shRNA, and p65 was immunoprecipitated using c-myc-specific agarose beads. 
Acetylated p65 (Ac-p65) and total p65 were detected using antibodies to acetylated 
lysine or p65, respectively. (b) HEK293 cells were transiently transfected with 
scrambled (sc) or CCTη shRNA, and endogenous acetylated CBP (Ac-CBP) and 
total CBP were detected using antibodies to acetylated lysine or CBP after 
immunoprecipitation, respectively. (c) HEK293 cells were transfected or not with 
scrambled (sc) or CCTη siRNA, stimulated with TNF (10ng/ml) for indicated times 
and nuclear extracts were prepared. CCTη was immunoprecipitated using TCP-1η 
antibody. Unrelated EP-1 antibody was used as a goat IgG control (*). (d) Rela–/– 
MEF reconstituted with either p65 wt, K122/123R, K221R or K310R mutant were 
exposed to scrambled or CCTη siRNA and stimulated with TNF (10 ng/ml) for 
indicated times. Cxcl10 mRNA levels were analyzed by qPCR as described under 
“Materials and Methods”. Data represent mean relative mRNA levels ± SEM (n≥3). 
CCTη and p65 were detected in cell extracts by western blotting (representative of 
three independent experiment). 
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acetylation, presumably by CBP/p300. 
 While CCT proteins were predominantly described as 
cytoplasmic, their nuclear localization and function has recently been 
reported as well (272-275). Since p65 acetylation is thought to be a 
nuclear event (176) and given that CBP/p300 is expressed in the 
nucleus (276-278) we assessed whether chaperonin CCTη was 
expressed in the nucleus as well. CCTη was detected in the nucleus of 
HEK293 cells stimulated with TNF after immunoprecipitation (see Figure 
2.5.c). Specificity was confirmed by lack of nuclear CCTη in CCTη 
siRNA-transfected cells (see Figure 2.5.c). 
 Given that CBP/p300 can acetylate p65 on multiple lysines, we 
assessed whether the effect of CCTη on NF-κB-dependent gene 
regulation occurs through acetylation on specific K residues. We 
compared TNF-induced Cxcl10 mRNA expression in p65-/- MEF 
reconstituted with wild type p65, K122/123R, K221R or K310R p65 
mutants, expressing or not CCTη. All MEF lines showed comparable 
Cxcl10 mRNA levels, as assessed 1 h after TNF stimulation (see Figure 
2.5.d). CCTη knockdown in MEF expressing wild type p65 increased 
Cxcl10 expression at 16 h after TNF stimulation, as compared to 
scrambled siRNA transfected controls (see Figure 2.5.d). Similar 
increase was observed in MEF expressing the p65 K310R mutant (see 
Figure 2.5.d). K221 mutation abolished p65 transcriptional activity at 16 
h after TNF stimulation (see Figure 2.5.d), possibly by enhancing IκBα 
binding and leading to p65 nuclear export, as previously reported (199). 
CCTη knockdown did not restore the transcriptional activity of this p65 
mutant (see Figure 2.5.d). In contrast to the p65 K221 mutant and in 
agreement with the study published by Kiernan et al. (198), the 
K122/123R mutation enhanced p65 transcriptional activity 16 h after 
TNF stimulation, as compared to MEF expressing wild type p65 (see 
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Figure 2.5.d). Inhibition of CCTη failed to modulate the transcriptional 
activity of this p65 mutant, suggesting that CCTη facilitates p65 
acetylation on K122 and/or K123, reducing p65 DNA binding and gene 
transcription, implicating CCTη in the termination of NF-κB activity. 
 
IV. Discussion 
 
CCT is a ubiquitously expressed multimer protein complex involved in 
protein folding as well as assembly of protein complexes in an ATP-
dependent manner. Though originally described as a cytosolic protein 
involved in actin and tubulin folding (246, 247, 279), CCT is also 
expressed in the nucleus (272-275) (see Figure 2.5.c). CCT can interact 
with a range of proteins, including von Hippel-Lin (VHL)-elongin BC 
tumor suppressor complex (249), cell-division cycle protein 20 (Cdc20) 
(250), sphingosine kinase 1 (251), Polo-like kinase 1 (252), HDAC3 
(253), huntingtin (254), as among others (248). This suggests the 
involvement of CCT in various cellular functions beyond cytoskeleton 
organization, such as cell cycle, transcription, chromatin remodeling and 
protein degradation.  
 CCT is composed of eight different subunits (CCTα-θ) that share 
similar domains and amino acid sequences conserved across species 
(243-245). Here we identify the chaperonin CCT subunit η (CCTη) as an 
evolutionary conserved regulator of NF-κB-dependent transcription that 
exhibits its effect via a mechanism that targets p65 acetylation. While we 
have focused specifically on the CCTη subunit, it is likely that a 
functional chaperonin complex is needed to regulate NF-κB 
transcription. This notion is supported by the observation that knock-
down of the CCT subunits α or ζ had comparable effects to that of CCTη 
knockdown in regulating TNF-induced reporter activity. Moreover, others 
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have also shown that knockdown of individual CCT subunits reduces the 
expression and activity of the CCT chaperonin complex (74, 280). 
 We have established that CCTη regulates NF-κB transcriptional 
activity, presumably by targeting p65 after its nuclear translocation. 
CCTη knockdown modulated both TNF- and IL-1β-driven NF-κB 
activation (see Figure 2.2.), suggesting that CCTη acts downstream of 
IKK activation, a common denominator of the signal transduction 
pathways triggered by cross-linking of the TNF and IL-1 receptors (270). 
In keeping with this notion, CCTη failed to modulate IκBα degradation as 
well as p65 nuclear translocation (see Figure 2.3.). Consecutively, we 
found that CCTη knockdown increased NF-κB binding to DNA κB 
consensus sequence (see Figure 2.4.), presumably by altering p65 
acetylation. 
 In Drosophila cells, Tcp-1η knockdown reduces NF-κB-driven 
reporter activity, which contrasts to mammalian cells in which CCTη 
knockdown promotes NF-κB activity in response to TNF (see Figures 
2.1.c, 2.1.d). This apparent discrepancy could result from opposing 
functional outcome of Rel acetylation in Drosophila vs. mammalian cells. 
Whereas Dorsal and Dif acetylation have not been previously shown to 
regulate their transcriptional activity, p65 acetylation affects NF-κB-
dependent transcription in different ways. While K310, K314 and K315 
acetylation enhances p65 and hence NF-κB transcriptional activity 
without affecting DNA binding (199, 200)), K218 and K221 acetylation 
increases NF-κB transcriptional activity by inhibiting its removal from 
DNA by newly synthesized IκBα and termination of the transcriptional 
response (199). In contrast, K122 and K123 acetylation reduces p65 
transcriptional activity by decreasing DNA binding in an IκBα-
independent manner (198). Hence, the impact of p65 acetylation may be 
dependent on the promoter context as well as kinetics of the 
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transcriptional event. Supporting this notion, CCTη knockdown in 
mammalian cells decreased IκBα and CXCL2 expression, as assessed 
1 h after TNF stimulation while increasing that of TNF, IL8, CCL5 and 
CXCL10, as assessed 3 and/or 16 h thereafter (see Figure 2.2.a), 
suggesting a different impact of acetylation on early- and late-phase of 
NF-κB transcriptional activity. 
 p65 acetylation is controlled via opposing effects of HATs and 
HDACs (176). Chaperonin CCT is required for the formation of an 
enzymatically active HDAC3–SMRT complex (253) that can regulate late 
phase NF-κB activity by reducing p65 DNA binding, leading to 
termination of NF-κB dependent transcription (199). This is consistent 
with the observation that SMRT and CCT co-localize to the promoter 
region of NF-κB dependent genes (281). Based on these findings, one 
would expect CCTη knockdown to enhance p65 DNA binding by 
increasing p65 acetylation, presumably by decreasing the amount of 
functionally active HDAC3. This is, however, not the case, as CCTη 
knockdown decreased p65 acetylation (see Figure 2.5.a).  
 HAT CBP/p300 is a major p65 acetyltransferase (198-200), 
whose catalytic activity is regulated by a multiplicity of factors (282), 
including auto-acetylation (271). We found that CCTη knockdown 
reduced acetylation of endogenous CBP (see Figure 2.5.b), pointing at 
reduced HAT activity possibly accounting for diminished p65 acetylation. 
Additional studies will be necessary to address the exact mechanism by 
which CCTη regulates CBP activity. One possibility is the involvement of 
cyclin E/cyclin-dependent kinase 2 (Cdk2), which phosphorylates CBP 
thereby increasing its HAT activity (283). The chaperonin CCT is 
essential for cyclin E maturation and cyclin E/Cdk2 complex formation in 
yeast and CCTβ/cyclin E association has been shown in mammalian 
cells (255). 
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 Regulation of p65 activity by acetylation is target residue 
dependent. While K310 deacetylation diminishes p65 transcription 
without affecting DNA binding, decreased K221 acetylation favors IκBα 
binding, promoting its removal from DNA and nuclear export (199). It is 
therefore unlikely that CCTη modulates acetylation of these residues 
during late phase of NF-κB activation. Consistent with this, CCTη 
knockdown increased transcriptional activity of p65 K310R mutant 16 h 
after TNF stimulation in a similar manner, as observed in MEF 
expressing wild type p65 (see Figure 2.5.d). On the other hand, the p65 
K221R mutant showed significantly lower transcriptional activity, as 
assessed 16 h after TNF stimulation (see Figure 2.5.d), possibly 
reflecting enhanced nuclear export after de novo IκBα synthesis (199), 
and was therefore insensitive to CCTη knockdown (see Figure 2.5.d). 
We cannot, however, exclude that CCTη knockdown down-regulates 
K310 acetylation at earlier –time points, which could explain 
transcriptional repression of IκBα and CXCL2 genes as assessed 1 h 
after TNF stimulation (see Figure 2.2.a).  
 Acetylation of p65 K122 and K123 inhibits DNA binding, 
promoting termination of NF-κB-dependent transcriptional response 
(198). In line with this, the p65 K122/123R mutant failed to terminate NF-
κB-dependent transcription reflected by increased Cxcl10 mRNA, as 
compared to p65 wt or p65 K310R and K221R mutants (see Figure 
2.5.d). Interestingly, the kinetics of mRNA expression of this mutant was 
similar to that observed in CCTη depleted cells expressing wild type p65, 
and was insensitive to CCTη knockdown (see Figure 2.5.d). This 
suggests that CCTη regulates NF-κB-dependent transcription via K122 
and K123 acetylation. 
 In conclusion this study identifies the chaperonin subunit CCTη 
as a negative regulator of NF-κB transcriptional activity via a mechanism 
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involving the modulation of p65 acetylation, presumably by altering CBP 
activity. We propose that CCT chaperonin might be involved in 
terminating NF-κB signaling and as such may be important for the 
resolution of inflammation. 
 
V. Materials and Methods 
 
Cell Culture 
Drosophila S2 cells were kindly provided by Monica Bettencourt Dias 
(Instituto Gulbenkian de Ciência, Oeiras, Portugal) and were grown at 
25°C in Schneider’s Drosophila medium (Invitrogen). HeLa and human 
embryonic kidney 293 (HEK293) cells were obtained from ATCC. Mouse 
embryonic fibroblasts (MEF) isolated from Rela-/- mice were kindly 
provided by Dr. Amer Beg (Moffitt Cancer Center, Tampa, FL) and have 
been previously described (108). Rela–/– MEF were stably transfected 
with human RelA wt, K122/123R, K221R and K310R mutant 
recombinant retroviruses essentially as described (219). Cells were 
grown at 37°C in Dulbecco's modified Eagle's medium (MediaTech) 
supplemented with 10% fetal bovine serum, 100 units/ml penicillin G and 
100 µg/ml streptomycin B (all Atlanta Biologicals) in a humidified 
atmosphere containing 5% CO2. 
 
Plasmid Constructs 
Drosomycin-luciferase (Drs-luc) and Toll 10b expression vectors were 
kindly provided by Dr. Mika Ramet (University of Tampere, Tampere, 
Finland) and were described elsewhere (135). Dorsal and Dif were 
amplified from the original pAct-dl and pAct-Dif vectors (kind gift from Dr. 
Ylva Engstrom, Stockholm University, Stockholm, Sweden (268)) by 
PCR (Dorsal 5’-GAT CCT CGA GAT GTT TCC GAA CCA GAA CAA 
TGG AG-3’ and 5’-TCG ATC TAG ACG TGG ATA TGG ACA GGT TC-
 64 
3’; Dif 5’-GAT CCT CGA GAT GTT TGA GGA GGC TTT C-3’ and 5’-
TCG ATC TAG ATT TGA ATG GCT GAA TTC CCA AG-3´) and cloned 
(EcoRV/XbaI) and (XhoI/XbaI) into pAc5.1/V5-HisA vector (Invitrogen), 
respectively. NF-κB luciferase reporter construct, i.e. κB-luc, has been 
described elsewhere (284). Scrambled and CCTη shRNA constructs 
were cloned by inserting annealed oligonucleotides containing a 5’-GAG 
TGT TTG AGT TTG AGA TCC-3’ or a unique 19bp sequence derived 
from the mRNA transcript of CCTη gene (5’-GCC ACA AAC ATT CTC 
AAC A-3’) between the unique BglII and HindIII enzyme sites of the 
pSUPER vector (OligoEngine). N-terminal myc-tagged p65 expression 
vector has been described (285). C-terminal HA-tagged CBP was 
expressed from a pcDNA3 vector. p65 K122/123R, K221R and K310R 
expression vectors were generated by cloning a p65 sequence 
containing K122/123R, K221R and K310R mutation, respectively, into a 
pLXIH vector as described (219). All constructs were verified by 
automated DNA sequencing using dye termination chemistry.  
 
Transient transfection and reporter assay 
S2 cells were cultured in 12-well plates (5x105 cells per well) and a day 
after exposed to 1 µg of total DNA (150 ng Drs-luc, 5 ng Toll 10b, 50 ng 
Dorsal, 50 ng Dif) and 5 µl of Cellfectin transfection reagent according to 
manufacturer’s instructions (Invitrogen) in Drosophila SFM medium 
(Invitrogen) for 12 h at 25°C. Cells were washed and transferred into 96-
well plates containing lacZ dsRNA (900ng per 5x104 cells). After 
incubation for three days, firefly (Luc) and Renilla (Ren) luciferase 
activity were measured using Dual-luciferase Reporter Assay System 
(Promega). HEK293 cells were grown in 12-well plates and transfected 
at 90% confluency. Cells were exposed to 1 µg of total DNA (300 ng of 
reporter plasmid, 500 ng of shRNA plasmid and 40 ng of 
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cytomegalovirus enhancer/β-galactosidase control plasmid) and 1 µl of 
Lipofectamine 2000 reagent according to manufacturer’s instructions 
(Invitrogen) in Dulbecco's modified Eagle's medium for 3 h. After addition 
of fetal bovine serum to a final concentration of 10%, cells were 
incubated (three days, 37°C), stimulated with TNF (10 ng/ml, 6 h), lysed 
with passive lysis buffer (Promega) and supernatants were assayed for 
luciferase and β-galactosidase activity as described elsewhere (284). 
 
RNA interference, transient transfection and reporter assay 
S2 cells were cultured in 12-well plates and transfected as above (150 
ng Drs-luc reporter plasmid, 5 ng Toll 10b plasmid). Cells were washed, 
diluted to 1x106 cells/ml and a total of 10 µl of cells were added to the 
dsRNA-containing 384-well plate (250 ng dsRNA/well), resulting in a 
final concentration of 1x104 cells per well. Plates were gently centrifuged, 
cells were incubated (30 min, room temperature) and 30 µl of 
Schneider’s medium containing 15% fetal bovine serum was added. 
Plates were sealed to prevent evaporation and incubated for three days 
at 25°C. Luc and Ren activity was measured using Dual-luciferase 
Reporter Assay System according to manufacturer’s instruction 
(Promega). 87 wells not containing dsRNA on each experimental plate 
were used to calculate the coefficient of variation (CV) for Luc and Ren 
activities. All three experimental plates showed CV of 7.4±1.7% for Luc 
and 30.3±14.5% for Ren. Because of the aberrant Ren activity in our 
experimental system, possibly due to the affected Actin promoter-driven 
expression by certain dsRNA (286), Luc values could not be normalized 
to Ren values. The positive control in screen and data processing, 
dsRNA of DIAP1 inhibitor of apoptosis, led to a very significant reduction 
of Luc signals in two out of three experimental plates that were 
considered for further analysis. Experimental data were normalized by 
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setting the average Luc value of wells not containing dsRNA to 1. Values 
lying outside the mean ± 2SD boundaries in two experiments were 
considered indicative for putative candidate genes. 
 
dsRNA synthesis and screen confirmation 
dsRNAs targeting putative genes identified in the screen were generated 
by in vitro transcription of a PCR-generated DNA template (RNAi probes, 
FlyBase) containing the T7 promoter sequence on both ends 
(RiboMAXTM Large Scale RNA Production System-T7, Promega) and 
purified using Mini Quick Spin RNA Columns (Roche). Transiently 
transfected S2 cells (150 ng Drs-luc, 50 ng Dorsal, 50 ng Dif, 5 ng Toll 
10b per 5x105 cells) were exposed to dsRNA (900 ng per 5x104 cells) in 
96-well plate, incubated for three days and Luc and Ren activity was 
measured using Dual-luciferase Reporter Assay System (Promega). 
 
CCTη  knockdown by siRNA 
siRNA knockdown of CCTη was performed in a 12-well plate format in 
HeLa (6x104 cells per well), HEK293 (3x105 cells per well) and MEF 
(5x104 cells per well) cells. Cells were exposed to 50 nM siGENOME 
Non-Targeting siRNA #1 or CCTη siRNA and 1 µl of DharmaFECT1 
transfection reagent according to manufacturer’s instructions (Thermo 
Scientific). CCTη siRNA target sequences were human: 5’-GCC ACA 
AAC ATT CTC AAC A-3’ and mouse: 5’- GCC ACA AAC ATC CTC AAC 
A -3’. 
 
Gene expression analysis 
Real-time quantitative PCR (qPCR) was carried out using SYBR Green 
chemistry (Invitrogen) on a Chromo4 continuous fluorescence monitoring 
thermocycler (MJ Research) as described previously (219). Relative 
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transcript levels were determined by normalization to the housekeeping 
gene hypoxanthine guanine phosphoribosyl transferase (HPRT). Primers 
used for expression analysis in HeLa cells were: IκBα (5’-TCC TGT TGA 
AGT GTG GGG CTG ATG-3’ and 5’-CCT CCA AAC ACA CAG TCA 
TCA T-3’), CXCL2 (5’-CAC TCA AGA ATG GGC AGA AAG-3’ and 5’-
TCA GGA ACA GCC ACC AAT AAG-3’), IL8 (5’-TCC TGA TTT CTG 
CAG CTC TGT-3’ and 5’- TGT GGT CCA CTC TCA ATC ACT C-3’), 
TNF (5’-AGT GCT GGC AAC CAC TAA GAA-3’ and 5’-ATT CCA GAT 
GTC AGG GAT CAA-3’), CXCL10 (5’-CCT CTC CCA TCA CTT CCC 
TAC-3’ and 5’-GCT GAT TTG GTG ACC ATC ATT-3’), CCL5 (5’-TGC 
CCA CAT CAA GGA GTA TTT-3’ and 5’-CCA TCC TAG CTC ATC TCC 
AAA-3’) and HPRT (5’-TTC TGT GGC CAT CTG CTT AGT-3’ and 5’-
GCC CAA AGG GAA CTG ATA GTC-3’). Primers used for expression 
analysis in MEF were: Cxcl10 (5’-AAG TCA GCC AAT CAG GAC TCA-3’ 
and 5’-GTT GGC TCG GGA TGT CTC T-3’). Primers for the mouse Hprt 
have been described elsewhere (219). Expression levels of 
unstimulated, scrambled siRNA-exposed cells were set to 1, and fold 
induction for other experimental groups was calculated. CXCL10 mRNA 
levels of TNF-unstimulated HeLa cells were not consistently detectable; 
expression level of CXCL10 mRNA in CCTη siRNA-exposed cells 16 h 
after TNF was set to 100 and relative values for other experimental 
groups were calculated. 
 
Preparation of subcellular extracts, EMSA and western blotting 
HeLa cells were transfected with siRNA as described above and 
incubated for three days before stimulation with TNF (10 ng/ml). 
Preparation of cytoplasmic/nuclear extracts and EMSA were carried out 
as described previously (285). Briefly, cells were lysed in hypotonic 
buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5% TritonX-
100, supplemented with protease inhibitors) and centrifuged (600 g, 5 
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min, 4°C). Supernatant (cytoplasmic fraction) was transferred into new 
tubes and the remaining pellet (nuclear fraction) was washed once in 
hypotonic buffer and lysed (20 mM HEPES pH 7.9, 25% glycerol, 1.5 
mM MgCl2, 20-800 mM NaCl, 0.2 mM EDTA, 1 mM PMSF, 1 mM DTT, 
proteasome inhibitors). Nuclear extracts were incubated with 100,000 
cpm of double-stranded [γ-32P]ATP-radiolabled NF-κB oligonucleotide 
(5’-AGT TGA GGG ACT TTC CCA GGC-3’; 30 min, room temperature; 
PerkinElmer) and the resulting DNA-protein complexes were separated 
on a 6% polyacrylamide gel in Tris/glycine/EDTA buffer pH 8.5. 
Experimental data were analyzed by setting the net intensity of EMSA 
bands to 100 and calculating the percentage of intensity for each data 
point. For supershift analysis, labeled DNA-protein complexes were 
incubated with 1 µg of p65 (sc-8008x, Santa Cruz) or p50 (sc-114x, 
Santa Cruz) specific antibodies or non-immune rabbit IgG (I5006, 
Sigma) (1 h, 4°C) prior to separation. For western blotting, proteins 
contained in cytoplasmic and nuclear fractions were resolved by 
electrophoresis on 10% SDS-polyacrylamide gels, transferred to 
polyvinylidene fluoride membranes and detected with antibodies against 
IκBα (IMG-127A, Imgenex), p65 (sc-372, Santa Cruz), p50 (sc-7178, 
Santa Cruz), CCTη (sc-13889, Santa Cruz), GAPDH (MAB374, 
Millipore) and Sp1 (sc-59, Santa Cruz). Primary antibodies were 
detected using HRP-conjugated secondary antibodies (Santa Cruz). 
 
Immunoprecipitation and protein acetylation 
HEK293 cells were grown in 12-well plates and transfected with calcium 
phosphate. Cells were exposed to 1.6 µg of total DNA (50 ng of myc-
tagged p65, 200 ng of HA-tagged CBP expressing construct and 1 µg of 
shRNA plasmid), incubated for three days and stimulated with TNF (10 
ng/ml, 30 min). Cells were lysed (50 mM HEPES pH 7.9, 250 mM NaCl, 
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1% NP-40, 1 mM EDTA, protease inhibitors) and centrifuged (10 min, 
16000 g, 4°C). Supernatants were incubated with 15 µl c-myc-
conjugated agarose beads (2 h, 4°C, Sigma). For CBP detection, cells 
were transfected with CCTη or scrambled shRNA, stimulated with TNF 
(10 ng/ml, 30 min) and cell extracts were incubated with 1 µg CBP 
antibody (o/n, 4°C, sc-369, Santa Cruz) and 20 µl Protein-A Sepharose 
beads (1 h, 4°C, GE Healthcare). For CCTη detection, HEK293 cells 
were exposed or not to CCTη or scrambled siRNA and stimulated with 
TNF (10 ng/ml) for indicated times. Nuclear extracts were incubated with 
1 µg TCP-1η antibody (sc-13889, Santa Cruz) and 20 µl Protein-A 
Sepharose beads. Precipitated proteins were washed in lysis buffer, 
resuspended in 2x SDS sample buffer, resolved by SDS-PAGE and 
subjected to western blotting with antibodies detecting acetylated lysine 
(9814S, Cell Signaling), p65 (sc-372, Santa Cruz), CBP or CCTη. 
Primary antibodies were detected using Protein-A-HRP conjugates 
(Millipore) or respective secondary antibodies. Purity of nuclear extracts 
was confirmed using GAPDH antibody (MAB374, Millipore). 
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REGULATION OF NF-κB ACTIVITY BY 
SUBNUCLEAR LOCALIZATION 
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I. Summary 
 
RelA is a member of the nuclear factor kappa B (NF-κB) family of 
transcription factors regulating inflammation as well as cell growth and 
programmed cell death (PCD). Distinct mechanisms have evolved to 
control NF-κB activity. The central one relies on the inhibitory effect 
exerted by inhibitors of κB (IκB) molecules that bind transcriptionally 
active NF-κB family members such as RelA, retaining them in the 
cytoplasm. Proteolytic degradation of IκB is required for NF-κB nuclear 
translocation and initiation of transcription. RelA translocation into 
specific nuclear bodies adds an additional layer of control over NF-κB-
dependent gene transcription, a mechanism regulated by post-
translational modifications, including RelA phosphorylation and 
ubiquitination. RelA serine (S) 276 phosphorylation controls NF-κB 
transcriptional activity by promoting its interaction with cofactors of 
transcriptional machinery, as well as by inhibiting RelA ubiquitination and 
subsequent proteasomal degradation. Here we provide evidence that 
RelA S276 phosphorylation also regulates its translocation into 
promyelocytic leukemia protein (PML) nuclear bodies. We show that the 
hypophosphorylated RelA S276A mutant translocates preferentially to 
PML nuclear bodies via a mechanism that depends on RelA DNA 
binding. This occurs presumably via the activation of protein kinase A 
(PKA). 
 
II. Background 
 
 The mammalian nuclear factor kappa B (NF-κB)/Rel family of 
transcription factors (TF) is composed of homo- or heterodimeric 
complexes resulting from the interaction of five members, i.e. p65/RelA, 
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RelB, c-Rel, p105/p50 and p100/p52. These share within their N-terminal 
region a Rel Homology Domain (RHD), responsible for dimer formation, 
interaction with IκB, nuclear translocation and DNA binding (86). RelA, 
RelB and c-Rel also contain a C-terminal transactivation domain (TAD), 
defining these members transcriptionally active (86). Among these, RelA 
plays a predominant role in the regulation of so called proinflammatory 
genes associated with stress responses to injury and/or microbial 
infection (140). While NF-κB activation is strictly required to trigger 
inflammation, uncontrolled NF-κB activity can be associated with inability 
to resolve inflammation leading to tissue damage. Presumably, this 
contributes in a critical manner to the pathogenesis of immune-mediated 
inflammatory diseases, in which inflammation is underlying cause of 
disease. (84) 
 Under homeostasis, transcriptionally active NF-κB dimers are 
retained in the cytoplasm by inhibitory proteins of the IκB family (89). 
p100 and p105, on the other hand, contain IκB-like ankyrin repeats 
within their C-terminal region, sequestering these proteins in the 
cytoplasm (86). Proteolytic degradation of IκB is required for NF-κB 
nuclear translocation and binding to the κB consensus sites within the 
promoter regions of NF-κB-dependent genes, where dimer composition 
can confer some level of specificity towards different κB sites (287). One 
of these NF-κB-dependent genes is IκBα, which interacts with the 
promoter-bound RelA leading to its nuclear export, a feedback loop that 
contributes to termination of NF-κB transcriptional response (150, 151). 
 The specificity of NF-κB transcriptional response is achieved by 
numerous post-translational modifications, including some that target 
directly Rel proteins (175, 176). RelA phosphorylation at S276 induces 
its conformational changes, regulating its transcriptional activity by 
modulating the interaction of RelA with other proteins. These include 
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transcriptional co-activators, e.g. CREB-binding protein (CBP)/p300 
(181), positive transcription elongation factor b (P-TEFb) (288), as well 
as transcriptional repressor histone deacetylase 1 (HDAC1) (182). RelA 
S276 phosphorylation can also inhibit RelA ubiquitination and 
degradation via a mechanism that inhibits binding of the E3 ubiquitin 
ligase suppressor of cytokine signaling 1 (SOCS-1) (289).  
 Nuclear bodies are a heterogeneous group of dynamic 
subnuclear structures, implicated in the regulation of gene transcription 
(232). Nucleoli, the most prominent of all nuclear bodies, are associated 
with the genes encoding 35S ribosomal RNA, regulating their 
transcription (290). Moreover, nucleoli can also sequestrate several cell-
cycle checkpoint control proteins, e.g. murine double minute 2 (Mdm2) 
(291), cell division cycle protein 14 (Cdc14) (292) and tumor suppressor 
proteins, e.g. retinoblastoma protein 1 (pRb1) (293), suggesting an 
important role of nucleoli in cellular proliferation and cellular stress 
responses. Along this, nucleolar RelA sequestration can also regulate 
NF-κB-driven gene transcription (233). 
 Other nuclear bodies, e.g. nuclear speckles and PML nuclear 
bodies, are also involved in transcriptional regulation. While not serving 
as sites of active transcription, speckles are enriched in pre-messenger 
(m)RNA splicing machinery necessary for pre-mRNA processing (230). 
In addition, a subset of transcription factors can localize to nuclear 
speckles, suggesting their regulatory role in transcription (230). 
 The physiological relevance of PML nuclear bodies was first 
suggested in studies with acute promyelocytic leukemia patients (294, 
295). The identification of proteins associated with PML bodies provided 
clues to the function of these subnuclear compartments implicating PML 
bodies in the transcriptional regulation. This can occur via the physical 
association of PML bodies with the transcriptionally active gene loci, e.g. 
major histocompatibility (MHC) class I gene cluster (296), by 
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sequestration of transcriptional cofactors, e.g. CBP (236), or by the 
induction of TF post-translational modifications, e.g. p53 phosphorylation 
(297, 298) and acetylation (299). RelA translocation into PML nuclear 
bodies can also down-regulate NF-κB-dependent transcription via a 
mechanism involving RelA ubiquitination by a nuclear protein containing 
postsynaptic density 65-disc large-zonula occludens 1 (PDZ) and 
abnormal cell lineage 11-islet 1-mechanosensory abnormal 3 (LIM) 
domains (PDLIM2) (211). Several other proteins involved in NF-κB-
dependent transcription, e.g. CBP/p300, IKKε, can also be sequestered 
in PML nuclear bodies (190, 236), suggesting that PML nuclear bodies 
may enable the fine control of NF-κB transcriptional activity via a 
mechanism involving post-translational modifications. Here we present 
evidences that hypophosphorylated RelA S276A mutant translocates to 
PML nuclear bodies, an event possibly associated with its gene-specific 
transcriptional activity. 
 
III. Results 
 
In the experiments presented below, we have co-expressed N-terminal 
EGFP-tagged wild type RelA (EGFP-RelA), used as a reporter protein, 
together with different N-terminal myc-tagged RelA variants as effector 
proteins in ~7-times molar excess (HEK293FT cells) or ~3.5-times molar 
excess (COS7 cells). Because of the high molar ratio of effector versus 
reporter protein, the premise is that the EGFP-RelA reporter is 
expressed primarily as a heterodimer with the different myc-tagged RelA 
effector proteins. This is supported by our observation that co-
expression of different myc-tagged RelA effector proteins with EGFP-
RelA reporter protein imposes localization of reporter-effector 
heterodimers. The co-expression of EGFP-RelA reporter protein with 
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different effector proteins, allows the visualization of the heterodimers 
while presumably not influencing their localization. We will therefore, for 
the simplicity reason, refer to different heterodimers only by the name of 
the effector protein.  
   
            
 
Figure 3.1. Distinct RelA S276A subnuclear localization. (a) HEK293FT or (b) 
COS7 cells were transiently co-transfected with EGFP-tagged RelA (EGFP-RelA) 
expression construct together with RelA wild type (myc-RelA-wt) or RelA-S276A 
mutant (myc-RelA-S276A). Cells were fixed and subcellular distribution of EGFP-
RelA (green) and DNA (blue or red) was analyzed by fluorescent microscopy. 
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1. Subnuclear localization of the RelA S276A mutant 
RelA S276 phosphorylation is essential to sustain NF-κB transcriptional 
activity (182, 288, 289). RelA translocation into distinct nuclear 
compartments also regulates its transcriptional activity (233). To assess 
whether S276 phosphorylation influences RelA subcellular localization, 
the fine nuclear localization of RelA was assessed in HEK293FT cells 
transiently co-transfected with EGFP-RelA together with 
hypophosphorylated form of RelA, mimicked by the RelA S276A 
mutation, (myc-RelA-S276A) versus control HEK293FT cells, transiently 
co-transfected with the wild type RelA (myc-RelA-wt). While the RelA-wt 
had a homogenous nuclear localization (see Figure 3.1.a), RelA-S276A 
translocated into distinct nuclear compartments (see Figure 3.1.a). A 
similar nuclear distribution was observed in COS7 cells (see Figure 
3.1.b), suggesting that this phenomenon is not cell type-specific.  
 
2. Hypophosphorylated RelA S276A mutant translocates to PML 
nuclear bodies 
Sequestration of several transcription factors as well as transcriptional 
cofactors into distinct nuclear bodies regulates gene expression (232). 
We assessed whether RelA-S276A would translocate to specific nuclear 
bodies by labeling cells transiently co-transfected with EGFP-RelA and 
myc-RelA-S276A with antibodies against fibrillarin, anti-splicing factor 
sc-35 or PML, marker proteins for nucleolus, nuclear speckles or PML 
nuclear bodies, respectively. Whereas RelA-S276A was excluded from 
nucleolus and nuclear speckles, it colocalized with PML nuclear bodies 
(see Figure 3.2.), implicating PML bodies in the regulation of NF-κB-
dependent gene expression via a mechanism that involves RelA S276 
phosphorylation.
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Figure 3.2. RelA S276A mutant translocates to PML nuclear bodies. (a) 
HEK293FT cells were transiently co-transfected with EGFP-tagged RelA (EGFP-
RelA) expression construct together with RelA-S276A mutant (myc-RelA-S276A). 
Cells were fixed and subnuclear distribution of EGFP-RelA (green), nucleolus 
(fibrillarin; red) and nuclear speckles (sc-35; red) was analyzed by fluorescent 
microscopy. (b) COS7 cells were transfected as in (a), fixed and subnuclear 
distribution of EGFP-RelA (green) and PML nuclear bodies (PML; red) was analyzed 
by fluorescent microscopy. 
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3. PKA regulates RelA subnuclear localization 
RelA S276 can be phosphorylated by PKAc while catalytically inactive 
form of PKAc, mimicked by K72M point mutation, (DN-PKA) acts as a 
dominant negative mutant interfering with NF-κB activation, presumably 
by preventing RelA S276 phosphorylation (300). To assess whether 
PKAc regulates RelA translocation into distinct nuclear compartments, 
RelA subnuclear localization was visualized in HEK293FT cells 
transiently co-transfected with EGFP-RelA and myc-RelA-wt together 
with the DN-PKA or empty vector as a control. While RelA-wt had 
 
 
            
 
 
 
Figure 3.3. PKA activity influences RelA subnuclear localization. HEK293FT 
cells were transiently co-transfected with EGFP-tagged RelA (EGFP-RelA) 
expression construct and RelA wild type (myc-RelA-wt) plus catalytically inactive 
form of PKAc (DN-PKA) or empty vector (PCDNA3) as a control. Cells were fixed 
and subcellular distribution of EGFP-RelA (green) and DNA (red) was analyzed by 
fluorescent microscopy. 
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homogeneous nuclear distribution in control cells, the expression of DN-
PKA resulted in its translocation into distinct nuclear compartments (see 
Figure 3.3.). This suggests that recruitment of RelA to those nuclear 
compartments is associated with decreased RelA S276 phosphorylation 
resulting from PKA inhibition. 
 
4. RelA S276A subnuclear localization depends on DNA binding but 
not on the presence of TAD 
RelA transcriptional activity requires the interaction of its TAD with co-
activators and components of the basal transcriptional machinery. RelA 
S276 phosphorylation facilitates these interactions, as illustrated for the 
transcriptional co-activator CBP/p300 (181) that enhances NF-κB-
dependent transcription. RelA S276A mutant, on the other hand, 
associates preferentially with transcriptional co-repressor HDAC1, 
reducing NF-κB activity (182, 219). To assess whether RelA 
transcriptional activity and RelA nuclear distribution are functionally 
linked, we made use of a construct encoding for the RHD portion of the 
RelA-wt (myc-RelA-RHD) and lacking TAD, which binds DNA and 
functions as a dominant negative mutant, repressing NF-κB-dependent 
transcription (301). RelA subnuclear distribution was monitored in 
HEK293FT cells transiently co-transfected with EGFP-RelA together with 
myc-RelA-RHD or myc-RelA-wt as a control. RelA-RHD had 
homogenous nuclear distribution similarly to control cells co-expressing 
RelA-wt (see Figure 3.4.a), suggesting that translocation of RelA into 
distinct nuclear compartments was probably not due to its insufficient 
transcriptional activity, mimicked by the lach of TAD.  
 We next asked whether the TAD portion of RelA was responsible 
for the translocation of RelA S276A to distinct nuclear compartments. 
RelA subnuclear localization was assessed in HEK293FT cells 
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Figure 3.4. RelA subnuclear localization does not depend on its 
transcriptional activity. HEK293FT cells were transiently co-transfected with 
EGFP-tagged RelA (EGFP-RelA) expression construct together with (a) RelA wild 
type (myc-RelA-wt) or RelA RHD wild type (myc-RelA-RHD) or (b) myc-RelA-
S276A or RelA RHD S276A mutant (myc-RelA-S276A-RHD). Cells were fixed and 
subcellular distribution of EGFP-RelA (green) and DNA (red) was analyzed by 
fluorescent microscopy. 
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transiently transfected with EGFP-RelA together with the construct 
encoding for the RHD portion of the RelA-S276 (myc-RelA-S276-RHD) 
and lacking TAD or full length myc-RelA-S276A as a control. RelA-
S276A translocated into distinct nuclear compartments independently of 
the presence of TAD (see Figure 3.4.b), indicating that RHD but not the 
TAD is required for the observed RelA S276A subnuclear localization.  
 The RelA RHD is required for NF-κB dimer formation, nuclear 
translocation, DNA binding and interaction with IκB (86). Overexpressed 
RelA can translocate to the nucleus (see Figure 3.1.), probably 
       
 
   
 
                
        
 
Figure 3.5. RelA-DNA binding influences RelA subnuclear localization. 
HEK293FT cells were transiently co-transfected with EGFP-tagged RelA (EGFP-
RelA) expression construct plus RelA wild type (myc-RelA-wt) or RelA wild type 
DNA binding deficient mutant (myc-RelA-BM). Cells were fixed and subnuclear 
distribution of EGFP-RelA (green) and DNA (red) was analyzed by fluorescent 
microscopy. 
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overcoming the endogenous mechanisms regulating IκB-dependent 
RelA cytoplasmic localization. Hypophosphorylated RelA binds DNA with 
lower affinity as compared to wild type RelA, presumably via a 
mechanism involving the interaction of RelA N- and C-terminal regions, 
masking the DNA binding domain within RHD. This mechanism is 
regulated by PKA and involves phosphorylation of RelA S276 (181). To 
investigate if DNA binding is important for RelA nuclear distribution, RelA 
subnuclear localization was monitored in HEK293 cells transfected with 
EGFP-RelA together with RelA DNA binding-deficient mutant (myc-RelA-
BM) or myc-RelA-wt as a control. RelA-BM translocated into distinct 
nuclear compartments with a pattern similar to that associated with the 
expression of RelA-S276A, as compared to cells expressing RelA-wt 
(see Figure 3.5.). This suggests that RelA DNA binding prevents RelA 
translocation into distinct nuclear compartments. 
 
IV. Discussion 
 
We have co-expressed N-terminal EGFP-tagged wild type RelA (EGFP-
RelA) as a reporter protein, together with different myc-tagged RelA 
variants. This manipulation was necessary because EGFP-tagged RelA-
S276A effector protein, i.e. EGFP-RelA-S276A, did not visibly localize 
into specific subnuclear structures when expressed alone (see 
Supplementary Figure 3.1.). The reason for this is not entirely clear. One 
possibility is that the concentrations needed to accumulate enough EGF-
RelA-S276A in PML bodies do not permit the visualization of subnuclear 
structures because of the saturating concentrations of the fluorescent 
EGFP-tag. An alternative interpretation would be that the N-terminal 
EGFP tag interferes with RelA trafficking into PML nuclear bodies, a 
notion in keeping with the different subnuclear localization of N-terminal 
and C-terminal YFP-tagged RelA (302). Because the EGFP-RelA 
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reporter protein in our experimental system should be preferentially in 
heterodimeric formation with the myc-tagged effector protein, the 
translocation of heterodimers into PMLs would not be inhibited. 
 PML nuclear bodies regulate the availability and activity of 
transcription factors as well as chromatin-remodeling processes (231, 
303). In keeping with this notion, PML nuclear bodies can activate p53 
by promoting its acetylation and phosphorylation (299). In addition, 
several other transcription factors and regulators localize dynamically to 
PML nuclear bodies. These include CBP/p300 (236, 304), a 
transcriptional co-activator of NF-κB-dependent transcription and a 
major RelA acetyltransferase as well as transcriptional co-repressors 
HDACs (305), which can also deacetylate RelA. 
   
        
  
 
Supplementary Figure 3.1. RelA subcellular localization. HEK293FT cells 
were transiently transfected with EGFP-tagged RelA wild type (EGFP-RelA-wt) or 
EGFP-tagged RelA S276A mutant (EGFP-RelA-S276A) expression construct. 
Cells were fixed and subcellular distribution of RelA (green) and DNA (red) was 
analyzed by fluorescent microscopy. 
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 RelA translocation into PML nuclear bodies is controlled by 
phosphorylation and/or ubiquitination reducing NF-κB-dependent gene 
expression (190, 211). The mechanisms underlying this phenomenon 
are not fully understood. We found that RelA translocation to PML 
nuclear bodies is controlled by S276 phosphorylation. This notion is 
supported by the observation that hypophosphorylated RelA S276A 
mutant accumulates into PML nuclear bodies (see Figure 3.2.). The 
interplay between RelA S276 phosphorylation and its subsequent 
ubiquitination has been previously identified in that RelA S276 
phosphorylation reduces its ubiquitination by SOCS-1 thus increasing 
the half-life of RelA (289). Therefore, It would be interesting to assess 
whether subnuclear localization of RelA S276A is dependent on 
ubiquitination as well as to assess RelA protein stability in PML nuclear 
bodies. 
 RelA S276 can be phosphorylated via the activation of at least 
three protein kinases, namely, PKA (181), mitogen- and stress-activated 
kinase 1 (MSK1) (185) and Pim-1 (289). While we did not assess the 
effect of MSK1 and Pim-1 activity on the RelA subnuclear localization, 
we did so for PKA and found that its activity was necessary to prevent 
the translocation of RelA to PML nuclear bodies (see Figure 3.3.). Our 
data also supports the notion that RelA translocation into PML nuclear 
bodies is dependent on RelA DNA binding, as suggested by the 
observation that the RelA DNA binding-deficient mutant translocates into 
PML nuclear bodies (see Figure 3.5.). While it is generally accepted that 
RelA phosphorylation does not influence DNA binding, 
hypophosphorylated S276 RelA probably binds DNA with lower affinity. 
This is supported by the observation that inhibition of PKA activity 
decreases RelA DNA binding (300), an effect most probably driven by 
the interaction between N- and C-terminal regions of RelA, which masks 
the DNA binding region within the RHD of RelA. RelA S276 
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phosphorylation by PKA weakens this interaction allowing RelA DNA 
binding upon RelA nuclear translocation (181). On the other hand, DNA 
binding might be needed for efficient RelA phosphorylation, a notion 
supported by the observation that the phosphorylation of the DNA 
binding-deficient mutant is strongly reduced as compared to wild type 
RelA (285). Although we did not investigate whether S276 was 
hypophosphorylated in RelA DNA binding-deficient mutant, it is also 
plausible that the redistribution of the DNA binding-deficient mutant to 
the aforementioned subnuclear structures could be linked to its 
hypophosphorylated status. 
 While the RelA S276A mutant is less transcriptionally active than 
its wild type counterpart, this effect is not general, given that RelA S276A 
has comparable transcriptional activity to wild type RelA on a subset of 
promoters (219). One of the identified genes is the major 
histocompatibility (MHC) class I which is efficiently induced by the 
S276A mutant (219). It is noteworthy that the MHC class I gene cluster 
on chromosome 6 is associated with PML bodies in human primary 
fibroblasts (296). Moreover, PML nuclear bodies are associated with 
components of the transcriptional machinery such as nuclear DNA 
helicase II, CBP/p300, and RNA polymerase II (306, 307). This suggests 
that PML bodies may serve as a scaffold for factors involved in gene 
expression and thus direct transcriptional activity of hypophosphorylated 
S276 RelA to a subset of genes located on PML-associated chromatin 
regions. On the other hand, RelA S276A decreases the expression of 
IκBα, promoting RelA nuclear retention (308). Sequestration of 
hypophosphorylated RelA in PML nuclear bodies could therefore serve 
as a mechanism limiting the expression of genes efficiently transcribed 
by S276A in the absence of sufficient IκBα expression, thus maintaining 
tissue homeostasis. 
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V. Materials and Methods 
 
Cell Culture 
HEK293FT and COS7 cells were obtained from ATCC and grown (37 
°C, 95% humidity, 5% CO2) in Dulbecco's modified Eagle's medium 
(MediaTech) supplemented with 10% fetal bovine serum, 100 units/ml 
penicillin G, and 100 µg/ml streptomycin B (all Atlanta Biologicals). 
 
Plasmid Constructs 
EGFP-tagged RelA wild type (EGFP-RelA) was obtained by cloning 
human RelA cDNA in pEGFP-C3 vector (Clontech). EGFP-tagged RelA 
S276A mutant (EGFP-RelA-S276A) was generated by site-directed 
mutagenesis using EGFP-RelA as a template.  RelA RHD S276A mutant 
(myc-RelA-S276A-RHD) was generated by site-directed mutagenesis 
using myc-RelA-RHD as a template. Catalytically inactive murine PKAcα 
(DN-PKA) was generated by introducing a K72M substitution by site-
directed mutagenesis using pFC.PKA (Stratagene) as a template (309). 
Other expression constructs used in this study have been previously 
described including N-terminal myc-tagged RelA wild type (myc-RelA-wt) 
and RelA DNA binding-deficient mutant (myc-RelA-BM) (285), N-
terminal myc-tagged RelA S276A mutant (myc-RelA-S276A) (219), RelA 
RHD wild type (myc-RelA-RHD) (301). All cloned sequences were 
confirmed by automated DNA sequencing using dye termination 
chemistry.  
 
Antibodies 
Fibrillarin, nuclear speckles and PML nuclear bodies are detected using 
MCA-38F3 (EnCor), S4045, (Sigma) and sc-5621 (Santa Cruz) primary 
antibodies, respectively. Secondary antibodies used are DyLight 646 
Donkey Anti-Mouse IgG (H + L) (715-495-150, Jackson 
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ImmunoResearch) and DyLight 646 Donkey Anti-Rabbit IgG (H + L) 
(711-495-152, Jackson ImmunoResearch). 
 
Transient transfection 
HEK293FT cells were seeded on collagenized cover slips in a 12-well 
plate (2.5x105 cells per well) and transfected at 90% confluency using 
calcium phosphate method. Cells were exposed to 1.6 µg total DNA and 
0.125 M CaCl2, 1X HeBS. COS-7 cells were seeded on collagenized 
cover slips in a 12-well plate (1x105 cells per well) and transfected at 
90% confluency. Cells were exposed to 0.3 µg of total DNA and 2 µl of 
Lipofectamine reagent, according to manufacturer’s instruction 
(Invitrogen) in Dulbecco’s modified Eagle’s medium for 5h. After addition 
of fetal bovine serum to a final concentration of 10%, cells were 
incubated (one day, 37 °C) and used for immunostaining. The amounts 
of EGFP-RelA indicator protein and corresponding effector RelA protein 
used for transfections were 20ng and 200ng, respectively in HEK293FT 
cells and 50ng and 250ng, respectively in COS7 cells. 
 
Immunostaining 
One day post-transfected HEK293FT or COS7 cells were washed in 
phosphate-buffers saline (PBS), fixed (4% paraformaldehyde in PBS, 10 
min, RT), permeabilized (0.5 % Triton X-100 in PBS, 5 min, RT) and 
subsequently blocked (1% donkey serum, 0.05 % Tween 20 in PBS, 20 
min, RT). Cells were incubated with specific primary antibodies (1% 
serum, 0.05 % Tween 20 in PBS, 1 h, RT), washed and incubated with 
fluorochrome-conjugated secondary antibodies (1% serum, 0.05 % 
Tween 20 in PBS, 1 h, RT). Nuclear DNA was stained with TO-PRO-3 (1 
mM; Invitrogen) when indicated and cover slips were mounted with 
SlowFade Gold antifade reagent (Invitrogen). Otherwise, cover slips 
were mounted with SlowFade Gold antifade reagent containing DAPI 
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(Invitrogen). Subcellular distribution of EGFP-tagged RelA, nucleolus, 
nuclear speckles and PML nuclear bodies was analyzed using either 
Nikon Eclipse TE2000 microscope equipped with a 40x objective or a 
Leica confocal laser-scanning microscope equipped with 60x objective. 
Pictures were acquired with a charge-coupled device and images were 
processed with IPLab software (Scanalytics, Vers. 3.9.3). 
 
IV. Author contribution 
 
N. Pejanovic and J. Anrather planed the experiments and N. Pejanovic 
performed the experiments described in this chapter.  
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I. Summary 
 
Heme oxygenase-1 (HO-1; encoded by the Hmox1 gene) catalyzes the 
degradation of free heme into biliverdin (BV), via a reaction that releases 
iron (Fe) and carbon monoxide (CO). We report that HO-1 down-
regulates the proinflammatory phenotype associated with endothelial cell 
(EC) activation by reducing intracellular nonprotein-bound Fe (labile Fe). 
EC isolated from Hmox1–/– mice have higher levels of intracellular labile 
Fe and reactive oxygen species (ROS) as compared with EC isolated 
from Hmox1+/+ mice. Basal and tumor necrosis factor (TNF)-induced 
expression of vascular adhesion molecule (VCAM)-1, intercellular 
adhesion molecule (ICAM)-1, and E-selectin were increased in Hmox1–/– 
vs Hmox1+/+ EC, an effect reversed by Fe chelation using deferoxamine 
mesylate (DFO). Fe chelation inhibits TNF-driven transcription of Vcam-
1, Icam-1, and E-selectin, as assessed using luciferase reporter assays. 
This effect is associated with inhibition of the transcription factor (TF) 
nuclear factor kappa B (NF-κB) via a mechanism that is not associated 
with the inhibition of inhibitor of κB α (IκBα) phosphorylation/degradation 
or NF-κB (i.e. RelA) nuclear translocation, although it affects very 
modestly NF-κB binding to DNA κB consensus sequences in the Vcam-
1 and E-selectin promoters. HO-1 inhibits NF-κB (i.e. RelA) 
phosphorylation at serine (S) 276, a phospho-acceptor that is critical to 
sustain TNF-driven NF-κB activity in EC. This effect was mimicked by Fe 
chelation as well as by antioxidant N-acetylcysteine (NAC). In 
conclusion, we demonstrate a novel mechanism via which HO-1 down-
modulates the proinflammatory phenotype of activated EC, i.e. the 
inhibition of RelA phosphorylation at S276. 
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II. Background 
 
Under homeostasis, EC regulate blood flow and orchestrate leukocyte 
trafficking throughout tissues, via expression of genes that regulate 
vasoconstriction, thrombosis and inhibit leukocyte adhesion (310, 311). 
Under inflammatory conditions however, EC undergo profound 
phenotypic modifications, becoming highly vasoconstrictive, pro-
thrombotic and pro-adhesive, a phenomenon referred to as EC 
activation (310). These phenotypic modifications rely on the down-
regulation of the expression of vasodilatory, anti-thrombotic and anti-
adhesive genes as well as on the induced expression of several 
immediate early-responsive vasoconstrictive, pro-thrombotic and pro-
adhesive genes (311). Expression of these proinflammatory genes 
occurs through a mechanism that requires the activation of the NF-κB 
(312, 313). 
 The NF-κB family of TF is composed of five members sharing a 
consensus Rel homology domain (RHD), i.e. p50, p52, cRel, RelB, and 
RelA (314), the latter of which is probably the predominant active form in 
EC (140). NF-κB proteins form homodimers and heterodimers that can 
bind κB DNA motifs in the promoter regions of "NF-κB-dependent 
genes" (315). In quiescent EC, NF-κB dimers are maintained mostly in 
the cytoplasm by virtue of their interaction with IκB molecules that 
occlude the nuclear localization signals (NLS) (88, 316) in their RHD. 
However, when exposed to proinflammatory agonists such as TNF, IκBs 
are phosphorylated, polyubiquitinated, and degraded via the 26S 
proteosome pathway (317) so that nuclear localization signal exposure 
on NF-κB dimers allows for nuclear translocation and binding to DNA κB 
motifs (88). 
 There are additional mechanisms that modulate NF-κB 
 95 
transcriptional activity (86). These include, but are not restricted to, 
phosphorylation of S205 (219), S276 (185, 285, 300), S281 (219), and 
S311 (186) in the N-terminal domain of RelA. Modulation of these 
phospho-acceptors is under the control of several kinases, including 
protein kinase A (PKA) (300), mitogen- and stress-activated kinase-1 
(MSK1) (185), and protein kinase C ζ (PKCζ) (186, 285). The 
phosphorylation status of RelA controls not only its transcriptional activity 
but also specificity for different subsets of target genes (219). How these 
phospho-acceptors modulate RelA activity is not clear but presumably 
involves the interaction of RelA with co-activators such as the cyclic 
AMP-responsive element binding protein (CREB)-binding protein 
(CBP)/p300 (300, 318). 
 Although essential to elicit inflammatory responses, the 
expression of proinflammatory genes associated with EC activation must 
be tightly regulated so as to prevent unfettered inflammation. One of the 
mechanisms via which this occurs relies on the expression of "protective 
genes" (319). These have a dual role in that they regulate not only NF-
κB activity but in addition protect EC from undergoing apoptosis (319). 
We have previously demonstrated that the stress responsive enzyme 
HO-1 (encoded by the Hmox1 gene) acts in such a manner (320, 321). 
 When exposed to proinflammatory agonists, EC up-regulate the 
expression of HO-1 via a mechanism that probably requires the relief of 
its constitutive transcriptional repression by the broad-complex tramtrack 
and bric a brac (BTB) and cap’and’collar (CNC) homologue 1 (BACH-1) 
(322, 323). Once BACH-1 is released from the Hmox1 promoter, binding 
of the transcription activator NF-E2-related factor-2 (NRF-2) occurs, 
leading to Hmox1 transcription (323). 
 Under inflammatory conditions, HO-1 becomes the rate-limiting 
enzyme in the catabolism of heme, a reaction that releases Fe from the 
inner core of the protoporphyrin ring of heme and generates BV as well 
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as the gas CO (52). The free Fe generated in this manner up-regulates 
the expression of heavy chain ferritin (FtH) (54), which forms a 
multimeric complex with the light chain ferritin and nucleates free Fe, 
impairing it from partaking in the generation of ROS via the Fenton 
reaction (324), a highly deleterious effect (325-327). Free Fe also 
induces the expression/activity of an ATPase Fe efflux pump that 
decreases cellular Fe content (328). 
 BV, another end product of heme catabolism by HO-1 (52), is 
converted into the antioxidant bilirubin (BR) (53) by biliverdin reductase 
(329). Although BR can inhibit NF-κB activation in EC (20), the relatively 
low level of biliverdin reductase expressed in EC makes it unlikely that 
this antioxidant would act as an autocrine manner to regulate NF-κB 
activity. Therefore, we reasoned that HO-1 might control NF-κB 
activation in EC via its ability to down-modulate the levels of intracellular 
labile Fe. We provide evidence that the reduction of EC labile Fe content 
associated with HO-1 expression inhibits specifically the phosphorylation 
of RelA at S276 and probably at S205, thus reducing NF-κB 
transcriptional activity. This mechanism underlies the inhibition of 
proinflammatory gene expression associated with the expression of HO-
1 in EC and should contribute in a critical manner to the resolution of 
inflammatory reactions such as afforded by HO-1 expression.  
 
III. Results 
 
1. Reduction of EC labile Fe associated with HO-1 expression 
down-modulates VCAM-1 expression 
HO-1 deficient mice (70) and humans (71) have deregulated Fe 
metabolism and widespread EC activation/injury, suggesting that HO-1 
expression is essential in the regulation of Fe homeostasis (70, 330) and 
 97 
         
 98 
Figure 4.1. HO-1 regulates VCAM-1 expression via modulation of EC labile Fe 
content. a) Endoglin/CD105 was detected by flow-cytometry in MEC from Hmox1+/+ or 
Hmox1-/- BALB/c mice. Grey histograms represent control IgG staining and black 
histograms anti-CD105 staining. b) Hmox1+/+, Hmox1+/- and Hmox1-/- genotypes were 
verified by PCR. c) HO-1 protein was detected by western blot using whole cell extracts 
from Hmox1+/+ and Hmox1-/- MEC. d) Labile and total Fe were quantified in Hmox1+/+ 
and Hmox1-/- MEC. Results are shown as mean ± standard deviation from 6 
independent samples in one out of two independent experiments. e) Vcam-1 mRNA 
expression in the liver of Hmox1+/+ and Hmox1-/- mice, quantified by qRT-PCR. Values 
are normalized to Hprt mRNA and shown as mean fold increase ± standard deviation, 
relative to Hmox1+/+ (n=3 pair matched animals for each genotype). Statistical 
significance was assessed using one-sample z-test. f) Vcam-1 mRNA expression in EC 
from Hmox1+/+ or Hmox1-/- mice, quantified by qRT-PCR. Values are normalized and 
shown as in (e) (n=3 independent wells in one out of two experiments). g) Surface 
VCAM-1 expression in EC from Hmox1+/+ or Hmox1-/- mice treated or not with DFO 
(250µM, 16h) was detected by flow-cytometry. Results shown are geometric mean 
fluorescence ± standard deviation from triplicate samples in one out of three independent 
experiments. *p<0.05, **p<0.01, ***p<0.001, ns = not significant (p>0.05). 
 
 
in preventing unfettered EC activation. Because a causal link between 
deregulated Fe metabolism and unfettered EC activation has not been 
established, we asked whether deregulated Fe metabolism would 
promote EC activation. Primary EC were isolated from Hmox1+/+ and 
Hmox1–/– mice and their phenotype was confirmed by flow cytometry, i.e. 
expression of endoglin/CD105 (see Figure 4.1.a). Genotype was 
confirmed by PCR (see Figure 4.1.b) and Western blotting (see Figure 
4.1.c). Labile Fe content increased by 23% in Hmox1–/– vs Hmox1+/+ EC 
(see Figure 4.1.d), while non-labile Fe content was similar whether or not 
HO-1 was expressed (see Figure 4.1.d), suggesting that HO-1 regulates 
specifically the labile Fe content of EC. 
 We then asked whether increased labile Fe content resulting 
from Hmox1 deletion would modulate the expression of adhesion 
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molecules in EC. Expression of Vcam-1 mRNA, an adhesion molecule 
associated with EC activation (310, 311), was increased by 3- to 4-fold in 
the liver of Hmox1–/– vs Hmox1+/+ mice as quantified by quantitative real-
time PCR (see Figure 4.1.e). To ascertain that HO-1 expression in EC 
accounted for this effect, Vcam-1 mRNA expression was quantified 
specifically in EC isolated from Hmox1–/– or Hmox1+/+ mice. The basal 
level of Vcam-1 mRNA expression increased by 4- to 5-fold in EC from 
Hmox1–/– vs Hmox1+/+ mice (see Figure 4.1.f). Expression of VCAM-1 
protein was also significantly increased in Hmox1–/– vs Hmox1+/+ EC (see 
Figure 4.1.g). This effect was probably due to higher levels of labile Fe in 
Hmox1–/– EC (see Figure 4.1.d), as Fe chelation by DFO reduced 
VCAM-1 expression in Hmox1–/– EC to levels similar to those of 
Hmox1+/+ EC (see Figure 4.1.g). Taken together, these observations 
suggest that HO-1 expression in EC might be a physiologic regulator of 
basal VCAM-1 expression, an effect that probably relies on the control of 
labile Fe. 
 
2. Down-regulation of labile Fe associated with the expression of 
HO-1 inhibits TNF-driven up-regulation of adhesion molecules in 
EC 
We have previously shown that when overexpressed in EC, HO-1 
inhibits the expression of adhesion molecules associated with EC 
activation, including VCAM-1, E-selectin, and ICAM-1 (321). We now 
asked to what extent this effect is associated with decreased labile Fe 
content (see Figure 4.1.d). Transient HO-1 overexpression in EC 
reduced labile Fe content by 17% as compared with control EC (see 
Figure 4.2.a). A similar effect was observed when nontransfected EC 
were treated with the Fe chelator DFO, i.e., an 18% reduction in labile 
Fe content as compared with untreated EC (see Figure 4.2.a). TNF, a 
well-established proinflammatory agonist, induced a transient increase of 
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Figure 4.2. HO-1 inhibits TNF-driven expression of VCAM-1, E-selectin and 
ICAM-1 via reduction of labile Fe content. a) Labile Fe was quantified in BAEC 
transiently transfected with control or HO-1 expression vectors, as well as in non-
transfected BAEC treated or not (NT) with DFO (250 µM, 16h). Mean values ± 
standard deviation (9 independent samples). b) Labile Fe was quantified in confluent 
BAEC not-treated (0) or treated with TNF (50 ng/ml). Mean values ± standard 
deviation from triplicate samples (one out of three representative experiments). c) 
Non-transduced, β-galactosidase and HO-1 recombinant adenoviruses transduced 
HUVEC (24h) were stimulated with TNF (6h). VCAM-1 was  detected  by  cellular  
ELISA.  d)  HUVEC  treated  with  DFO (250 µM, 16h)  and  stimulated  with increasing   
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concentrations of TNF (6h). VCAM-1 was detected by cellular ELISA. e) HUVEC were 
treated with increasing concentrations of DFO (1h) and stimulated with TNF (10ng/ml). 
VCAM-1 expression was assessed as in (c) and (d). Results shown in (c), (d) and (e) are 
mean values ± standard deviation from triplicate samples in one out of three independent 
experiments. f) HUVEC were not-treated (NT) or treated with the Fe chelator HBSer (5 
mM, 16h) and not further treated (Cont) or exposed to TNF (0.1 ng/ml, 8h). Mean values 
± standard deviations (triplicate samples in one out of four independent experiments). g, 
h and i) Confluent MEC from Hmox1-/- or Hmox1+/+ mice were treated with DFO (250 
µM, 16h) and TNF−α (50 ng/ml; 3h) when indicated (+). Vcam-1 (g), E-selectin (h) and 
Icam-1 (i) mRNA were quantified by qRTPCR. Values are normalized to Hprt mRNA and 
shown as mean number of molecules ± standard deviation (n=3 independent wells in one 
representative experiment). *p<0.05, **p<0.01, ***p<0.001, ns = not significant (p>0.05). 
 
 
12–20% in EC labile Fe content (see Figure 4.2.b), an effect in keeping 
with that reported in other cell types (331). HO-1 overexpression (see 
Figure 4.2.c) or Fe chelation by DFO (see Figure 4.2.d) reduced by 30–
40% the ability of TNF to up-regulate VCAM-1 expression in EC. The 
inhibitory effect of Fe chelation was dose-dependent in that higher DFO 
concentrations enhanced its effect (see Figure 4.2.e). To exclude the 
possibility that DFO would function independently of its Fe-chelating 
activity, experiments were performed using HBSer, a "milder" Fe 
chelator (332). HBSer mimicked the effect of DFO, but only when TNF 
concentrations were <1 ng/ml, i.e., a 45% reduction in VCAM-1 
expression, as compared with control EC (see Figure 4.2.f). Similar 
results were obtained using SIH, a cell-permeable Fe chelator (333) 
(data not shown). These data suggest that despite their relative 
differences in efficiency, it is the Fe chelation activity of these 
compounds, i.e., DFO, HbSer and SIH, which affords their effects. 
 To ascertain whether, when expressed under physiological 
conditions, HO-1 controls the induction of VCAM-1 expression in 
response to TNF, Vcam-1 mRNA expression was quantified by 
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quantitative real-time PCR after the exposure of Hmox1–/– or Hmox1+/+ 
EC to TNF. Accumulation of Vcam-1 mRNA was ∼5-fold higher in 
Hmox1–/– vs Hmox1+/+ EC (see Figure 4.2.g). Higher Vcam-1 mRNA 
expression in Hmox1–/– EC was ablated by DFO, suggesting that it is the 
higher labile Fe content in Hmox1–/– EC that accounts for this effect (see 
Figure 4.2.g). 
 We then asked whether, when expressed under physiological 
conditions, HO-1 would control the expression of other TNF-responsive 
adhesion molecules in EC. Up-regulation of E-selectin (see Figure 4.2.h) 
and Icam-1 (see Figure 4.2.i) mRNA in response to TNF was increased 
by ∼3- and ∼11-fold in Hmox1–/– vs Hmox1+/+ EC, respectively. Higher E-
selectin (see Figure 4.2.h) and Icam-1 (see Figure 4.2.i) mRNA 
expression in Hmox1–/– EC was ablated by DFO, suggesting again that it 
is the higher labile Fe of Hmox1–/– EC that accounts for this effect. Taken 
together, these data suggest that, when expressed under physiological 
conditions, HO-1 reduces the expression of adhesion molecules 
associated with EC activation, most probably via down-modulation of 
labile Fe.  
 
3. Fe chelation inhibits the transcription of genes encoding 
adhesion molecules in EC 
We tested whether down-modulation of labile Fe inhibits Vcam-1, E-
selectin, or Icam-1 transcription. EC were transiently transfected with a 
VCAM-1-luc reporter and treated or not treated with DFO. Induction of 
VCAM-1 reporter activity by TNF was reduced by 77–100% in EC 
treated with DFO vs control EC (see Figure 4.3.a). This effect was dose 
dependent in that increasing DFO concentrations (60–250 µM) 
enhanced its inhibitory effect (see Figure 4.3.a). The inhibitory effect of 
DFO was observed across a wide range of TNF concentrations (0.16–
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Figure 4.3. Fe chelation inhibits TNF-driven Vcam-1, E-selectin and Icam-1 
transcription. a) and b) BAEC were transiently transfected with a VCAM-1 luciferase 
reporter (46) and treated with a) increasing concentrations of DFO (16h) and TNF (10 
ng/ml, 6h) or b) DFO (250 µM, 16h) and increasing concentrations of TNF (6h). c) and 
d) BAEC were transiently transfected with an E-selectin luciferase reporter (46) and c) 
treated as in (a) or d) treated as in (b). e) and f) BAEC were transiently transfected 
with an ICAM-1 luciferase (46) reporter and e) treated as in (a) or f) treated as in (b). 
Results shown are mean luciferase normalized to β-galactosidase units ± standard 
deviation, from triplicate samples in one out of three independent experiments. 
(*p<0.05)  
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100 ng/ml) (see Figure 4.3.b). Finally, this effect was not associated with 
detectable cytotoxicity, as assessed by flow cytometry (data not shown). 
 DFO also reduced TNF-driven E-selectin reporter expression by 
65–80% as compared with control EC (see Figure 4.3.c). Higher DFO 
concentrations (60–250 µM) afforded higher inhibition (see Figure 4.3.c), 
an effect observed over a broad range of TNF concentrations (0.001–10 
ng/ml) (see Figure 4.3.d). Similarly, DFO reduced TNF-driven Icam-1 
reporter expression by 20–45%, again in a dose dependent manner (see 
Figure 4.3.e) and over a broad range of TNF concentrations (0.001–10 
ng/ml) (see Figure 4.3.f). Taken together these observations suggest 
that down modulation of Fe content impairs TNF from inducing Vcam-1, 
E-selectin, and Icam-1 transcription in EC. 
 
4. Reduction of EC labile Fe content inhibits NF-κB activity 
Induction of Vcam-1, E-selectin, and Icam-1 transcription by TNF is 
strictly dependent on activation of the transcription factor NF-κB in EC 
(301, 312, 313, 320). Therefore, we reasoned that the reduction of labile 
Fe might inhibit NF-κB activation (see Figure 4.3.). EC were transiently 
transfected with a synthetic NF-κB-luc reporter derived from the porcine 
E-selectin promoter (284) plus or minus an HO-1 expression vector. 
TNF-driven NF-κB reporter activity was reduced by 42–57% in EC 
transfected with HO-1 as compared with control EC (see Figure 4.4.a). 
The inhibitory effect of HO-1 was dose dependent; i.e., higher HO-1 
expression resulted in lower NF-κB reporter activity (see Figure 4.4.a). 
This effect was observed over a broad range of TNF concentrations (1–
10 ng/ml) (see Figure 4.4.b). Given that HO-1 overexpression reduces 
the labile Fe content of EC (see Figure 4.2.a), we asked whether Fe 
chelation would mimic the inhibitory effect of HO-1. DFO inhibited TNF-
driven NF-κB reporter activity by 63–78% as compared with control EC 
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not treated with DFO (see Figure 4.4.c). This effect was dose 
dependent; i.e., higher DFO concentrations resulting in lower NF-κB 
reporter activity (see Figure 4.4.c), and this was observed over a broad 
range of TNF concentrations (1–10 ng/ml) (see Figure 4.4.d). These 
data suggest that HO-1 inhibits NF-κB activation via a mechanism 
probably involving the reduction of labile Fe content in EC. 
           
 
Figure 4.4. HO-1 over-expression and Fe chelation inhibit NF-κΒ activation in EC. 
a) BAEC were transiently co-transfected with a NF-κB luciferase reporter derived from 
the porcine E-selectin promoter (43) (κB-luc) plus pcDNA3-HO-1 (3000 ng DNA/3x105 
cells) and stimulated with TNF (10 ng/ml, 6 h) or not (NT). b) BAEC were transiently 
transfected as in (a) and stimulated with increasing concentrations of TNF. c) BAEC 
were transiently transfected with a NF-κB luciferase reporter (κB-luc), treated with 
DFO (16h) and stimulated with TNF (10 ng/ml, 6 h) or not (NT). d) BAEC were 
transiently transfected as in (c), treated with DFO (250 µM, 16h) and stimulated with 
TNF (6h). Results shown are mean luciferase normalized to β-galactosidase units ± 
standard deviation from triplicate samples in one out of three independent 
experiments. *p<0.05. 
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5. Reduction of labile Fe in EC does not affect IκBα 
phosphorylation/degradation or RelA nuclear translocation 
When exposed to DFO under the same experimental conditions shown 
to inhibit NF-κB activation (see Figures 4.4.c and 4.4.d), TNF-driven 
IκBα phosphorylation and/or IκBα degradation was not affected as 
compared with control EC (see Figure 4.5.a). DFO also did not alter de 
novo IκBα synthesis after TNF stimulation as compared with control EC 
(see Figure 4.5.a). In addition, DFO failed to modulate the levels of RelA 
protein expression or RelA phosphorylation at the C-terminal region, i.e., 
S536, as compared with control EC (see Figure 4.5.a). RelA nuclear 
translocation in response to TNF was also not affected by DFO as 
compared with control EC (see Figure 4.5.b). Total nuclear RelA was 
also not significantly modulated by DFO as assessed by Western blot 
analysis (see Figure 4.5.c) (334). 
 
6. Fe chelation interferes modestly with NF-κB binding to specific 
κB DNA binding motifs in the promoter region of Vcam-1, E-
selectin, or Icam-1 
Given that Fe chelation failed to modulate IκBα 
phosphorylation/degradation (see Figure 4.5.a) and/or RelA nuclear 
translocation (see Figures 4.5.b and 4.5.c), we reasoned that inhibition 
of NF-κB activity (see Figure 4.4.) might occur "downstream" of nuclear 
translocation. Binding of NF-κB to κB DNA binding motifs derived from 
the Vcam-1, E-selectin, and Icam-1 promoters was compared by EMSA, 
using nuclear extracts from EC pre-exposed or not pre-exposed to DFO 
(16 h) and stimulated or not stimulated thereafter with TNF (60 min). 
DFO failed to modulate NF-κB binding to a "standard" κB binding motif 
derived from the Ig promoter (Ig-κB) as compared with control EC (see 
Figure 4.5.d). In a similar manner, DFO failed to modulate the very 
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Figure 4.5. Fe chelation does not affect IκΒα phosphorylation/degradation or NF-κB 
nuclear translocation while inhibiting moderately NF-κB binding to specific κB 
DNA binding motifs in the Vcam-1, E-selectin and Icam-1 promoters. a) Confluent 
BAEC either not treated (control) or pre-treated with DFO (250 µM, 16h) were stimulated 
with TNF (10 ng/ml). IκBα, phosphorylated IκBα (p-IκBα), RelA and Ser536 
phosphorylated RelA (p-RelA-Ser536) were detected by western blot. Immunoblots are 
representative of three independent experiments. b) BAEC treated as in (a), RelA 
(green) and DNA (blue) were immunostained with anti-RelA antibody and DAPI, 
respectively. Images (400x) were acquired by fluorescence microscopy and are 
representative of four fields from one out of three representative experiments. c) BAEC 
were treated as in (a). RelA was monitored in cytoplasm and nucleus by western blot. d) 
BAEC were treated as in (a). EMSA were performed using nuclear extracts (N.Ext) plus 
radiolabeled oligonucleotides corresponding to the κΒ binding sites from the human Ig 
locus (Ig-κB), Vcam1 (-167bp; VCAM-1.1 and -152bp; VCAM-1.2), E-selectin (-99bp) and 
Icam1 (- 1390bp) promoters. Specific (red arrows; I-IV) and non-specific (black arrows, 
ns) complexes are shown. Binding specificity was assessed using for each probe using 
20 fold molar excess of cold probe (*). 
 
 
 
modest binding of NF-κB to the –167-bp Vcam-1κB binding motif 
(VCAM1.1). There was a slight but reproducible inhibition of NF-κB 
binding to the –152-bp Vcam-1κB binding motif (VCAM1.2) in EC treated 
with DFO, as compared with control EC (see Figure 4.5.d). DFO reduced 
very slightly NF-κB binding to the –99bp E-selectin κB binding motif 
while not affecting NF-κB binding to the –1390-bp Icam-1κB DNA 
binding motif (see Figure 4.5.d) as compared with control EC. In all 
cases, the characteristic pattern of NF-κB/DNA binding was observed, 
namely the appearance of "specific bands" upon TNF stimulation that 
were competed out using 20-fold excess unlabeled κB probe, 
corresponding to the probe used in each EMSA, respectively (see Figure 
4.5.d). 
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7. Fe chelation inhibits RelA transcriptional activity 
Because the inhibition of NF-κB activation by HO-1 or Fe chelation (see 
Figure 4.4.) was not associated with the inhibition of NF-κB nuclear 
translocation (see Figures 4.5.b and 4.5.c), and only to a modest extent 
with DNA binding (see Figure 4.5.d), we tested whether the inhibitory 
effect of HO-1 acted directly on RelA, presumably the main NF-κB 
transactivator in EC (140). EC from Hmox1+/+ and Hmox1–/– mice were 
transiently transfected with increasing amounts of RelA plus an NF-κB 
luciferase reporter derived from the porcine E-selectin promoter (284). 
RelA activity was 2–3-fold higher in EC from Hmox1–/– mice as 
compared with EC from Hmox1+/+ mice (see Figure 4.6.a). This suggests 
that, when expressed under physiologic conditions, HO-1 inhibits RelA 
activity. 
 We then asked whether Fe chelation would inhibit RelA activity. 
Expression of the same NF-κB luciferase reporter was increased by 
∼40-fold when EC were co-transfected with RelA, RelA plus p50, or RelA 
plus cRel expression vectors as compared with control EC that did not 
overexpress these NF-κB family members (see Figure 4.6.b). Fe 
chelation by DFO inhibited RelA-, RelA plus p50-, and RelA plus cRel-
driven reporter transactivation by ∼45–57% as compared with control EC 
(see Figure 4.6.b). Fe chelation did not alter RelA expression as 
assessed by Western blot analysis using an anti-Myc-tagged Ab 
recognizing specifically overexpressed RelA (see Figure 4.6.c). Inhibition 
of RelA activity was also observed in HEK293 cells transiently co-
transfected with RelA and the same NF-κB luciferase reporter (see 
Figure 4.6.d), illustrating that this effect is not restricted to EC. 
 We then asked whether Fe chelation would inhibit endogenous 
Vcam-1, E-selectin, and Icam-1 transcription when driven specifically by 
RelA. For this purpose, RelA–/– MEF were transduced or not transduced 
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Figure 4.6. Fe chelation inhibits RelA transcriptional activity. a) Hmox1+/+ and 
Hmox1-/- EC transiently co-transfected with RelA and a NF-κB luciferase reporter 
derived from the porcine E-selectin promoter (κB-luc)(43). Mean fold induction of 
luciferase/β-galactosidase (compared to EC not transfected with RelA) ± standard 
deviation (triplicates in one out of two independent experiments). b) BAEC transiently 
co-transfected with the same NF-κB luciferase reporter as in (a)  plus control  pcDNA3  
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(Cont), RelA, RelA plus p50 or RelA plus cRel. Cells were either not treated (NT) or 
treated with DFO (250 µM, 16h). Mean fold luciferase/β-galactosidase induction versus 
control (cont) EC ± standard deviation (triplicate samples in one out of three independent 
experiments). c) Over-expressed RelA was detected by western blot using an antibody 
recognizing the c-myc tag in the N-terminus of RelA. d) HEK-293 cells were transiently 
co-transfected and treated as in (b). e) RelA-/- MEF were transduced with a control or a 
RelA recombinant retrovirus and treated (NT) as in (a). mRNA was quantified by qRT-
PCR. Mean fold luciferase/β-galactosidase induction versus control (cont) EC ± standard 
deviation (triplicate samples in one experiment). f) BAEC were transiently co-transfected 
and treated with DFO (250 µM, 16h) or SIH (100 µM, 16h). Mean fold luciferase/β-
galactosidase induction versus control untreated (NT) EC ± standard deviation (triplicate 
samples in one out of three independent experiments). g) Hmox1+/+ or Hmox1-/- EC 
were pre-treated or not with DFO (250 µM; 12-16h) and exposed or not to TNF (50 
ng/ml; 1h). ROS were detected by flowcytometry using CM-H2DCFDA. Geo means ± 
standard deviation (one triplicate sample in one out of four independent experiments). h) 
BAEC were transiently transfected as in (f) and when indicated treated with NAC (25 µM, 
16h). Mean fold luciferase/β-galactosidase induction versus control untreated (NT) EC ± 
standard deviation (triplicate samples in one out of three independent experiments). 
*p<0.05, **p<0.01, ***p<0.001. 
 
 
with a recombinant RelA retrovirus, allowing for the assessment of RelA-
driven Vcam-1, E-selectin, and Icam-1 mRNA transcription by 
quantitative real-time PCR. RelA–/– MEF reconstituted with RelA 
expressed Vcam-1, E-selectin, and Icam-1 mRNA transcripts that were 
∼150-, ∼2500-, and ∼30.000-fold more abundant to those detected in 
RelA–/– MEF, respectively (see Figure 4.6.e). DFO inhibited by 69, 58, 
and 70% Vcam-1, E-selectin, and Icam-1 mRNA expression driven by 
RelA, respectively (see Figure 4.6.e). This observation provides direct 
evidence that Fe chelation inhibits RelA-mediated transcription of 
endogenous Vcam-1, E-selectin, and Icam-1. 
 As for DFO, SIH, a cell-permeable Fe chelator (333), also 
inhibited RelA activity as assessed in EC transiently co-transfected with 
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RelA plus NF-κB luciferase reporter (see Figure 4.6.f). This suggests 
that the inhibitory effect of these molecules is due to their Fe-chelating 
activity. We reasoned that the reduction of EC labile Fe content might 
down-regulate RelA activity by disabling labile Fe from promoting the 
generation of ROS through the Fenton reaction. If this is the case, then 
HO-1 expression should inhibit ROS accumulation in EC. Intracellular 
ROS content was ∼2-fold higher in EC isolated from Hmox1–/– vs 
Hmox1+/+ mice (see Figure 4.6.g), suggesting that when expressed 
under physiologic conditions, HO-1 limits the accumulation of ROS in 
EC. Fe chelation by DFO reduced intracellular ROS in Hmox1–/– EC to 
levels similar to those of Hmox1+/+ EC (see Figure 4.6.g). This suggests 
that the higher levels of intracellular ROS in Hmox1–/– EC is due to the 
higher levels of intracellular labile Fe in these cells (see Figure 4.1.d). 
Similar results were observed using another Fe chelator, i.e., SIH (data 
not shown). TNF failed to increase ROS levels in EC as compared with 
untreated EC (see Figure 4.6.g). 
 If HO-1 inhibits RelA activity by disabling labile Fe from 
promoting the generation of ROS, then an antioxidant such as N-
acetylcysteine (NAC) should mimic the inhibitory effects of HO-1 and/or 
that of Fe chelation. In keeping with this notion, NAC inhibited by ∼50% 
RelA activity as assessed in EC transiently co-transfected with RelA plus 
NF-κB luciferase reporter (see Figure 4.6.h). 
 
8. Fe chelation targets the N-terminal domain of RelA 
We used a series of chimeric DNA constructs encoding the N- or C-
terminal domains from RelA that allowed us to test whether Fe chelation 
inhibits RelA activity via a mechanism that targets its N- and/or C-
terminal domains (285). The chimeric constructs were transiently co-
transfected in EC with a NF-κB luciferase reporter derived from the 
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Figure 4.7. Fe chelation modulates RelA transcriptional activity via a mechanism 
that targets the N-terminal domain of RelA. a) BAEC were transiently transfected 
with an NF-κB luciferase reporter derived from the porcine E-selectin promoter (κB-
luc)(43) plus an expression vector encoding the full length RelA or the N-terminal 
domain of RelA (aa2-320) fused to the VP16 TAD (RelA(2-320)/VP16). EC were not 
further treated (NT) or treated with DFO (250 µM, 16h). Shown is mean luciferase 
normalized to β-galactosidase units ± standard deviation (triplicate sample in one out 
of three independent experiments). b) BAEC were transiently co-transfected and 
treated  as  in  (a) and over-expressed RelA and RelA (2-320) /VP16 were detected by 
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western blot using an anti-c-myc antibody, recognizing the c-myc tag in the N-terminus of 
these constructs. c) BAEC were transiently transfected with teto-luciferase reporter (teto-
luc) alone (control), co-transfected with teto-luc plus TET/VP16 or a construct encoding a 
TET DNA binding domain fused to the RelA TAD (TET/RelA(268-551). EC were treated 
as in (a). d) BAEC were transiently transfected with NF-κB luciferase reporter (κB-luc) 
alone (Control) or co-transfected with κB-luc (same as in (a)) plus an expression vector 
encoding the TET DNA binding domain fused to the full length RelA (TET/RelA). EC 
were treated as in (a) and (b). e) BAEC were transiently transfected with teto-luciferase 
reporter (teto-luc) alone (control) or co-transfected with teto-luc plus TET/RelA and 
treated as in (a-c). Data illustrated in (a-e) are mean luciferase normalized to β-
galactosidase units ± standard deviation (triplicate sample in one out of three 
independent experiments). f) BAEC were transiently transfected and treated as in (e) 
and TET/RelA was detected by western blot using an anti-RelA antibody. *p<0.05. 
 
 
porcine E-selectin promoter (284). DFO inhibited by 83% the 
transcriptional activity of a chimeric construct in which the N-terminal 
domain of RelA was fused to a VP16 TAD (RelA (2–320)/VP16), as 
compared with control EC not treated with DFO (see Figure 4.7.a). This 
inhibitory effect was similar to the one exerted over the full length RelA 
(see Figure 4.7.a). Fe chelation did not modulate the expression of RelA 
(2–320)/VP16 as assessed by Western blot analysis (see Figure 4.7.b). 
Because RelA (2–320)/VP16 can bind DNA κB sequences via the N-
terminal domain of RelA and promote gene transcription via the VP16 
TAD, these data suggest that Fe chelation targets the N-terminal domain 
of RelA. 
 DFO failed to inhibit the transcriptional activity of a chimeric 
construct consisting of tet° binding protein TET in its N-terminal portion 
fused to the C-terminal portion of RelA (TET/RelA (286–551)), as 
assessed using a tetracycline operon luciferase reporter (tet°-luc) (see 
Figure 4.7.c). DFO also failed to suppress tet°-luc transcription driven by 
a chimeric construct consisting of TET fused to VP16 (see Figure 4.7.c). 
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This suggests that Fe chelation does not target the C-terminal domain of 
RelA. 
 We then asked whether the inhibition of RelA transcriptional 
activity by Fe chelation targets DNA binding via the RHD. To this aim, 
we made use of a chimeric DNA construct in which TET was fused via 
its C-terminal domain to RelA. This chimeric protein (TET/RelA) can 
transcribe a NF-κB luciferase reporter via DNA binding through the RelA 
RHD (see Figure 4.7.d). The same chimeric protein (TET/RelA) can also 
transcribe a tet° luciferase reporter via DNA binding through the TET 
domain (see Figure 4.7.e). Fe chelation by DFO inhibited by 30% 
TET/RelA-driven NF-κB reporter activity (see Figure 4.7.d) but failed to 
inhibit TET/RelA-driven tet° reporter activity (see Figure 4.7.e). DFO had 
no effect on TET/RelA expression as assessed by Western blot analysis 
(see Figure 4.7.f). Taken together, these data suggest that Fe chelation 
inhibits RelA activity via a mechanism that involves the recognition of κB 
DNA motifs by the RHD. 
 
9. Fe chelation targets S276 and S205 in the N-terminal domain of 
RelA 
We hypothesized that Fe chelation might target one or several phospho-
acceptors in the N-terminal domain of RelA, an effect that would be 
consistent with the observed inhibition of RelA activity (86, 219, 285). 
We tested this hypothesis specifically for the phospho-acceptors S205, 
S276, S281, and S311. EC were transiently co-transfected with wild-type 
RelA or with RelA S205A, S276A, S281A, and S311A point mutants plus 
an NF-κB luciferase reporter derived from the porcine E-selectin 
promoter (284). DFO inhibited by 53 and 43% wild-type RelA and S311A 
RelA-driven transactivation, respectively, as compared with control EC 
not treated with DFO (see Figure 4.8.a). This suggests that Fe chelation
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Figure 4.8. Fe chelation modulates RelA transcriptional activity via S205 and 
S276. BAEC were transiently co-transfected with RelA or RelA S205A, S276A, S281A 
or S311A point mutants plus an NF-κB luciferase reporter derived from the a) porcine 
E-selectin (κB-luc)(43), b) human VCAM-1 (VCAM-1.2-κB-luc)(12), c) human ICAM-1 
(ICAM-1-κB-luc)(12) or d) human E-selectin (E-selectin-κB-luc)(12) promoters. EC 
were either not further treated (NT) or treated with DFO (250 µM, 24-48h). The data 
illustrated in (a-d) represents mean luciferase normalized to β-galactosidase units ± 
standard deviation (triplicate in one out of at least two independent experiments for 
each promoter used). e and f) Confluent MEF (e) or MEC (f) were either left untreated 
(-) or treated (+) with DFO (250 µM, 16h) and not further treated (-) or treated (+) with 
TNF (50 ng/ml, 15 min). RelA was immunoprecipitated (IP), total RelA and RelA 
Ser276 phosphorylation were detected by western blot (WB). Immunoprecipitation with 
irrelevant Ig was performed as a negative control. *p<0.05. 
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does not act via S311 to suppress RelA activity. Because the 
transcriptional activity of the RelA S205A, S276A, and S281A point 
mutants is abolished using this NF-κB reporter (see Figure 4.8.a) (219), 
we made use of synthetic NF-κB reporters consisting of two tandem 
decameric κB sites derived from the human Vcam-1 (VCAM-1.2-κB-luc), 
E-selectin (E-selectin-κB-luc), or Icam-1 (ICAM-1-κB-luc) promoters 
(219). 
 Fe chelation inhibited by 38% the transcription of VCAM-1.2-κB-
luc driven by wild-type RelA. It also inhibited by 52 and 32% transcription 
driven by the RelA S281A or S311A point mutants, respectively (see 
Figure 4.8.b), while it failed to inhibit RelA S205A- or S276A-driven 
transcription (see Figure 4.8.b). Similar results were obtained using the 
ICAM-1-κB-luc reporter; i.e., Fe chelation inhibited by 53% 
transactivation by wild-type RelA but failed to inhibit transactivation by 
RelA S205A or S276A point mutants (see Figure 4.8.c). Fe chelation 
inhibited by 38% the transactivation of ICAM-1-κB-luc by the S311A 
RelA mutant while RelA S281A activity was abolished using this reporter 
(see Figure 4.8.c). Similarly, Fe chelation inhibited by 25% the 
transactivation of the E-selectin-κB-luc reporter by wild-type RelA (see 
Figure 4.8.d), consistent with our previous observation that HO-1 and/or 
Fe chelation are less efficient in blocking E-selectin as compared with 
VCAM-1 expression (321). Again, Fe chelation failed to suppress S205A 
or S276A RelA-driven E-selectin-κB-luc reporter transactivation (see 
Figure 4.8.d). Taken together, these data suggest that Fe chelation 
inhibits RelA activity via a mechanism that targets specifically RelA S205 
and S276 but not S281 or S311. 
 We then asked whether Fe chelation modulates RelA 
phosphorylation at S276, an effect that would justify its inhibitory effect 
(see Figure 4.8.a–d) (219, 285). As described previously (285), RelA 
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S276 is constitutively phosphorylated in resting MEF (see Figure 4.8.e) 
as well as in MEC (see Figure 4.8.f). Exposure to TNF failed to increase 
RelA S276 phosphorylation in MEF (see Figure 4.8.e) but did so in MEC 
(see Figure 4.8.f). Fe chelation by DFO decreased S276 phosphorylation 
by 50–60% in resting as well as in TNF-stimulated MEF (see Figure 
4.8.e). Fe chelation fully suppressed TNF-driven S276 phosphorylation 
in MEC (see Figure 4.8.f) while not affecting basal RelA S276 
phosphorylation (see Figure 4.8.f). Taken together, these observations 
suggest that down-modulation of labile Fe inhibits RelA S276 
phosphorylation, thus explaining its ability to suppress RelA activity (219, 
285). 
 
IV. Discussion 
 
Given that HO-1 overexpression reduces cellular Fe content (328) we 
asked whether HO-1 would act in a similar manner when expressed 
under physiologic conditions in EC. Our data suggest that this is the 
case, because labile Fe content was significantly higher in EC isolated 
from Hmox1–/– mice as compared with those isolated from Hmox1+/+ 
mice (see Figure 4.1.d). Based on the above, we suggest that HO-1 
might act as a physiologic regulator of EC labile Fe content, a notion in 
keeping with the deposition of labile Fe in the vasculature of Hmox1-
deficient mice (70) as well as that associated with the one reported case 
of HMOX1 deficiency in humans (71). 
 Several mechanisms have been proposed as to how HO-1 
modulates cellular labile Fe content, including through the up-regulation 
of FtH (54) and/or the activation of ATPase Fe efflux pumps (328). Given 
that free Fe can induce the expression of FtH, one would predict that 
increased labile Fe content in Hmox1–/– EC would lead to higher FtH 
expression (54). However, FtH expression was very significantly 
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decreased in Hmox1–/– vs Hmox1+/+ EC (data not shown). One possible 
explanation for this apparently contradictory observation would be that 
the accumulation of ROS in Hmox1–/– (see Figure 4.6.g) might promote 
FtH degradation (335), an effect that could account for an overall 
decrease in FtH expression and thus for the increased labile Fe content 
observed in Hmox1–/– EC (see Figure 4.1.d). 
 EC from Hmox1–/– mice expressed higher basal levels of VCAM-
1 as compared with EC from Hmox1+/+ mice (see Figures 4.1.e–g). This 
suggests that HO-1 is a physiologic regulator of VCAM-1 expression in 
EC. Increased VCAM-1 expression in Hmox1–/– EC was reversed by Fe 
chelation (see Figure 4.1.g), suggesting that there is a functional link 
between the ability of HO-1 to down-regulate labile Fe and to inhibit 
VCAM-1 expression. 
 HO-1 overexpression in EC decreases labile Fe content to the 
same extent as Fe chelation by DFO (see Figure 4.2.a), an effect that 
probably explains the ability of HO-1 to inhibit the up-regulation of 
VCAM-1 expression in response to proinflammatory agonists such as 
TNF. That labile Fe may be involved in the regulation of proinflammatory 
gene expression in response to TNF is suggested by the observation 
that TNF triggers a transient rise of labile Fe content in EC (see Figure 
4.2.b). When labile Fe is decreased, either by overexpressing HO-1 or 
by chelating Fe, the ability of TNF to induce the expression of VCAM-1 is 
inhibited (see Figures 4.2.c–f), a finding in keeping with our previous 
results (321). The physiologic relevance of these findings is supported 
by the observation that Hmox1 deletion increases TNF-driven VCAM-1 
expression, an effect reversed when labile Fe is chelated by DFO (see 
Figure 4.2.g). Similar effects were observed for other adhesion 
molecules such as E-selectin (see Figure 4.2.h) and ICAM-1 (see Figure 
4.2.i), suggesting that the inhibitory effects of HO-1/Fe chelation can be 
extended to other proinflammatory genes associated with EC activation. 
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 The observation that Fe chelation inhibits TNF-driven Vcam-1 
(see Figures 4.3.a and 4.3.b), E-selectin (see Figures 4.3.c and 4.3.d), 
and Icam-1 (see Figures 4.3.e and 4.3.f) transcription suggests that NF-
κB, a transcription factor required for TNF-driven transcription of these 
genes in EC (301, 312, 321), might be the target of Fe chelation (321). 
Although our data suggest that this is the case (see Figure 4.4.a–d), we 
found that inhibition of NF-κB does not occur at the level of IκBα 
phosphorylation/degradation (see Figure 4.5.a), C-terminal RelA 
phosphorylation, i.e. S536 (see Figure 4.5.a), or RelA nuclear 
translocation (see Figure 4.5.b), and most probably not via the inhibition 
of NF-κB binding to κB DNA binding motifs in the promoter of Vcam-1, 
E-selectin, or Icam-1 (see Figure 4.5.d). Fe chelation inhibits RelA 
transcriptional activity via a mechanism that targets specifically its N-
terminal domain (see Figures 4.7.a and 4.7.b). 
 Because N-terminal phosphorylation is required to support 
RelA transactivation activity (219, 285), we tested whether Fe chelation 
inhibited RelA activity via a mechanism dependent on S phospho-
acceptors in the N-terminal domain of RelA. Fe chelation failed to inhibit 
the transcriptional activity of RelA S205A or S276A point mutants as 
assessed by using synthetic NF-κB luciferase reporters containing κB 
DNA motifs from the human Vcam-1 (see Figure 4.8.b), Icam-1 (see 
Figure 4.8.c), or E-selectin (see Figure 4.8.d) promoters. This led to the 
hypothesis that HO-1 and/or Fe chelation might interfere with S276 
phosphorylation. We found that Fe chelation inhibits RelA S276 
phosphorylation (see Figure 4.8.e and 4.8.f) in a manner that should 
account for its inhibitory effect over RelA activity (219, 285). Whether Fe 
chelation modulates RelA S205 phosphorylation could not be 
established, as reagents are not available to monitor this phospho-
acceptor. 
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 A likely scenario to explain the inhibitory effects observed would 
be that labile Fe availability, which promotes the generation of ROS (see 
Fig 4.6.g) via the Fenton reaction (330), might regulate the expression 
and/or activity of kinase(s) and/or phosphatase(s) that target RelA at 
S276 and/or S205 (see Figure 4.8.a–d) and thus regulate RelA activity 
(318). The notion that labile Fe targets RelA activity via ROS is 
supported by the observation that the antioxidant NAC, a radical 
scavenger and glutathione precursor, suppressed RelA activity in a 
manner that mimicked Fe chelation (see Figure 4.6.h). This inhibitory 
effect is in keeping with our previous observation that BR, another potent 
antioxidant (53), also inhibits NF-κB activation in EC (321). Whether BR 
targets RelA in a similar manner to Fe chelation, i.e., inhibiting RelA 
S276 phosphorylation, remains to be established but is likely to be the 
case. 
 Putative candidate kinases modulated by ROS and targeting 
RelA activity in EC include PKA (180, 182), MSK1 (185), and PKCζ 
(219, 285). Among these, PKA, which has been shown to target RelA 
S276, is probably the most likely candidate because Fe chelation can 
regulate its expression/activity (336). Whether the ability of HO-1 and/or 
Fe chelation to inhibit RelA activity acts via PKA remains to be 
established. 
 We suggest, that the putative kinase(s) and/or phosphatase(s) 
that target RelA S276 interfere with the mechanism via which the RHD 
promotes transcriptional activity upon binding to κB DNA motifs. This is 
supported by the observation that Fe chelation inhibits the transcriptional 
activity of a RelA chimeric protein (TET/RelA) only when this protein 
binds DNA via the RHD (i.e., binding to κB DNA recognition motifs in a 
NF-κB reporter; Figure 4.7.d) but not when the same protein binds DNA 
via its TET domain (i.e., binding to tet° recognition motifs in a Tet 
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reporter) (see Figure 4.7.e). It is possible that such kinase(s) and/or 
phosphatase(s) might target RHD after binding to κB DNA recognition 
motifs. This hypothesis remains, however, to be tested. 
 The mechanism via which HO-1 controls NF-κB activation in EC 
provides clues as to its protective effect in the context of vascular 
inflammation (337-339). We suggest that down-regulation of EC labile 
Fe content may inhibit specifically the expression of proinflammatory 
genes associated with EC activation, e.g., adhesion molecules, while 
sparing that of anti-apoptotic genes (340). Such an effect is consistent 
with targeting of RelA S276, a phospho-acceptor that controls RelA cis-
acting element specificity (219). That is, by down modulating S276 RelA 
phosphorylation, HO-1 and/or Fe chelation might direct this NF-κB family 
member to transcribe specific subsets of genes (219). It is likely that this 
would occur via modulation of RelA interaction with co-activators 
required to support the transcription of specific gene subsets (318). Such 
a mechanism would explain how HO-1 has reached a "functional 
compromise" in which it inhibits specifically the transactivation of 
proinflammatory genes but probably not that of anti-apoptotic genes 
required to support its cytoprotective effects, i.e., A1 and c-inhibitor of 
apoptosis (IAP)2 (340). These two biologic effects, i.e., anti-inflammatory 
and cytoprotective, are accomplished by different end products of heme 
degradation, i.e., labile Fe controls NF-κB while CO is cytoprotective 
without interfering with NF-κB (321). 
 In conclusion, the effects reported hereby provide clues as to our 
understanding of the protective effect of HO-1 in countering the 
pathogenesis of inflammatory diseases, including autoimmune 
neuroinflammation (339) as well as neuroinflammation emanating from 
unfettered responses to microbial challenge, e.g., cerebral malaria (338). 
Our present data support the notion that these protective effects are 
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mediated, at least partially, via the ability of HO-1 to modulate EC labile 
Fe content, an effect that regulates NF-κB activity in a manner that is 
anti-inflammatory and cytoprotective. Finally, these data might also help 
in providing a mechanism for the palliative effects of Fe chelation 
therapies. 
 
V. Materials and Methods 
 
Mice 
BALB/c Hmox1–/– mice, generated by S.-F. Yet of the Pulmonary and 
Critical Care Division, Brigham and Women’s Hospital (341), were 
maintained at the Instituto Gulbenkian de Ciência (Oeiras, Portugal) 
under specific pathogen-free conditions in accordance with guidelines 
from the Animal Use and Institutional Ethical Committee of this institute. 
Genotypes were verified by genomic PCR using the following primers: 
Hmox1 (5'-GGT GAC AGA AGA GGC TAA G-3' and 5'-CTG TAA CTC 
CAC CTC CAA C-3') and neomycin (5'-TCT TGA CGA GTT CTT CTG 
AG-3' and 5'-ACG AAG TGA CGC CAT CTG T-3'). 
 
Cell culture 
Murine endothelial cells (MEC) were isolated as described (342). Briefly, 
three hearts were mechanically minced, digested (2.2U/ml collagenase 
A at 37°C for 30 min; Sigma-Aldrich), washed, and labeled with rat anti-
mouse PECAM-1 Ab (CD31; BD Pharmingen) plus goat anti-rat IgG 
microbeads MACS (Miltenyi Biotec). Labeled EC were purified in 
magnetic separation columns as per the manufacturer’s instructions 
(Miltenyi Biotec). EC phenotype was assessed by cobblestone 
morphology and confirmed by flow cytometry (CD31/CD105 expression). 
MEC were passaged 1/3 and used between passages 6 and 12. Bovine 
aortic endothelial cells (BAEC) were obtained as previously described 
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(321) or purchased from Vec Technologies or Cell Systems and cultured 
on gelatinized plates in complete medium (MCDB-131; 20% FCS, 20 
mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin; 
Invitrogen Life Technologies). BAEC were passaged 1/3 and used 
between passages 6 and 10. Immortalized human epithelial kidney 293 
(HEK-293) cells were obtained from American Type Culture Collection 
and cultured as for BAEC. Pooled HUVEC (Clonetics) were cultured in 
EBM-2 medium supplemented according to the provider’s instructions 
(Clonetics). HUVEC were passaged 1/3 and used between passages 4 
and 6. Mouse embryonic fibroblasts (MEF) from RelA–/– mice were 
provided by Dr. A. Beg from Columbia University, New York, NY (343). 
MEF were cultured in DMEM (Mediatech) supplemented with FCS 
(10%), penicillin (50 U/ml), and streptomycin (50 µg/ml) (Atlanta 
Biologicals). RelA–/– MEF were stably transfected with human RelA 
recombinant retroviruses essentially as described (219). 
 
Immunoprecipitation 
Cells were lysed in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM 
MgCl2, 5 mM KCl, 1% Triton X-100, and a Roche Protease Inhibitor 
Cocktail (complete EDTA-free, one tablet per 10 ml of lysis solution). 
Soluble fractions were incubated with a protein G-Sepharose 
bead/antibody complex in borate-buffered solution with 1% Triton X-100 
(for 4 h at 4°C). RelA was immunoprecipitated with anti-mouse mAb (2 
µg; catalog no. SC-8008, Santa Cruz Biotechnology). 
Immunoprecipitated proteins were washed in lysis buffer, resuspended 
in 2x sample buffer, heated to 100°C for 5 min, resolved by SDS-PAGE, 
and subjected to Western blotting. 
 
Western blots 
Cells were lysed in Laemmli sample buffer and proteins were resolved 
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by electrophoresis on 8–10% SDS-polyacrylamide gels (344), 
transferred to polyvinylidene fluoride membrane (Bio-Rad), and blotted 
with Abs to HO-1 (catalog no. SPA-895 or SPA-896, Stressgen), RelA 
(catalog no. SC-372, Santa Cruz Biotechnology), phospho-S536-RelA 
(catalog no.3031, Cell Signaling), phospho-S276-RelA (catalog no.3037, 
Cell Signaling), IκBα (catalog no. SC-371, Santa Cruz Biotechnology), 
phospho-S32-S36-IκBα (catalog no.9246, Cell Signaling), c-Myc (clone 
9E10; American Type Culture Collection), or α-tubulin (clone DM 1A; 
catalog no. T-9026, Sigma-Aldrich). Primary Abs were detected using 
HRP-conjugated secondary Abs (Pierce). Labeling was visualized using 
SuperSignal West Pico Chemiluminescent Substrate (Pierce) and 
exposed to BioMax film (Kodak). 
 
Flow cytometry 
Confluent EC (∼4 x 105) were washed in PBS and detached with 0.125% 
trypsin/0.05% EDTA (at 37°C for 5 min; Invitrogen Life Technologies). 
Digestion was stopped with complete MCDB-131 medium and cells were 
pelleted by centrifugation (200 xg at 4°C for 3min), resuspended in 150µl 
of FACS medium (PBS, 3% FCS, and 0.01% sodium azide), transferred 
into round-bottom 96-well plates (TPP) and pelleted (200 xg at 4°C for 3 
min). Supernatant was removed and cells were incubated in 25–50 µl of 
FACS medium with primary Ab (5 µg/ml for 30 min at 4°C) against 
endoglin/CD105 (catalog no.550546, BD Biosciences), PECAM/CD31 
(catalog no.553370, BD Biosciences), or VCAM-1/CD106 (catalog 
no.553331, BD Biosciences). Cells were washed in FACS medium (3x 
200 µl at 200 xg and 4°C for 3 min) and primary Abs were detected 
using FITC-labeled secondary Abs (catalog no. F-6258, Sigma-Aldrich) 
in FACS medium (25 µl for 30 min at 4°C). Cells were costained with 
propidium iodide (0.5µg/ml) to assess cellular viability. Fluorescence was 
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measured by flow cytometry on a FACSCalibur device (BD Biosciences). 
 
Cellular Fe assay 
Labile and non-labile Fe were measured essentially as described 
previously (345) using Ferene-S (346). Briefly, confluent EC (1 x 107) 
were harvested by trypsinization, pelleted (200 xg at 4°C for 3 min), 
washed three times with Fe-depleted PBS (1% Chelex-100 for 12 h) 
(Bio-Rad), and digested (0.5 ml of 25% perchloric acid at 4°C for 30 
min). Supernatants (containing labile Fe) were collected after 
centrifugation (10,000 xg at 4°C for 15 min), pellets were digested (0.1 
ml of 10 M nitric acid at 60°C for 16 h), pH was neutralized (10 M 
NaOH), cellular debris was pelleted (10000 xg at 4°C for 15 min), and 
supernatants were collected as the non-labile cellular Fe fraction. Fe in 
both fractions was converted to the ferrous (Fe2+) form using sodium 
ascorbate (0.25 M, 0.1 ml) plus an equal volume of ammonium acetate 
(40%). Ferene-S (600 µM; BioVectra) was added and OD was measured 
at λ594 nm. Fe levels were normalized to total protein content as 
determined by Bradford assay. Fe fractions are expressed as moles of 
Fe per milligram of cellular protein. Assays were performed at least in 
triplicate for each condition. 
 
Quantitative real-time PCR 
cDNA was obtained from total RNA as described (347). The relative 
number of mRNA transcripts was assessed using LightCycler real-time 
quantitative PCR (Roche) using FastStart DNA SYBR Green I mix 
(Roche). The transcript number was calculated using a 2–ΔCT method 
(relative number) (348) or quantified as an absolute value using standard 
cDNA plasmids encoding the same sequences as the ones amplified by 
PCR. Results were normalized to hypoxanthine-guanine-
phosphoribosyltransferase (HPRT) (349). PCR primers used were as 
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follows: 5'-TGG GAG AGA CAA AGC AGA AG-3' and 5'-AGA TGG TCA 
AAG GGA TAC AC-3' or 5'-TGC CGA GCT AAA TTA CAC ATT G-3' and 
5'-CCT TGT GGA GGG ATG TAC AGA-3' for Vcam-1; 5'-GCC TTG GTA 
GAG GTG ACT GAG-3' and 5'-GAC CGG AGC TGA AAA GTT GTA-3' 
for Icam-1; 5'-CTG CTC TTG TTT TTG TTC TC-3' and 5'-CTT CCA TAG 
TCA GGG TGT TC-3' for E-selectin; and 5'-GCT GGT GAA AAG GAC 
CTC T-3' and 5'-CAC AGG ACT AGA ACA CCT GC-3' for Hprt. 
 
Reporters and expression constructs 
Rattus norvegicus Hmox1 cDNA was expressed in pcDNA3 (Invitrogen 
Life Technologies) (58). N-terminal Myc-tagged RelA, p50, and cRel 
expression vectors have been described in Refs. (285) and (340), 
respectively. The NF-κB luciferase (luc) reporter (κB-luc) consists of 
three NF-κB binding sites, i.e., NF-E-selectin, κB-2, and κB-3, derived 
from the porcine E-selectin promoter (284). Other NF-κB luciferase 
reporter constructs, i.e., VCAM-1.2-κB-luc, ICAM-1-κB-luc, and E-
selectin-κB-luc have been described elsewhere (219). Briefly, the 
minimal SV40 promoter in the pGL3-promoter vector (Promega) was 
replaced with a minimal 5'-GAT CTG GGT ATA TAA TGG ATC CCC 
GGG TAC GCA GCT CAA GCT-3' promoter, and the synthetic 
oligonucleotides coding for the κB consensus sequence derived from the 
Vcam-1, Icam-1, or E-selectin promoter were cloned upstream of this 
minimal promoter so that they differ only in their decameric κB 
consensus sequences. The prototypical sequence used was 5'-GCT-κB-
decamer-CTGAGCTCCT-κB-deamer-CTCAGCT-3', in which the 
decameric κB consensus were GGGATTTCCC for VCAM-1.2-κB-luc, 
TGGAAATTCC for ICAM-1-κB, and GGGGATTTCC for E-selectin-κB-
luc (219). The human VCAM1 (–1716/+119) luciferase reporter was 
kindly provided by W. C. Aird (Department of Molecular Medicine, Beth 
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Israel Deaconess Medical Center, Boston, MA) (350). The porcine E-
selectin (–1286/+482) luciferase reporter has been described (351). The 
ICAM-1-luc (–339/-30) luciferase reporter was kindly provided by J. S. 
Pober (Boyer Center for Molecular Medicine, Yale University School of 
Medicine, New Haven, Connecticut) (352). The tetracycline operon (tet°) 
luciferase reporter (tet°-luc) contains seven upstream tet° sequences 
derived from the tet° flanked by two divergently orientated 
cytomegalovirus minimal promoters driving the full-length firefly 
luciferase gene (H. Bujard, University of Heidelberg, Germany) (285). N-
terminal Myc-tagged RelA and serine to alanine (S205A, S276A, S281A, 
and S311A) RelA mutants have been described (219). Myc-tagged RelA 
chimeric expression vectors have been described elsewhere (285). 
Briefly, RelA (2–320)/VP16 is composed of the RelA RHD (aa 2–320) 
fused to virion protein 16 (VP16) (285). TET/RelA (aa 2–551) is 
composed of a tet° DNA binding domain (TET) fused to the full-length 
RelA (285). TET/RelA (268–551) is composed of TET fused to the RelA 
transactivation domain (TAD) (aa 268–551) (285). TET/VP16 is 
composed of TET fused to VP16 (285). The pSV-β-galactosidase 
reporter (Promega) consists of the lacZ gene from Escherichia coli under 
the control of the SV40 early promoter and enhancer, providing for 
constitutive expression in EC. The pCAGGS-AFP vector drives 
enhanced GFP expression by a CMV/actin hybrid promoter (353). The 
pRL-SV40 control vector contains the cDNA encoding Renilla luciferase 
under the control of the SV40 early promoter and enhancer (Promega). 
 
Recombinant adenoviruses 
HUVEC were transduced with recombinant adenoviruses as described 
(321). The recombinant β-galactosidase adenovirus was a gift from R. 
Gerard (University of Texas Southwest Medical Center, Dallas, TX). The 
recombinant HO-1 adenovirus containing the entire coding region of the 
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R. norvegicus HO-1 cDNA has been described (321). 
 
Transient transfection and luciferase assays 
BAEC, HUVEC, and HEK-293 cells were transfected at 60–70% 
confluence using the Lipofectamine 2000 reagent according to the 
manufacturer’s instructions (Invitrogen Life Science Technologies). In 
BAEC and HEK-293, 3 µg of total DNA was used per well of a 6-well 
plate with 2 µl of Lipofectamine 2000. For HUVEC, 1.5–2.5 µg of DNA 
was used with 1 µl of Lipofectamine 2000. The total amount of DNA was 
kept constant using pcDNA3 (Promega). Briefly, cells were washed and 
placed in serum and antibiotic-free medium followed by the addition of 
the DNA/Lipofectamine and replaced thereafter (2.5 h) with medium 
containing sera. Transfection efficiency was determined by either flow 
cytometry or fluorescence microscopy in cells co-transfected with 
pCAGGS-AFP. Transfection efficiency was typically 50% for BAEC, 
>95% for HEK-293, and 5–20% for HUVEC. 
 Luciferase assays were performed using a single (firefly) 
luciferase assay system (Promega) according to manufacturers 
instructions with a β-galactosidase control expression vector (pSV-β-
galactosidase) as the control for transfection and extraction efficiency. β-
Galactosidase expression was detected using Galacto-Light Plus β-
Galactosidase Reporter Gene Assay System (Applied Biosystems). 
Alternatively, a Dual Luciferase Assay System (Promega) was used with 
a Renilla control expression vector (pRL-SV40). Assays were performed 
in triplicate and luciferase values were normalized to either β-
galactosidase or Renilla luciferase. 
 
Cellular ELISA 
Two days postconfluence, HUVEC were exposed to human recombinant  
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TNF at the indicated concentrations and times. The procedure has been 
described in detail elsewhere (321). 
 
Immunostaings 
Confluent EC were washed in PBS and fixed with 3.7% 
paraformaldehyde (20 min at room temperature). Immunostainings were 
performed using an anti-RelA mAb (catalog no. SC-372, Santa-Cruz 
Biotechnology) plus a FITC-labeled goat anti-rabbit polyclonal Ab 
(Pierce). DNA was stained using 20 ng/ml 4',6-diamidino-2-phenylindole 
(DAPI; Sigma-Aldrich). Stainings were detected using a fluorescence 
microscope (Leica DMRA2) at λEx480/40 nm and λEm527/30 nm for FITC and 
λEx360/40 nm and λEm470/40 nm(where Ex is excitation and Em is emission) 
for DAPI. Images were acquired using Metamorph version 4.6r5 
software (Universal Imaging Corporation) and analyzed with NIH ImageJ 
software. 
 
Reagents 
Human recombinant TNF (R & D Systems) was resuspended in PBS 
plus 0.1% BSA and added directly to culture medium. Deferoxamine 
mesylate (DFO) (Sigma-Aldrich) was dissolved in culture medium at 30 
and 250 µM. N-(2-hydroxybenzyl)-L-serine (HBSer; 0.5–5 mM) (354) 
was a gift from R. Tyrrell, Department of Pharmacology, University of 
Bath, Bath, U.K. (332). Salicylaldehyde isonicotinoylhydrazone (SIH; 5–
100 µM) (gift from Dr. P. Ponka, McGill University, Montreal, Quebec, 
Canada) was prepared as described (333). N-acetyl-L-cysteine (Sigma-
Aldrich) was dissolved in culture medium, neutralized to pH 7.5 with 0.2–
1 M NaOH, and added to culture medium (0.5 and 25 mM). 5-(and-6)-
Chloromethyl-2',7'-dichlorofluorescein diacetate, acetyl ester (CM-
H2DCFDA, Molecular Probes) was dissolved in DMSO (Sigma-Aldrich) 
and added to culture medium (3 µM). 
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ROS detection 
Cellular ROS content was assayed by flow cytometry using CM-
H2DCFDA. Two days postconfluence, MEC were collected by 
trypsinization, pelleted (200 xg at 4°C for 3 min), washed in PBS, and 
incubated with CM-H2DCFDA (3 µM in PBS; 37°C for 15 min). Cells 
were washed twice in PBS with 2% FCS and resuspended in PBS with 
2% FCS (37°C for 30 min). Fluorescence was measured by flow 
cytometry (FACSCalibur; BD Biosciences) and data were analyzed using 
FlowJo software (Tree Star). Propidium iodide (5 µg/ml) was used to 
exclude dead cells. 
 
EMSA 
Nuclear extracts were obtained from confluent BAEC as described (285, 
340). Protein concentration was determined by Bradford assay. EMSA 
was performed essentially as previously described (285, 340). Briefly, 
double-stranded oligonucleotides were generated with the following 
sequences. 5'-AGT TGA GGG GTT TCC CCC AGG C-3' (VCAM-1.1); 
5'-AGT TGA GGG GAT TTC CCC AGG C-3' (VCAM-1.2); 5'-AGT TGA 
GTG GAA ATT CCC AGG C-3' (ICAM-1); 5'-AGT TGA GGG GGA TTT 
CCC AGG C-3' (E-selectin); and 5'-AGT TGA GGG GAC TTT CCC AGG 
C-3' (Ig-κB). Oligonucleotides were labeled by phosphorylation with [γ-
32P]ATP. EMSA was visualized in the form of autoradiographs indicating 
DNA/protein binding. 
 
Statistical analysis 
Statistical significance was assessed using an unpaired two-tailed t test 
assuming unequal variances as specified in Results according to 
experimental design, except for data in Figure 4.1.e where a one-
sample, one-tailed z test was used. 
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CHAPTER V 
GENERAL DISCUSSION 
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1. One transcription factor - many transcriptional responses 
 
Living in an ever-changing environment, cells have evolved numerous 
mechanisms to sense their environment, communicate with each other 
and integrate the information allowing for continuous adaptation to the 
environment. A significant part of this signal integration and decision-
making process occurs at the level of regulation of gene transcription 
(76). While the entire human transcriptional machinery is estimated to 
consist of 1,000 to 2,000 TFs regulating the expression of ~30,000 
genes, little is known about the specificity of their regulatory functions, 
levels and patterns of their expression and their interactive networks 
(355). Much of the diversity of transcriptional responses is due to TF 
binding to DNA regulatory regions that depends largely on post-
translational regulatory mechanisms targeting the TF as well as histones 
embedded by the DNA (215, 356). The NF-κB family of TFs represents 
one of the best-characterized TF in which post-translational modulations 
play a central role in the transcription of hundreds of target genes 
controlling inducible and cell type specific responses that are central to 
maintain organism integrity. Due to its dominant role in regulating cell 
survival, proliferation and PCD associated with inflammatory and 
immune responses, NF-κB has gained a tremendous research interest 
soon after its discovery and has since served as a model system for 
understanding basic mechanisms of transcriptional regulation in higher 
eukaryotes (80). 
 NF-κB originated at the dawn of the Metazoan (101) serving ever 
since as a common integrator of diverse environmental cues, triggering 
specific adaptive responses, which probably contributed to the 
complexity of mechanisms controlling its transcriptional activity. The 
central mechanism regulating the activity of this TF, relying on the 
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degradation of its constitutive inhibitors IκBs, has been traced back to 
ancient arthropods, such as the horseshoe crab (97). To what extent the 
other mechanisms responsible for the diversity of NF-κB-dependent 
responses are evolutionary conserved is a matter of debate. Post-
translational modifications probably evolved as an additional mechanism 
capable of fine-tuning NF-κB activity by regulating different events 
interfering with its function. These include NF-κB stability, subcellular 
localization, interaction with IκB, DNA, transcriptional cofactors and 
chromatin remodeling complexes (176). These different mechanisms of 
action are best illustrated for RelA, the major transcriptionally active 
member of the NF-κB family. It is increasingly accepted that the RelA 
transcriptional activity is not solely regulated by a single post-
translational modification. Rather, a combinatorial usage of both 
activating and inhibiting post-translational modifications in response to a 
particular stimulus are ensuring the specific temporal and spatial 
transcriptional rate of a particular RelA-dependant gene. Thus, post-
translational modifications should be represented as a sequence of 
coordinated events leading to the activation or the inhibition of RelA-
dependent transcription.  
 Phosphorylation of RelA S276 is one of the best-characterized 
post-translational modifications targeting this TF. Following LPS 
stimulation, PKA-mediated RelA phosphorylation at S276 induces 
conformational changes promoting the interaction of RelA with the 
transcriptional activator HAT CBP/p300, while diminishing the binding of 
transcriptional repressors such as HDACs (182). Besides controlling 
chromatin accessibility for the transcriptional machinery, the opposing 
effects of HATs and HDACs also regulate RelA transcriptional activity by 
targeting different RelA lysine (K) residues for acetylation and 
deacetylation, respectively (see Chapter I Section II.2.3.2.). Depending 
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on the K residue, RelA acetylation status influences its transcriptional 
activity by increasing or decreasing the IκB and/or DNA binding (i.e. 
K122, K123, K218, K221), regulating other post-translational 
modifications (i.e. K310) as well as by an unknown mechanism (i.e. 
K314, K315) (198-200). Several of these K residues can undergo other 
post-translational modifications such as methylation and ubiquitination. 
Contrary to RelA K314 and K315 acetylation, which promote NF-κB-
dependent transcription, methylation of these K residues decreases NF-
κB transcriptional activity by promoting RelA ubiquitination and 
proteasomal degradation (204). K310 monomethylation contrary to 
acetylation also inhibits RelA transcriptional activity via a mechanism 
that involves histone H3 K9 methylation (203). It is therefore possible 
that acetylation of these residues could promote RelA transcriptional 
activity by preventing the inhibitory effect associated with their 
methylation. On the other hand, both K218 and K221 acetylation and 
methylation promote RelA transcriptional activity, possibly regulating 
different sets of NF-κB-dependent genes (199, 205). Moreover, K123, 
K310 and K315 have recently been identified to undergo ubiquitination 
as well (212). Thus the balance of and the competition between different 
post-translational modifications rather than a single post-translational 
modification are likely to be essential in regulating the transcriptional rate 
of a particular gene in a cell-type- or a stimulus-dependent way. 
 RelA S276 phosphorylation and its consequent binding to 
CBP/p300 are critical for RelA transcriptional activity. This regulatory 
mechanism relies on at least three different kinases targeting 
cytoplasmic as well as nuclear RelA S276 in response to distinct 
signaling pathways (see Chapter I Section II.2.3.1.). Moreover, one of 
these kinases, i.e. PKA, also phosphorylates evolutionary conserved 
S276 phosphorylation site in Drosophila, as illustrated by its effect in 
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controlling the nuclear translocation of the Drosophila RelA homologue 
Dorsal (177, 189). Phosphorylation of RelA S276 is, however, not 
globally required for its transcriptional activity, but it is rather dependent 
on the nature of the DNA sequence to which it is bound, regulating 
transcription in a promoter specific manner (219). We found that RelA 
phosphorylation mutant, mimicked by S276A mutation, translocates to 
PML nuclear bodies, an effect possibly associated with its gene-specific 
transcriptional activity (see Chapter III Figures 3.1. and 3.2.). While the 
implications of this phenomenon are to be addressed, there are several 
possible explanations for RelA translocation into the PML nuclear 
bodies. PML nuclear bodies can both positively and negatively regulate 
transcription. RelA translocation into PML nuclear bodies has been 
previously implicated in the regulation of its transcriptional activity, 
leading to RelA proteasomal degradation and hence termination of NF-
κB-dependent gene transcription (211). While we did not assess the 
stability of RelA inside the PML nuclear bodies, based on this 
observation, it is possible to predict that translocation of 
hypophosphorylated RelA to PML nuclear bodies could precede its 
degradation. On the other hand, PML nuclear bodies can store 
accumulated nuclear proteins independently of their degradation (231). 
RelA S276A mutant decreases the expression of IκBα, promoting RelA 
nuclear retention (308). In one scenario, RelA S276A sequestration in 
PML nuclear bodies could induce gene transcription of a RelA S276 
phosphorylation state-independent subset of NF-κB dependent gene, 
such as the major histocompatibility (MHC) class I (219). In this case, 
PML nuclear bodies could serve as a site of active transcription or by 
regulating RelA post-translational modifications as shown for other TF 
(299). In another scenario, PML nuclear bodies could regulate 
termination of NF-κB activity, serving as a nuclear pool of 
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transcriptionally inactive RelA in the absence of substantial RelA-IκBs 
nuclear export, independently of its degradation. It should be noted that 
RelA phosphorylation at other phospho-acceptor sites such as S468 can 
mediate its translocation to other nuclear compartments, such as 
illustrated by the speckled nuclear distribution of RelA in response to 
TNF (190). This possibly promotes COMMD1-mediated RelA 
ubiquitination followed by its proteasomal degradation (191).  
 
2. NF-κB in physiology and pathology  
 
The TF NF-κB is critically involved in the regulation of both homeostatic 
and pathological processes. While a complexity of mechanism regulating 
NF-κB transcriptional activity have evolved, aimed at re-establishing 
homeostasis in response to different forms of stress, deregulated NF-κB 
activity per se can lead to a number of pathological conditions including 
immune-mediated inflammatory diseases. The role of NF-κB in 
inflammation is complex and the timing of specific NF-κB-dependent 
gene expression patterns highly correlates with ongoing physiological 
processes over the course of inflammation (357). Hence, first genes to 
be expressed facilitate neutrophil infiltration, following the expression of 
genes facilitating macrophage recruitment to the site of inflammation, 
with a concomitant expression of genes helping tissue repair and 
restoration of homeostasis (357). As such, NF-κB-dependent pro-
inflammatory responses must be shut down after clearing the injurious 
stimulus. Still, NF-κB activity is required in what concerns its pro-
apoptotic function in neutrophils as well as its anti-inflammatory and anti-
apoptotic functions in other cells (358). Supporting this notion, genetic 
deletion of a major transcriptionally active NF-κB family member RelA is 
lethal because it promotes PCD in response to pro-inflammatory 
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agonists such as TNF (108). Thus, the mechanisms controlling NF-κB 
activity are critical for the resolution of inflammation. One of the 
mechanisms regulating termination of NF-κB activation probably relies 
on NF-κB post-translational modifications, which can besides other 
processes inhibit NF-κB DNA binding as well as promote NF-κB 
interaction with IκBα, translocation to specific subnuclear compartments 
or NF-κB degradation (176). This can be achieved via different 
mechanisms including via the action of stress-responsive genes, such as 
HO-1 (see Chapter IV). We demonstrate that HO-1 controls RelA 
phosphorylation at S276, an effect that can itself regulate RelA 
translocation to specific subnuclear compartments such as PML bodies 
(see Chapters III, IV). We also show that a member of CCT family of 
proteins with chaperone activity can regulate RelA transcriptional activity 
in a promoter-specific context by modulating RelA K122/123 acetylation, 
and as such contribute to the resolution of inflammation (see Chapter II). 
 HO-1 is a stress responsive gene that uncouples inflammatory 
responses from tissue damage and disease (68). This notion is 
supported by the observation that inflammatory responses fail to restore 
homeostasis in the absence of HO-1 (339, 359). While there are many 
mechanisms involved in salutary effects of HO-1, we found that one of 
these mechanisms in EC probably relies on its ability to control the 
extent of NF-κB activation. Expression of HO-1 acts directly or indirectly 
to control cellular labile Fe content, an effect associated with the 
inhibition of RelA S276 phosphorylation controlling NF-κB activity (see 
Chapter IV Figures 4.1.d, 4.2.a and 4.8.). If not tightly controlled, cellular 
labile Fe can be highly deleterious, promoting the generation of ROS 
(see Chapter IV, Figure 4.6.g) via the Fenton reaction. Along with 
numerous harmful effects, the oxidative stress associated with the 
accumulation of ROS can modulate NF-κB-dependent transcription via 
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different mechanisms (360) including throughout the activation of PKA 
(180, 182) and MSK1 (185), two kinases targeting RelA S276 for 
phosphorylation (180, 185). Reducing the accumulation of reactive labile 
Fe and hence accumulation of ROS could therefore regulate PKA 
expression/activity and thus a likely scenario to explain regulatory effect 
of HO-1 over NF-κB activity would be throughout inhibition of PKA-driven 
RelA S276 phosphorylation, thus inhibiting NF-κB transcriptional activity 
(see Chapter IV Figure 4.8.). Inhibition of PKA activity, on the other 
hand, can induce RelA translocation to PML nuclear bodies, an effect 
presumably associated with inhibition of RelA S276 phoshorylation (see 
Chapter III Figures 3.1. and 3.3). It would be therefore interesting to 
assess whether HO-1, by inhibiting RelA S276 phosphorylation, also 
promotes RelA translocation to specific nuclear compartments such as 
PML nuclear bodies. While PML nuclear bodies can regulate the activity 
of TF by regulating its post-translational modifications as well as 
availability of components of the transcriptional machinery (231), 
translocation of RelA into PML nuclear bodies could be associated with 
the gene-restricted transcriptional activity of differentially phosphorylated 
S276 RelA (219). This mechanism could possibly underlie the inhibition 
of proinflammatory gene expression associated with the HO-1 
expression in EC (see Chapter IV). 
 The specific environmental conditions have likely shaped the 
mechanisms underlying a particular RelA post-translational modification 
dictating a specific gene expression pattern required for an adequate 
response to such condition. As such, S276 phosphorylation can be 
induced in a response to a wide range of environmental conditions (176), 
selectively regulating the expression of a subset of NF-κB-dependent 
genes (219). While we did not assess the effect of HO-1 on a broad 
array of RelA-dependent genes, this could possibly explain how HO-1 
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has reached a "functional compromise" in which it inhibits specifically the 
transactivation of proinflammatory genes but probably not that of 
cytoprotective genes, some of which are required to support the 
cytoprotective effects of HO-1, i.e. A1 and c-inhibitor of apoptosis (IAP) 2 
(340). 
 Given a long history of HO-1 and NF-κB co-existence and the 
number of environmental conditions linked with the expression of both 
NF-κB and HO-1, it is not surprising that one of the HO-1 protective 
effects that has evolved is to inhibit RelA S276 phosphorylation. Other 
stress-responsive genes have been shown to reduce NF-κB activation 
including several NF-κB-dependent genes, e.g. A20, IκBs, serving as a 
negative feedback loop aiming in termination of NF-κB-dependent 
transcription (150, 151, 361). Thus controlling the HO-1 activity could be 
a valuable therapeutic target in several inflammatory pathological 
conditions associated with increased RelA S276 phosphorylation such 
as polymicrobial infection-induced lung inflammation (362) and others 
(363, 364). Indeed, other anti-inflammatory drugs exert their effects by 
inhibiting RelA S276 phosphorylation (365). 
 Persistent NF-κB activation has been linked with the initiation 
and progression of tumor formation, an effect associated with sustained, 
inflammatory cell infiltration and production of cytokines, chemokines 
and growth factors as well as cell proliferation and survival (85). The role 
of RelA S276 phosphorylation in these oncogenic processes has been 
recently suggested as well. PKA-mediated RelA S276 phosphorylation 
contributes to the malignant phenotype of head and neck squamous cell 
carcinoma (HNSCC) (366). Given that HO-1 can inhibit RelA S276 
phosphorylation, acting as an anti-inflammatory gene, this could possibly 
be added on the list of mechanisms affording the anti-tumorogenic role 
of HO-1. Supporting this notion, other anti-inflammatory drugs can stop 
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tumor progression including colorectal cancer (367), an effect associated 
with the nucleolar RelA translocation, inhibition of NF-κB-dependent 
transcription and the induction of PCD (234). We have shown that 
hypophosphorylated S276 RelA translocates to PML nuclear bodies. As 
RelA translocation to PML nuclear bodies can induce RelA ubiquitination 
and subsequent proteasomal degradation (211), this could possibly 
serve as a mechanism by which HO-1 could exert its anti-tumorogenic 
function in the context of the inflammation. On the other hand, however, 
it is important to note that HO-1 is a cytoprotective gene and its 
prolonged activity could also promote tumor formation. Indeed, HO-1 
activity has been associated with several cancer formations, i.e. 
lymphosarcoma, prostate cancers, pancreatic carcinoma and squamous 
carcinoma (368). 
 Despite the extensive research about NF-κB transcriptional 
regulation, much remains unknown. One goal that would bring us closer 
to understanding the complexity of NF-κB-driven responses is to identify 
novel regulators of NF-κB transcriptional activity. To that aim we have 
performed an RNAi screen and identified the chaperonin CCT as an 
evolutionary conserved regulator of NF-κB transcriptional activity that 
exhibits its effect by modulating RelA acetylation (see Chapter II Figures 
2.1. and 2.5.a). CCT controls RelA activity in a promoter-specific context, 
depending on kinetics of the NF-κB transcriptional response. While 
promoting transcription during the early phase of RelA activation, CCT 
diminishes gene expression during the late phase of RelA transcriptional 
activity (see Chapter II, Figure 2.2.). Supporting this, other genes, such 
as COX2, that promote inflammation during the initiation stages by 
producing pro-inflammatory mediators, e.g. PGE2, can switch their action 
towards anti-inflammatory, e.g. production of 15-deoxy-Δ12,14-PGJ2, 
promoting the resolution of inflammation. (see Chapter I Section I). 
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Whereas acetylation can affect RelA activity on different levels, our data 
suggests that during the late phase of RelA activation, CCT acts via a 
mechanism that targets specifically RelA K122/123 acetylation, an effect 
associated with decreased DNA binding and termination of NF-κB-
dependent gene expression (see Chapter II Figures 2.4. and 2.5.d) 
(198). Understanding of the mechanisms underlying RelA acetylation 
under physiological conditions is still very limited. While acetylation can 
either increase or decrease levels of transcription, due to the lack of 
appropriate approaches and means available to date, increased RelA 
acetylation is generally associated with a concomitant increase in NF-κB 
activity and prognosis of immune-mediated inflammatory diseases such 
as associated with Haemophilus influenzae infection (369) or chronic 
obstructive pulmonary disease (COPD) (370). On the other hand, RelA 
acetylation can also be associated with the expression of anti-
inflammatory NF-κB-dependent genes such as IL-10 in response to 
infection by Mycobacterium tuberculosis or leprae, Candida albicans or 
viruses including Morbilliviruses, i.e. Measles virus, as well as the human 
immunodeficiency virus-1 (HIV), (371).  
 CCT was considered as an exclusive mediator of actine and 
tubuline folding with its effects on other proteins folding being 
appreciated only recently (see Chapter I Section III.2.). It is therefore not 
surprising that the role of CCT in disease is largely unknown and it is 
mainly associated with “misfolding” diseases, which include besides 
others Alzheimer’s, Parkinson’s and Huntington’s disease (372). 
Physiological roles of CCT also include cell cycle progression, 
cytoskeletal protein polymerization and fibroblast motility and contractility 
(74, 75), processes involved in tissue repair responses and resolution of 
inflammation. At the same time proper termination of NF-κB activity is 
critical for the resolution of inflammation and return to homeostasis. We 
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hereby show that CCT regulates NF-κB-mediated transcription, 
diminishing RelA DNA binding via a mechanism targeting specifically 
RelA K122/123 acetylation during the late phase of NF-κB transcriptional 
activity. We infer that such an effect would be consistent with CCT role in 
resolution of inflammation (see Chapter II). Furthermore, we found that 
CCT controls the acetylation of endogenous CBP (see Chapter II Figure 
2.5.b), pointing at reduced HAT activity. While CBP is the best-described 
RelA acetyl transferase, targeting all the K residues interfering with NF-
κB-driven transcription, the effect of CCT seems to be rather specific 
towards K122/123 acetylation (see Chapter II Figure 2.5.d). Additional 
studies will be necessary to address the exact mechanism by which CCT 
regulates NF-κB activity.  
 
3. NF-κB beyond comprehension 
 
Being central to homeostasis, NF-κB family of transcription factors has 
gained the attention of scientists like few others. While there are more 
than 30,000 questions answered about its role in physiological and 
pathological conditions, structure and function, ancient origin and 
evolutionary conservancy and mechanism regulating its activity, every 
novel insight into the complexity of NF-κB signaling system, however, 
opens many questions that would be of interest to address. One such 
question is indisputably the selectivity of NF-κB transcriptional 
responses. While post-translational modifications probably play a central 
role in fine-tuning NF-κB transcriptional activity, the complexity and 
variety of distinct functional outcomes underlying these modifications in a 
cell- and stimulus-specific manner are proving difficult to reveal their 
dynamic interaction networks under the physiological conditions (176). 
Moreover, several NF-κB family members as well as functional 
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outcomes underlying NF-κB post-translational modifications are highly 
redundant in mammalian cells. On the other hand, different NF-κB family 
members as well as the signal transduction pathways leading to its 
activation are highly evolutionary conserved. Thus, revealing 
mechanisms underlying NF-κB post-translational modifications in simpler 
organisms and using evolutionary comparison could possibly provide 
clues as to our understanding of the importance of a particular post-
translational modification in controlling NF-κB transcriptional activity. 
While little is known about the role of post-translational modifications 
regulating NF-κB transcriptional activity throughout evolution, it is 
becoming clear that post-translational modifications are widespread from 
archaebacteria to humans, increasing protein functional complexity when 
rapid and/or profound responses to environmental changes are required 
(373). Comparative analysis of NF-κB RHD domains among different 
species shows high conservation of several RelA residues undergoing 
post-translational modifications, i.e. K56, K79, K122, K123, S205, K218, 
K221, T254, S276, S281 (see Figure 5.1.), implying the mandatory 
character of these residues in regulating NF-κB transcriptional activity. 
On the other hand, several RelA residues undergoing post-translational 
modifications, i.e. K37, K310, S311, K314, K315 (see Figure 5.1.), seem 
to be used by evolution as a novelty, possibly enhancing the complexity 
of NF-κB transcriptional regulation. Finally, several RelA S, T and Y 
residues are highly conserved, e.g. Y36, S42, S51, T57, T78, S180, 
Y257 (see Figure 5.1.), but have not been described to undergo post-
translational modifications or to influence NF-κB transcriptional activity. 
Thus, understanding the sequence of and the interplay between different 
post-translational modifications could be of importance in developing 
therapeutic strategies that effectively target a specific NF-κB post- 
translational modification and hence the expression of genes regulated
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AqNFkB--46-VRLEIVEQPKSRGFRFRYDCEGQSHGGLPGENSEKNRRQKTYPTVHLKGYRGRARVMVSLVTDSDP-AMPHAHSIVGK---NAID-GRCVVEIGPETDMYAQ-142 
NvNFkB—-48-PYLEILEQPKPRGFRFRYPSEGPSHGGLPGQFS--TSKSKSYPSVQVNNYQGPCRIVVTLVTKDEP-YMLHAHSLTGK---NANEEGVVTVQVGPDQHMTAS-143 
CrNFkB--19-PYVRLVEQPASRALRFRYECEGRSAGSIPGANS--TAECKTYPTIQVVNYKGSAVVVVSCVTKEGPPFRPHPHNLVGR---EGCKKGICTMVIN-NHDMTCS-114 
Dif-----78—PHLRIVEEPTSNIIRFRYKCEGRTAGSIPGMNSS-SETGKTFPTIEVCNYDGPVIIVVSCVTSDEP-FRQHPHWLVSKEEADACKSGIYQKRLP-PEERRLV-176 
Dorsal--47-PYVKITEQPAGKALRFRYECEGRSAGSIPGVNS--TPENKTYPTIEIVGYKGRAVVVVSCVTKDTP-YRPHPHNLVGK---EGCKKGVCTLEIN-SETMRAV-141 
RelA----19-PYVEIIEQPKQRGMRFRYKCEGRSAGSIPGRRS--TDTTKTHPTIKINGYTGPGTVRISLVTKDPP-HRPHPHELVGK---DCRD-GFYEAELCPDRCIHS--112 
--------------------------36-37--42--45---51-52-56-57-60-62-66------75-78-79----------------------------------------- 
 
AqNFkB-143-FTSLGILHVTKKKVPEVLTRRLLQQTTPRGQMVDQMEV------------VDVDMTTAQL----------TSEEQDEIHQQAQTLAKSMNLSVVRLCFQAFL-222 
NvNFkB-144-FPNLGIQHVTKKNVVKVLMDRFIKWQTLQNATFAKLSEGIKDGVDLSLFGVNTAINSNKLGFDKNVALSVANQEAAKSREYAKQQAAAMDLSAVRLCFQAYL-245 
CrNFkB-115-FSSLGIQCVKRKDIEESLKLREMIKVDP-----------------------------------------------YRTGFDHRLQTSNIDLNVVRLCFQVFI-169 
Dif----177-LQKVGIQCAKKLEMRDSLVEREKRNIDP-----------------------------------------------FNAKFDHKDQIDKINRYELRLCYQAFI-231 
Dorsal-142-FSNLGIQCVKKKDIEAALKAREEIRVDP-----------------------------------------------FKTGFSHRFQPSSIDLNSVRLCFQVFM-196 
RelA---113-FQNLGIQCVKKRDLEQAISQRIQTNNNP-------------------------------------------------FQVPIEEQRGDYDLNAVRLCFQVTV-165 
------------------122/123-------------------------------------------------------------------------------------------- 
 
AqNFkB-223-P-DENGRYTIPIDPVFSNKVYDSKAPSAGTLKICRLDRTSGSVKGGDDVFLLCDKVQKNDIEVVFYEDKQETTGGMQLQPWMAKGRFGPNDVHHQYAIVFQT-323 
NvNFkB-246-P-DQDGNFTRPLKPVYSDAVLDSKEPSASQLKICRMDKNSGCVTGGDEIYLLCDKVQKDDIEIHFYEMDDITG----KYTWEDLGKFSPCDVHRQFAIVFKT-342 
CrNFkB-170-EGPQQGKYTVPLPPVVSDPIFDKK--AICELTINKLSHYSAPVCGGSEVILLCDKVAKDDIKVRFYEERAGRV------EWESFGEFHPNEVHKQVAIPFRT-263 
Dif----232-T---VGNSKVPLDPIVSSPIYGNS----SELTITRLCSCAATANGGNEIIMLCEKIAKDDIEVRFYETDKDGR-----ETWYANAEFQPTDVFKQMAIAFKT-321 
Dorsal-197-ESEQKGRFTSPLPPVVSEPIFDKK--AMSDLVICRLCSCSATVFGNTQIILLCEKVAKEDISVRFFEEKNGQS------VWEAFGDFQHTDVHKQTAITFKT-290 
RelA---166-R-DPSGRPLR-LPPVLSHPIFDNRAPNTAELKICRVNRNSGSCLGGDEIFLLCDKVQKEDIEVYFTG-----------PGWEARGSFSQADVHRQVAIVFRT-254 
--------------------------180------------195----203-205----------218/221---229---------------------------------254--- 
 
AqNFkB-324-PTFYNQAIEHPVQVWIALKRPSD-HETSEPKPFLYLPQEFDEERIGQKRRKKITHFNNFFEGPGGGGGAGGGAGGAGGNFFSRDFNYGSGGGYNSGFNFFGG-424 
NvNFkB-343-PPYWNIAIERPANVLVELRRKKNGGETSEPVQFTYQPQLFDKEAIGAKRRKTVPHFTEFLS--GGSSGATGG-----------------GGSSVSGFNFSAD-425 
CrNFkB-264-PRYRDENVQQPIPVFIQLYRPSD-GSSSDPRPFQLLPVNRDPEGLSRKRQKIEDG----CLDRFLKENIFGAARDAGGP----LTPHTIPRTIKQATRTVLK-356 
Dif----322-PRYRNTEITQSVNVELKLVRPSD-GATSAPLPFEYYPN---PELLTKHHRRVAQKTVESLKRSLMSTNLHPSKQVKTSSQYTIFPTPQIATTAPQTQLSPGM-419 
Dorsal-291-PRYHTLDITEPAKVFIQLRRPSD-GVTSEALPFEYVPMDSDPAHLRRKRQKTGGDPMHLLLQQQQKQQLQNDHQDGRQTNMNCWNTQNIP-PIKTEPRDTSP-390 
RelA---255-PPYADPSLQAPVRVSMQLRRPSD-RELSEPMEFQYLPDTDDRHRIEEKRKRTYETFKSIMK-KSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSS-354 
---------255-257---------------276---281----288----------------310/311-314/315---------------------------------------  
 
 
Figure 5.1. Protein sequence alignment of different Rel proteins. Comparative analysis of NF-κB RHD among different speciaes, i.e. 
Amphimedon queenslandica (Aq), Nematostella vectensis (Nv), Carcinoscorpius rotundicauda (Cr), Drosophila melanogaster (Dif, 
Dorsal) and Homo sapiens (RelA) shows high conservation of several RelA serine (S), threonine (T) and tyrosine (Y) residues 
undergoing phosphorylation (red), lysine (K) residues undergoing acetylation, methylation and/or ubiquitilation (blue) and S, T, Y and K 
residues not shown to undergo PTMs (bold black). 
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by that particular post-translational modification. It should be noted, 
however, that If post-translational modifications happen as a sequence 
of events, early upstream post-translational modification should not only 
regulate the transcription of subset of NF-κB-dependent genes but also 
induce or inhibit another post-translational modification and hence 
indirectly affect a different subset of genes regulated by that other post-
translational modification. As an example, RelA S276 phosphorylation 
can promote the binding of RelA to CBP/p300, which, in addition to 
acting as a transcriptional activator of NF-κB-dependent gene 
transcription, acetylates RelA at K310 (187). Moreover, K310 acetylation 
inhibits RelA K314 and K315 methylation and thus methylation-induced 
RelA ubiquitination and consequent degradation (204, 374). As such, 
modulating HO-1 activity and hence RelA S276 phosphorylation would 
likely affect broad range of genes whose transcription depends on both 
histone and RelA acetylation. On the other hand, modulating CCT 
activity and hence RelA acetylation would rather regulate only a specific 
subset of NF-κB dependent genes. Further understanding of the kinetics 
and the cross-talk between different NF-κB post-translational 
modifications over the course of inflammatory response is therefore 
required to provide new targets and strategies for antimicrobial 
therapies. 
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